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ABSTRACT 
The WHO currently recommends tenofovir (TFV) disoproxil fumarate (TDF) or TFV 
alafenamide (TAF) as a preferred first-line antiretroviral therapy (ART) for the treatment and 
prevention of HIV. However, mild to moderate TFV-related renal toxicity is an uncommon 
but significant complication for TDF therapy. Efavirenz (EFV) is also approved for first line 
treatment, with the approval of a lower dose treatment, 600mg to 400mg, offering an 
opportunity for a greater number of patients to receive ART for the same amount of current 
public health expenditure, whilst enabling the maintenance of viral load suppression and 
partial mitigation of adverse events. However, EFV displays broad inter-patient and inter-
population variability in its pharmacokinetics and displays a range of dose dependent adverse 
effects. In order to gain further understanding of the impact patient genetics has on response 
to ART, studies investigating the effect of single nucleotide polymorphisms (SNPs) within 
multi ethnic populations receiving either TFV or EFV were completed. Additional work was 
conducted to investigate potential drug-substrate interactions at the transporter level within 
proximal tubule cells (PTCs), and the ramifications this may have for diagnosis of renal 
impairment.  
 
This work was conducted through assessing the relationship between SNPs found within 
genes encoding transporters on the apical membrane of PTCs and a diagnosis of renal 
dysfunction, defined as kidney tubular dysfunction or chronic kidney disease within a 
Ghanaian population (Chapter 2). Additionally the association between pharmacogenetic 
variants linked to TDF metabolism or TFV excretion and TFV plasma and urine concentrations, 
in a majority Caucasian patient population, receiving TFV as part of their ART was 
investigated (Chapter 3). This thesis sought to assess whether SNPs in genes involved in EFV 
and nevirapine metabolism were linked to previously observed changes in the contraceptive 
subdermal implant levonorgestrels (LNG) pharmacokinetics, when prescribed alongside EFV, 
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within a Ugandan population (Chapter 6). In order to study the effect of transporter 
interactions at the site of TFV toxicity, the proximal tubule, a transiently transfected Human 
Embryonic Kidney 293 cell line overexpressing either multidrug and toxin extrusion protein 
(MATE) 1 or MATE2K was developed and assessed for correct functionality (Chapter 4). This 
cell line was then utilised for drug-substrate interaction studies between TAF and TFV and 
either the endogenous biomarker creatinine or the type 2 diabetes drug metformin (Chapter 
5).  
 
These studies provided a greater understanding of the contribution pharmacogenetics 
provides to the interaction observed between EFV and LNG, and outlined a genetic 
association between TFV transporter SNPs and TFV plasma and urine concentrations. 
Utilisation of these findings in future pharmacogenetics studies would aid in the 
understanding of the impact of genetic variants in different populations, and the 
consequences this has for achieving sustained virological response to ART. The study of the 
effect of TAF and TFV on MATE1 and MATE2K transport of metformin and creatinine 
produced novel data on these interactions. Overall, the studies included within this thesis 
have clinical impact through further elucidating the potential mechanisms of toxicity or 
treatment failure within patients receiving ART. 
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Chapter 1. General Introduction 
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1.1 CURRENT POSITION ON HIV TREATMENT 
The past two decades have yielded a revolution in the treatment of human 
immunodeficiency virus (HIV). Huge reductions in patient mortality have been observed, with 
the World Health Organisation (WHO) estimating the avoidance of 7.8 million deaths 
between the years 2000 and 2014. Scale-up of HIV response has reduced new infections from 
3.1 million in 2000 to 2.0 million in 2014 (WHO 2016). Success has been made possible in 
part through the development of highly active antiretroviral therapy (ART) and the licensing 
of generic drugs, which has resulted in greater accessibility of treatments for patients in low-
income countries.  
 
As of 2016, an estimated 36.7 million people lived with HIV worldwide. According to the 
WHO, in 2015 an estimated 19.7 million of those infected did not receive treatment (WHO 
2016). More work is still needed in order to achieve the UNAIDS 2020 90:90:90 target, an 
ambitious global treatment target to have 90% of HIV-positive people know their status, 90% 
receive sustained ART and to have 90% of patients being treated achieve viral suppression. 
If this target can be achieved it is predicted that 73% of people living with HIV will be virally 
suppressed (UnitedNations 2014). 
 
1.1.1 HIV antiretroviral drug regimen recommendations 
HIV drugs can be classified into six categories according to their mechanism of action. These 
are: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors (INSTI), entry inhibitors and 
fusion inhibitors. Antiretroviral drug regimens are now used in a multitude of combinations 
and settings, from therapy for HIV positive individuals to pre-exposure prophylaxis (PrEP) and 
post-exposure prophylaxis (PEP) for prevention. For PreP, the PROUD study demonstrated 
higher protection against HIV within participants receiving ART compared to that seen in 
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placebo-controlled trials, and no evidence of an increase in other sexually transmitted 
infections within the PrEP receiving participants (McCormack 2016). Current WHO 
recommendations for first line HIV therapy for adults and adolescents, is a combination of 
two NRTIs, tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) and 
emtricitabine (FTC) or lamivudine (3TC), combined with a third active antiretroviral drug 
(WHO 2016, AntiretroviralGuidelinesforAdults&Adolescents 2017). The third active agent 
can be an INSTI such as dolutegravir (DTG), or an NNRTI such as efavirenz (EFV) (400 mg or 
600 mg) or nevirapine (NVP). (WHO 2016, AntiretroviralGuidelinesforAdults&Adolescents 
2017) 
 
1.2 TENOFOVIR  
Tenofovir (TFV) is the active compound of the prodrugs TDF and TAF. TFV is not a cytochrome 
P450 (CYP) substrate and is excreted through a combination of glomerular filtration and 
proximal tubule secretion. TFV enters proximal tubule cells (PTCs) through organic anion 
transporter (OAT) 1 and 3 (SLC22A6 and SLC22A8) located on the basolateral membrane of 
PTCs and exits through multidrug resistance protein (MRP) 4 and MRP7 (ABCC4 and ABCC10) 
located on the apical cell membrane (Figure 1.1) (Pushpakom 2011, Moss 2014).  
 
Due to TFV’s hydrophilic nature, the drug has permeability-limited oral absorption. 
Therefore, highly lipophilic pro-drugs TDF or TAF are prescribed (Shaw 1997, Van Gelder 
2002). TDF is degraded by carboxylesterases into the active metabolite TFV after intestinal 
absorption (Van Gelder 2002). ABC transporters within the small intestine are considered as 
the rate-limiting barrier to oral drug absorption. Within the small intestine TDF and TAF 
passively diffuse into intestinal epithelial cells before being transported into the intestinal 
lumen by P-glycoprotein (P-gp) (encoded by ABCB1) and breast cancer resistance protein 
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(BCRP) (encoded by ABCG2), which are expressed at the apical membrane. TAF is not 
metabolised to TFV within the small intestine, but through intracellular metabolism by 
lysosomal serine protease cathepsin A in peripheral blood mononuclear cells and 
carboxylesterase 1 in the liver (Birkus 2016). Because of this, the systemic delivery of active 
drug differs between TAF and TDF, with higher systemic circulation of TFV for TDF compared 
to TAF. The enhanced systemic exposure of TAF, compared to TFV, is of benefit given that 
enhanced drug loading of TAF can occur within peripheral blood mononuclear cells before 
conversion to the active metabolite TFV, enabling a lower dose to prescribed that provides 
greater antiretroviral activity.  
 
Alterations in the transport of TAF or TDF within the small intestine has potential 
ramifications for overall TFV exposure, with inhibition of efflux intestinal transporters being 
recognised as a secondary mechanism for pharmacoenhancers to increase systemic 
exposure. Tong et al. previously observed increased TFV plasma pharmacokinetics within 
patients receiving PIs, which they demonstrated to occur through inhibition of intestinal 
efflux of TDF by P-gp (Tong 2007). Furthermore, COBI has been shown to inhibit P-gp and 
BCRP transport of TAF in vitro (Lepist 2012). Inhibition of TFV prodrug transport at the 
intestinal lumen results in increased TFV systemic exposure through reducing prodrug 
excretion, resulting in elevated prodrug absorption and subsequently increased breakdown 
to active TFV.  
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Figure 1.1: Tenofovir and creatinine transporter profiles within the proximal tubule. 
TFV enters the proximal tubule from the blood via basolaterally expressed OAT 1 and 3 and is removed into the 
urine via MRP 4 and 7. Creatinine is transported into proximal tubule cells via organic cation transporter (OCT) 2 
(SLC22A2) and is excreted by the multidrug and toxin extrusion protein (MATE) 1 and 2K.  
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1.2.1 Tenofovir-associated renal toxicity  
The mild to moderate renal toxicity observed within patients taking TFV is an uncommon but 
significant complication for first line HIV therapy (Rifkin 2004, Jülg 2005, Cooper 2010, 
Scherzer 2012, Quesada 2015). However incidence of kidney toxicity within patients 
receiving TAF has been reported to be significantly lower than for patients receiving TDF, 
most likely due to the reduced dose prescribed for TAF in comparison to TDF (Moss 2014, 
Sax 2015). In light of the predicted increase in use of TDF post-patent, its anticipated long-
term use in an ageing patient population, and its inclusion within PrEP, it is essential that 
TFV-associated renal toxicity is further investigated.  
 
TFV-associated renal toxicity is a result of the accumulation of TFV in PTCs, resulting in cell 
death (Herlitz 2010). TFV toxicity also presents less commonly as Fanconi Syndrome, acute 
kidney injury and kidney tubular dysfunction (KTD) (Karras 2003, Lee 2003, Malik 2005, Gupta 
2008, Scherzer 2012). In one clinic, TFV-associated nephrotoxicity accounted for more than 
20% of consultations and was the most common single reason for HIV-related referral to 
specialist renal services (Hall 2011). A time-dependent relationship is observed between TDF 
use and incidence of renal toxicity, with increased time on therapy resulting in higher 
incidence. In addition to this, advancing age has been associated with increased risk of renal 
toxicity (Goicoechea 2008, Hall 2011, Quesada 2015).  
 
Diagnosis of TFV-associated renal toxicity is commonly ascertained through the 
measurement of estimated glomerular filtration rate (eGFR). eGFR can be calculated through 
several predictive equations, the most clinically relevant being the Cockcroft–Gault equation 
and the Modification of Diet in Renal Disease equation (Estrella 2010, Hall 2011). Both 
equations use creatinine clearance, calculated from serum and urine creatinine 
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concentrations to predict eGFR. Creatinine is an endogenous waste product of skeletal 
muscle metabolism and is widely used as a biomarker for renal health (Hall 2011). Excretion 
of creatinine occurs predominantly through glomerular filtration, with proximal tubular 
secretion accounting for 15% of total renal clearance. Creatinine enters PTCs via OCT2 and is 
excreted by MATE transporters 1 and 2K (Figure 1.1) (Motohashi 2013). 
 
An increase in the serum concentration of creatinine is regarded as an indicator of declining 
renal health, although it has been suggested to poorly represent actual filtration rate in 
patients with renal disease (Bennett 1971, Carrie 1980). When glomerular filtration rate is 
low, the serum creatinine concentration and creatinine clearance rate are higher than the 
actual glomerular filtration rate, due to the additional secretion of creatinine by PTCs 
(Urakami 2004, Estrella 2010). As TFVs site of toxicity is the PTCs and creatinine excretion by 
PTCs is modest, a small decline in eGFR would be expected in TFV-associated renal toxicity. 
In the case of TFV-associated renal toxicity, tests of renal function that utilise changes in 
creatinine concentration are unlikely to be an adequate indicator of renal toxicity. This is 
because changes in serum creatinine concentration observed in patients diagnosed with TFV-
associated renal toxicity may be caused by TFV inhibiting creatinine excretion in PTCs rather 
than an actual change to eGFR. 
 
The site of TFV excretion and toxicity, the proximal tubule, is a site of potential drug-
transporter-mediated drug interactions that can contribute to TFV-associated renal toxicity. 
The combination of raltegravir (RAL) with TDF has been shown to result in increased area 
under the curve (AUC) of TFV, although not to a clinically relevant degree (Wenning 2008). 
This alteration in AUC may be due to inhibition of OAT1 by RAL, as previously shown in vitro 
(Moss 2011). In addition, co-administration of TDF with didanosine is no longer 
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recommended due to severe side effects. Both drugs are nephrotoxic and previous studies 
have shown that co-administration with TDF results in an increase in AUC of didanosine. This 
alteration in AUC may be attributed to inhibition of didanosine transport via OAT1 (Fulco 
2003).  
  
Incidence of TFV toxicity has been shown to increase when TDF is prescribed with 
concomitant PIs, and increases further with a ritonavir (RTV)-boosted PI (Gupta 2008, Calza 
2013). The use of lopinavir (LPV)/RTV in combination with TDF has previously been shown to 
increase plasma exposure of TFV and has been linked with a reduction in TFV renal clearance 
(Kearney 2006, Kiser 2008). The same relationship was observed between darunavir 
(DRV)/RTV and TDF with an increase in TFV plasma concentration and AUC, though not to a 
clinically relevant degree (Hoetelmans 2007). Given that RTV is a substrate of MRP2, which 
is situated on the apical membrane of PTCs, and is a known inhibitor of MRP4 and OAT3, it is 
likely that the observed interaction between RTV and TFV is a result of transporter inhibition 
(Huisman 2002, Cihlar 2007).  
 
1.3 EFAVIRENZ  
 
EFV is an NNRTI recommended by the WHO as part of first line ART and is traditionally 
prescribed as a 600 mg daily dose (WHO 2016). The ENCORE1 study found that 400 mg daily 
dosing of EFV is non-inferior to 600 mg in a diverse patient cohort, with equal representation 
of African, Asian and Caucasian ethnic-origin patients (ENCORE1 2014). The use of 400 mg 
EFV daily dosing offers opportunities for a greater number of patients to receive ART for the 
same amount of current public health expenditure, and enables the maintenance of viral 
load suppression whilst partially mitigating the risk of adverse events. Accordingly, 400 mg 
EFV is now a recommended alternative first line therapy in the WHO treatment guidelines 
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(Boffito 2017). However, it should be recognised that EFV use is widely expected to fall 
dramatically over the coming years due to the introduction of DTG, which has a better safety 
profile and higher barrier to resistance.  
 
Although generally well tolerated EFV displays a range of dose-dependent adverse events, 
the majority of which are mild to moderate in severity and subside within a few weeks of 
therapy initiation (Marzolini 2001, Apostolova 2017). The most frequently observed adverse 
events include central nervous system (CNS) symptoms and neuropsychiatric symptoms, 
including but not limited to dizziness, sleep disturbance and headaches (Apostolova 2015, 
Apostolova 2017). More severe neurological side effects such as severe depression, 
depersonalisation and mania have been shown to effect <2% of patients receiving EFV 
(Scourfield 2012).  Nevertheless, EFV-related neuropsychiatric effects have been reported to 
interrupt therapy in 2-24% of patients receiving EFV (Apostolova 2017).  The mechanism of 
these adverse events are yet to be fully clarified, however Gatch et al. and Dalwadi et al. 
demonstrated through in vivo and in vitro study that EFV interacts with the serotonin 
receptors 5-hydroxytryptamine (5-HT) 2A, 5-HT2B, 5-HT2C and 5-HT6 which may in part explain 
reported neuropsychiatric side effects such as night terrors (Gatch 2013). Furthermore in 
vitro study of chronic exposure to EFV demonstrated an antagonistic effect of EFV on 
serotonin transport by 5-HT2A and 5-HT2C, with an 81% reduction in 5-HT2A’s responsiveness to 
serotonin after 3 days of treatment with EFV (Dalwadi 2016). Incidence of EFV CNS toxicity 
have been shown to be exacerbated by elevated EFV plasma levels (Marzolini 2001, van Luin 
2009). Given that EFV displays broad inter-patient and inter-population variability in its 
pharmacokinetics, the relevance of the influence of genetics on EFV pharmacokinetics must 
be considered within the context of toxicity as well as virological response.   
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Studies indicate that EFV plasma clearance is lower in patients of African ancestry than those 
of European ancestry, due to the difference in frequency of CYP2B6 alleles (Barrett 2002, 
Csajka 2003, Haas 2004, Solus 2004, Holzinger 2012, Zanger 2013). EFV is primarily 
metabolised by CYP2B6, and more moderately by CYP2A6, CYP3A4 and UGT2B7 (Bélanger 
2009, Ogburn 2010). Additionally, EFV is an inducer of CYP3A4 and CYP2B6. This high level of 
CYP enzyme interaction contributes to a multitude of drug-drug interactions. This includes 
interactions with other antiretroviral drugs such as PIs, and with drugs prescribed 
concomitantly such as the anti-tuberculosis drug rifampicin (Barry 1999, López-Cortés 2002). 
Other factors have been shown to contribute to variability in EFV pharmacokinetics, including 
pregnancy and body weight (Haas 2004, Cressey 2012, Cho 2016). These factors are 
important in light of the findings of the ENCORE1 study, and to the broad application of low 
dose 400mg EFV (Orrell 2011). A study within a HIV positive tuberculosis co-infected 
population has demonstrated comparable viral loads between patients receiving 400mg  or 
600mg EFV in combination with TDF and FTC alongside rifampicin and isoniazid, regardless 
of CYP2B6 516G>T (rs3745274) or CYP2B6 983T>C (rs28399499) genotype (Maddalena 
Cerrone 2018). Furthermore, a study of pregnant and post-partum women demonstrated 
non-inferiority of 400mg EFV compared to 600mg regardless of CYP2B6 516G>T (rs3745274) 
or CYP2B6 983T>C (rs28399499) genotype (Lamorde 2017). These studies suggest the 
applicability of 400mg EFV to a wider range of patient demographics, with further study in 
larger patient populations needed to confirm these promising findings.  
 
1.4 GENETIC VARIANTS AND PHARMACOKINETICS  
Variation in the human genome sequence sometimes plays an important role in the 
pharmacokinetics and pharmacodynamics of drugs and has the potential to be used to 
predict a patient’s clinical outcome so that therapy can be tailored to genetically defined sub-
populations. However, a robust understanding of the molecular basis for differences in drug 
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response also require contextual understanding of other factors such as ethnicity, 
environment and culture. Single nucleotide polymorphisms (SNPs) can be classed as the 
deletion, insertion or substitution of a single nucleotide in a gene (Borges 2010). These 
changes can be found in the protein coding (exonic) or non-protein-coding (regulatory or 
intronic) regions of genes, or in intergenic regions. A SNP that results in the same amino acid 
sequence being produced is known as a synonymous SNP, whereas a SNP that results in 
either a different amino acid or a premature stop codon is classified as nonsynonymous. SNPs 
in introns may still be of pharmacological relevance due to the regulatory functions that are 
conducted by these regions, such as transcriptional regulation or messenger ribonucleic acid 
(mRNA) splicing (Elgar 2008, Heyn 2015). SNPs are usually associated via haplotype groups, 
which occur due to multiple SNPs being inherited together (Borges 2010). These SNPs can be 
said to be in linkage disequilibrium, the non-random association of alleles on the same 
chromosome within a particular population (Slatkin 2008).  
 
The study of SNPs in relation to their effect on the pharmacology of a drug focuses primarily 
on SNPs in genes relevant to the pharmacokinetics of the drug of interest. These include SNPs 
in genes involved in the production, through transcriptional regulation or direct coding, of 
transporters, enzymes and transcription factors. In the case of ART, the use of 
pharmacogenetic studies to identify SNPs that influence pharmacokinetics, efficacy or 
toxicity, has yielded clinically and/or mechanistically important information (Table 1.1). 
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Table 1.1: Clinical application of SNPs associated with changes in patient response to/pharmacokinetics of drug therapy. 
  
Gene Protein SNP Physiological effect Drug interaction Alteration in protein 
function 
Clinical recommendation 
HLA-B (Ma 2010) MHCII *5701 Hypersensitivity 
reaction 
Abacavir Increased Test for HLA-B*5701 allele before initiation of therapy 
in adults, adolescents and children. If positive for HLA-
B*5701 do not treat with abacavir. 
CYP2C19 (Scott 
2013) 
CYP2C19 *2 and *3 Reduction in 
metabolism 
Clopidogrel Inactivation If patient is heterozygous *2/*3 or homozygous for *2 
or *3 significantly reduced platelet expression is 
expected, increasing risk of adverse cardiovascular 
events. Alternative antiplatelet therapy should be 
prescribed. 
DPYD (Caudle 
2013) 
DPD *2A Inactivation of 
catalytic activity 
Fluoropyrimidines Inactivation If patient is heterozygous for *2A dose is reduced by a 
minimum of 50%, if patient is homozygous an 
alternative drug should be prescribed. 
TPMT (McLeod 
2000, Nguyen 
2011) 
TPMT *1, *2, *3A 
and/or *3C 
Severe 
myelosuppression 
Thiopurines Reduced or Inactive For patients who possess a single functional allele (*1) 
and a non-functional allele (*2, *3A or *3C) reduce 
azathioprine or 6-mercaptopurine dose by 30-70%, 
reduce thioguanine dose by 30-50%. Patients 
homozygous for non-functional alleles have initial 
dose of all drugs reduced by 10% and dosing 
frequency is extended, or an alternative drug is 
prescribed. 
CYP3A5 (Birdwell 
2015) 
CYP3A5 *3 Reduction in 
metabolism 
Tacrolimus No expression Patients who are homozygous for *3 should initiate 
therapy with standard recommended dose. Patients 
who are heterozygous *3 or do not possess the 
variant allele should start dose 1.5 to 2 times higher 
than the recommended starting dose. 
UGT1A1 (Marques 
2010, Dean 2015) 
UGT1A1 *28 Increased risk of 
neutropenia 
Irinotecan Reduced Patients homozygous for *28 receiving a dose <250 
mg/m2 require a dose reduction of 30%. 
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1.4.1 Influence of genetic diversity 
Variation between different ethnicities in modern humans has occurred due to migration, 
through colonisation events and rapid variations in population numbers over thousands of 
years (Marth 2003). An example of this is the colonisation of Europe around 40,000 years 
ago, which led to a reduction of genetic diversity within this population. This produced a 
bottleneck caused by a reduction in genetic diversity being followed by a gradual increase in 
human population size. Because of this, fewer recombination events occurred in European 
populations compared to those of ancient African ancestry. Therefore, people of European 
ancestry possess gene variants that remain coinherited as a result of fewer recombination 
events and those of ancient African ancestry have a greater diversity of gene variation due 
to a greater number of recombination events (Marth 2003, Ortega 2014). Large scale 
increases in human population size over the last 400 generations has skewed previous 
patterns of genetic variation and has resulted in greater incidence of rare variants, due to 
recent mutations, which may contribute to disease risk and alterations in pharmacological 
outcome (Keinan 2012, Ortega 2014).  
 
1.4.2 Population stratification 
The availability of high-throughput sequencing has enhanced the study of the development 
of human genetic diversity and the identification of low-frequency variants. Exome and 
whole genome sequencing has enabled the characterisation of huge numbers of common 
(>5% frequency) variants and the incidence of low-frequency variants, in ethnically diverse 
populations. The 1000 Genomes Project aimed to identify over 95% of SNPs at 1% frequency 
or above in a broad range of populations and found that people from populations of 
substantial African ancestry had up to three-times more low-frequency variants than those 
of European or East Asian origin. Additionally, for some common variants strong 
differentiation was observed between populations within ancestry-based groups, with a 
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difference in frequency of at least 0.25 between pairs of populations within an ancestry 
group (GenomesProjectConsortium 2012). These findings highlight the importance of 
studying SNPs within a wide range of ethnically diverse populations to ascertain the overall 
effect of a SNP for patients of different ethnicities. Furthermore, the extent of diversity 
between ethnic groups, that has been previously reported, means that study populations 
should be separated by ethnicity during statistical analysis, or appropriate steps must be 
taken (e.g. use of microsatellites) to ensure that a SNP association is not wrongfully 
attributed as statistically significant, due to population stratification. 
 
Population stratification occurs because of the collinearity between factors that influence a 
particular phenotype. To exemplify this with a non-genetic paradigm, it is difficult to 
dissociate the impact of body weight and gender on a particular phenotype (e.g. 
pharmacokinetics of a specific drug) when assessing their impact within a mixed gender 
cohort. Because women generally have a lower body weight than men, it may appear that 
there are gender differences, which are driven by the body weight. This collinearity is even 
more challenging when considering genetic associations within mixed ethnicity cohorts 
because there are likely to be many variants that differ in frequency between populations, 
and not all are usually considered. Thus, a polymorphism that is highly prevalent in one 
population compared to another may be statistically associated with the phenotype within a 
mixed-ethnicity population, because it is a marker of ethnicity (and therefore other unknown 
variants or groups of variants) rather than having a direct effect on the phenotype. For this 
reason, it is important to consider potential population stratification when conducting 
pharmacogenetic studies, particularly when trying to attribute a phenotype to a specific 
marker. Several approaches have been developed to account for population stratification in 
genetic association studies including the use of microsatellites (Wilson 2001, Lewis 2002, 
Apolinário 2017, Iacovacci 2017). 
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1.5 PHARMACOGENETICS STUDIES IN HIV 
In broad terms, pharmacogenetic studies in HIV have focused upon defining the importance 
of variants for either the efficacy or safety of antiretroviral drugs, with the aim of informing 
drug selection or dose optimisation within genetically predefined sub-populations. The 
combination of multiple antiretroviral drugs, as part of the WHO recommended three-drug 
antiretroviral treatment, adds further complexity to these studies. Co-administration of 
antiretroviral drugs alongside drugs to treat comorbidities must also be considered within 
pharmacogenetic studies. Drug-drug interactions between the antiretroviral drugs in 
isolation and with other drug regimens, and the potential side effects that this can elicit, may 
be exacerbated by genetic variations with the patient. Furthermore, the prescription of a 
suitable drug regimen may be hampered by a patient’s genetics resulting in alterations in 
outcome for one drug within the regimen. Pharmacokinetic boosters such as RTV, further 
complicate the picture, making the determination of a relationship between a patient’s 
genetics and the relevant drug more difficult to decipher.  
 
Since efficacy and safety are both underpinned by pharmacokinetics and biodistribution, 
most pharmacogenetic studies to date have focused on genes involved in drug metabolism 
enzymes, drug transporters, or nuclear receptor type transcription factors. Notwithstanding, 
probably one of the best examples of a clinically implemented genetic test is presented by 
the influence of the HLA-B*57-01 allele on abacavir hypersensitivity reactions. A list of key 
pharmacogenetic markers that have been shown to be important in the context of HIV 
therapy is given in Table 1.2, and these observations are also discussed in the sections below.
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Table 1.2: Population frequencies of SNPs previously associated with toxicity and/or pharmacokinetics of HIV antiretroviral drugs. 
 
Gene Protein SNP Drug interaction Allele frequencies (%) 
All AFR AMR EAS EUR SAS 
CYP2B6 CYP2B6 516G>T Efavirenz 
Nevirapine 
G T G T G T G T G T G T 
68.4 31.6 62.6 37.4 62.7 37.3 78.5 21.5 76.4 23.6 61.9 38.1 
983T>C  T C T C T C T C T C T C 
97.7 2.3 91.8 8.2 99.0 1.0 100 0.0 100 0.0 100 0.0 
15582C>T  C T C T C T C T C T C T 
71.1 28.9 91.8 8.2 64.8 35.2 56.4 43.6 68.0 32.0 65.8 34.2 
ABCB1 P-gp 1236C>T Efavirenz 
Raltegravir 
C T C T C T C T C T C T 
58.4 41.6 86.4 13.6 59.7 40.3 37.3 62.7 58.4 41.6 41.3 58.7 
4036A>G A G A G A G A G A G A G 
81.2 18.8 83.6 16.4 84.0 16.0 70.4 29.6 86.1 13.9 82.1 17.9 
3435C>T C T C T C T C T C T C T 
60.5 39.5 85.0 15.0 57.2 42.8 60.2 39.8 48.2 51.8 42.5 57.5 
ABCC2 MRP2 -24C>T Tenofovir 
 
 
 
 
 
C T C T C T C T C T C T 
86.5 13.5 96.9 3.1 83.4 16.6 78.3 21.7 79.3 20.7 90.5 9.5 
1249G>A G A G A G A G A G A G A 
81.3 18.7 81.1 18.9 84.1 15.9 90.4 9.6 79.6 20.4 72.2 27.8 
3563T>A T A T A T A T A T A T A 
96.3 3.7 94.4 5.6 96.3 3.7 100 0.0 93.0 7.0 98.3 1.7 
3972C>T C T C T C T C T C T C T 
71.2 28.8 78.4 21.6 65.9 34.1 75.3 24.7 62.9 37.1 69.5 30.5 
ABCC10 MRP7 526G>A Tenofovir 
Nevirapine 
G A G A G A G A G A G A 
63.5 36.5 97.0 3.0 55.9 44.1 41.4 58.6 54.0 46.0 56.4 43.6 
2843T>C T C T C T C T C T C T C 
80.0 20.0 69.2 30.8 81.4 18.6 92.0 8.0 76.8 23.2 84.5 15.5 
ABCG2 BCRP 421C>A Tenofovir 
Raltegravir 
C A C A C A C A C A C A 
88.1 11.9 98.7 1.3 85.9 14.1 70.9 29.1 90.6 9.4 90.3 9.7 
NR1I2 PXR 63396C>T Atazanavir C T C T C T C T C T C T 
46.6 53.4 63.5 36.5 51.6 48.5 37.7 62.3 34.0 66.0 42.6 57.4 
NR1I3 CAR 540C>T Efavirenz 
 
C T C T C T C T C T C T 
66.4 33.6 89.3 10.7 67.4 32.6 48.1 51.9 65.1 34.9 54.7 45.3 
1089C>T C T C T C T C T C T C T 
49.8 50.2 47.0 53.0 53.6 46.4 42.6 57.4 56.4 43.6 51.6 48.4 
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Data derived from Phase 3 of the 1000 Genome Project Ensembl datatbase (GenomesProjectConsortium 2015). 
All = total population studied (n = 2504). AFR = African (n = 661), AMR = American (n = 347), EAS = East Asian (n = 504), EUR = European (n = 503), 
SAS = South Asian (n = 489). 
African subpopulations: African Caribbean Barbados, African ancestry Southwest US, Esan Nigeria, Gambian in Western Division, Luhya Webuye 
Kenya, Mende Sierra Leone, Yoruba Ibadan Nigeria. 
American subpopulations: Colombian Medellin Colombia, Mexican ancestry Los Angeles California, Peruvian Lima Peru, Puerto Rican Puerto Rico. 
East Asian subpopulations: Chinese Dai Xishuangbanna China, Han Chinese Beijing China, Southern Han Chinese China, Japanese Tokyo Japan, Kinh 
Ho Chi Minh City Vietnam. 
European subpopulations: Northern and Western European ancestry Utah USA, Finnish Finland, British England and Scotland, Iberian Spain, 
Toscani Italy. 
South Asian subpopulations: Benglai Bangladesh, Gujarati Indian Houston USA, Indian Telugu UK, Punjabi Lahore Pakistan, Sri Lankan Tamil UK. 
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1.6 DRUG METABOLISM ENZYMES 
Drug metabolising enzymes have taken a central role in pharmacogenetics studies to date 
with a major focus on the CYP family, for which many antiretroviral drugs are substrates, 
including NRTIs, PIs, and entry inhibitors.  
 
1.6.1 CYP2B6  
Variations in CYP2B6 have been linked to alterations in protein activity via several 
mechanisms. The most common haplotype for CYP2B6 is CYP2B6*6 which is comprised of 
CYP2B6 516G>T (rs3745274) and 785A>G (rs2279343). As shown in Table 1.2, CYP2B6 
516G>T is found most commonly in South Asian populations and least frequently in East 
Asian populations. The variant is also very common in African populations. CYP2B6 516G>T 
is used as a marker for the effect of CYP2B6*6 and has been linked to alterations in EFV and 
NVP metabolism, pharmacokinetics and toxicity in a variety of populations (Haas 2004, 
Rotger 2005, Wyen 2008, Schipani 2011, Hui 2016, Nightingale 2016). The link between 
CYP2B6*6 and alterations in EFV and NVP pharmacokinetics is due to a 50-75% reduction in 
CYP2B6 expression occurring through aberrant liver mRNA splicing (Hofmann 2008).  
 
CYP2B6 516G>T screening alone is not adequate as an identifier for potential EFV toxicity 
(Pinillos 2016), and pharmacogenetics studies have identified other CYP2B6 SNPs that also 
contribute to inter-individual response to EFV and NVP. The CYP2B6*18 haplotype made up 
of 183G>A (rs2279344), 62G>A (rs12721649), 983T>C (rs28399499) and 17897C>T, is of 
interest as it results in the expression of a non-functional protein and is found predominantly 
in African populations (Table 1.2). CYP2B6 983T>C is the defining SNP of CYP2B6*18 and was 
first identified through genetic screening of the exon and flanking intronic regions of 11 CYP 
enzymes (Solus 2004, Wang 2006). Since its discovery it has been associated with increased 
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NVP steady state plasma exposure and increased EFV exposure, however associations with 
NVP have been conflicting, which may be due in part to the low frequency of CYP2B6 983T>C 
(Rotger 2005, Wyen 2008, Haas 2009).  
 
Overall it can be said that CYP2B6 polymorphisms have a huge impact on EFV and NVP 
pharmacokinetics and that incidence of occurrence of key SNPs within this enzyme are more 
predominant in African and South East Asian ethnicity groups. Although CYP2B6 
polymorphisms have proven to be of limited value in terms of personalisation of therapy, 
they have provided the genetic basis for differences in drug exposure between different 
populations.  
 
1.7 TRANSPORTERS  
Transporters are key to the absorption, distribution, metabolism and excretion of all drugs 
and so SNPs that alter transporter function and expression can result in variability in drug 
pharmacokinetics between individuals. Drug transporter variants have previously been 
associated with alterations in the pharmacokinetics and disposition of antiretroviral drugs, in 
some cases influencing the incidence of toxicity.  
 
1.7.1 ABC transporters  
ABC gene-encoded transporters are found within multiple locations in the body including the 
brain, liver and kidney. Because of this, alterations in the frequency of production or 
morphology of these transporters have potential ramifications for the transport of multiple 
endogenous substrates and xenobiotics. The most widely studied ABC transporter has been 
P-gp. ABCB1 pharmacogenetic studies to date have yielded highly conflicting data (Yen-
Revollo 2009, Swart 2012, Coelho 2013, Ngaimisi 2013, Dalal 2015, Russo 2016). 
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In the case of TFV, SNPs within ABCC genes have been established as risk factors for increased 
likelihood of developing TFV-associated KTD within multiple studies. This is due to some of 
the encoded MRP transporters transporting TFV across the apical membrane of PTCs within 
the kidney, into the lumen and out into the urine. Loss of function of these transporters 
results in a reduction in TFV transport, resulting in greater TFV accumulation in PTCs. This 
accumulation leads to mitochondrial toxicity and subsequent cell death (Lewis 1995, Kohler 
2009).  
 
ABCC2 encodes the MRP2 transporter, an efflux transporter located on the apical membrane 
of polarised cells. MRP2 is present in multiple locations including on hepatocytes, renal PTCs 
and intestinal epithelia (Pratt 2015). The ABCC2 ‘CATC’ haplotype is a combination of the 
polymorphisms –24C>T (rs717620), 1249G>A (rs2273697), 3563T>A (rs17222723) and 
3972C>T (rs3740066) and has been significantly associated with TFV-induced renal proximal 
tubulopathy (Rodríguez-Nóvoa 2009). The CGAC haplotype was found to safeguard against 
toxicity in a majority Caucasian population (Izzedine 2006). A study of Japanese patients 
found ABCC2 –24C>T allele T and 1249G>A allele G to be protective against TFV-induced KTD 
(Nishijima 2012). These results are surprising given that TFV has not been reported as a 
substrate of MRP2 as discussed previously (Moss 2014). Variation in allele frequencies 
between ethnicities is observed within each SNP of the haplotype group, with a 17.6% 
difference in variant allele frequency between African ancestry and East Asian ethnicity for 
ABCC2 –24C>T. Given that this SNP has been linked as both a protective and contributory 
SNP to TFV-induced renal dysfunction, differences in its frequency may affect the way this 
SNP can be used as a potential marker for kidney toxicity.   
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The efflux transporter MRP7 is expressed ubiquitously throughout the body and is encoded 
for by the ABCC10 gene. MRP7 was previously demonstrated to transport TFV (Pushpakom 
2011). ABCC10 526G>A (rs9349256) and 2843T>C (rs2125739) have previously been 
associated with TFV-induced KTD within a majority Caucasian study group (Pushpakom 
2011). ABCC10 526G>A was among the top 20 of 30 SNPs studied within a Genome Wide 
Association Study looking at Caucasian and Black participants, and was among the top 20 of 
594 SNPs studied within the Caucasian participants in the study to be linked with alterations 
in TFV clearance, however not to a statistically significant degree (P = 0.100) (Wanga 2015). 
An association of genetic polymorphisms with TFV-induced KTD was further established 
within two patients, both of whom were heterozygous for ABCC10 2843T>C (rs2125739) and 
ABCC2 –24C>T (rs717620) (Giacomet 2013). 
 
In addition to the observed interactions with TFV toxicity, ABCC10 2843T>C (rs2125739) has 
been associated with lower NVP plasma concentrations within a cohort of Caucasian and 
Black patients, and within the Caucasian patients in isolation, but not to a statistically 
significant degree within the Black participants (Liptrott 2012). This result is surprising given 
comparable frequency of the variant allele within both ethnicities in the study. This study 
provides further evidence for a direct functional effect of ABCC10 2843T>C that warrants 
further investigation within larger diverse study populations.  
 
SNPs within the ABCG2 gene, which encodes BCRP, have been associated with elevated 
plasma and urine TFV concentrations. ABCG2 421C>A (rs2231142) was associated with 
elevated TFV AUC in a study of majority African American participants. Patients possessing 
the variant allele had a 1.5-fold increase in TFV AUC compared to homozygous wild-type 
patients (Baxi 2017). ABCG2 421C>A has also been linked to higher peak RAL plasma 
concentrations (Tsuchiya 2016). This relationship between ABCG2 421C>A and elevated drug 
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pharmacokinetics was attributed within both studies to a hypothesised loss of function of 
BCRP caused by ABCG2 421C>A, resulting in a reduction in drug transport. This mechanism 
has been demonstrated in vitro for other BCRP substrates (Polgar 2008, Neumanova 2014).  
 
Within phase 3 of the 1000 Genomes project it was shown that the variant allele for ABCG2 
421C>A occurs at the lowest frequency within African participants (1.3%) and at highest 
frequency in East Asian populations (29.1%). The variation in frequency observed for this SNP 
highlights its potential clinical impact within particular populations (Table 1.2) and 
demonstrates the need for population-specific pharmacogenetic studies.  
 
1.8 TRANSCRIPTIONAL REGULATORS 
Alterations in transcriptional regulator expression through SNPs that reduce or increase 
function have the potential to produce wide-ranging effects, due to the intricate network of 
interactions that are associated with enzyme and transporter regulation. While nuclear 
receptors are classically involved in induction of drug metabolism, they also correlate with 
enzyme and transporter expression in patients not receiving enzyme inducers (Owen 2004, 
Albermann 2005, Vyhlidal 2006, Betts 2015).  
 
1.8.1 NR1I2 
NR1I2 encodes the pregnane X receptor (PXR), an important transcription factor in regard to 
the regulation of expression of CYP enzymes and transporters (Svärd 2010). P-gp expression 
has been directly correlated with CYP3A5 expression in the intestine, through co-regulation 
of expression of the two proteins by PXR (Burk 2004, Ufer 2008, Cascorbi 2011). The 
antiretroviral drug RTV has previously been confirmed as an activator of PXR (Luo 2002). This 
effect is not observed for the pharmacokinetic booster cobicistat (COBI) (Marzolini 2016). 
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Additionally, EFV has been demonstrated to induce CYP3A4 promoter activity through PXR 
activation (Hariparsad 2004). Significant differences in NR1I2 SNP frequencies have been 
observed between ethnicities (Table 1.2) (Swart 2012). 
 
NR1I2 63396C>T (rs2472677), has been significantly associated with below minimum 
effective concentrations of unboosted atazanavir (ATV) in a population of 43% Caucasian 
patients, the ethnicity of the remainder of the cohort was unspecified however the 
association was observed within the total population (Siccardi 2008). This observation was 
further confirmed through pharmacokinetic modelling, which demonstrated an association 
between NR1I2 63396C>T and variation in unboosted ATV clearance in a majority Caucasian 
population (Schipani 2010). The proposed mechanism of this interaction is that the presence 
of NR1I2 63396C>T results in increased expression and activity of PXR, resulting in increased 
expression of proteins transcriptionally regulated by PXR and thus increased metabolism of 
ATV by its PXR regulated metaboliser enzymes (Schipani 2010). These observations for ATV 
were partially validated in another predominantly Caucasian population (Kile 2012), but a 
Malawian cohort study showed no association between NR1I2 63396C>T and NVP 
pharmacokinetics (Brown 2012). However, frequency of the NR1I2 63396C>T variant allele T 
varies between European (66%) and African (36.5%) populations according to phase 3 of the 
1000 Genomes Project (Table 1.2).  
 
1.8.2 NR1I3  
NR1I3 encodes the constitutive androstane receptor (CAR) a transcription factor that 
functions to regulate the expression of a complex network of phase I and II metabolising 
enzymes. Being homozygous CC for the SNP NR1I3 453C>T (rs2307424) has been associated 
with early discontinuation of EFV therapy in a majority Caucasian study group (Wyen 2011). 
Furthermore, incidence of discontinuation was seen more frequently in Caucasian patients 
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compared to Black patients in the study. The variant allele was also seen more frequently in 
the Caucasian participants (32%) compared to the Black participants (15%) (Wyen 2011), 
suggesting that this effect may have more impact in Caucasian populations. Additionally, two 
separate studies have observed NR1I3 453C>T to be associated with early discontinuation of 
EFV in a Chilean population and a Bantu South African population (Swart 2012, Cortes 2013). 
Furthermore, within the Chilean population NR1I3 453C>T was also significantly associated 
with lower EFV plasma concentration (Cortes 2013).  
 
NR1I3 1089C>T (rs3003596) CC and CT genotypes have been significantly associated with a 
reduction in plasma EFV concentration in Bantu South Africans, suggesting that the presence 
of a C allele may result in increased NR1I3 expression, and therefore increased expression of 
proteins that metabolise EFV (Swart 2012). Statistically significant inter- and intra-ethnic 
variation has been observed for the frequency of both the NR1I2 and NR1I3 SNPs (Table 1.2) 
(Swart 2012). 
 
1.9 THESIS OBJECTIVES 
The primary aim of this thesis was to analyse the impact patient genetics has on adverse HIV 
drug response and drug-drug interactions, through studying multi-ethnic populations 
receiving one of two key antiretroviral drugs, TFV or EFV. Furthermore, we investigated 
potential interactions between TFV or its prodrug TAF with transporters at the site of TFV-
associated renal toxicity, with the goal of understanding how these interactions may 
influence the way in which TFV-associated renal toxicity is diagnosed. These aims were 
completed through the studies outlined below. 
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A HIV positive mixed gender population of Ghanaian adults was studied in order to determine 
the contribution of SNPs in transporters found within PTCs to the presentation of TFV-
associated renal dysfunction, defined as KTD or chronic kidney disease (CKD). The SNPs 
included in the study were found within ABCC10, ABCC2 and ABCC4, these genes were 
selected based on their protein expression on the apical membrane of PTCs.  
  
In order to further investigate the contribution of PTC transporter SNPs to the disposition of 
TFV, the effect of SNPs in genes linked to TFV excretion and TDF metabolism (ABCC2, ABCC4, 
ABCC10 and ABCG2) were studied in a HIV positive majority male Caucasian population. 
Additionally, the contribution of these SNPs to variability in TFV plasma and urine 
concentrations was investigated. 
 
A transiently transfected Human Embryonic Kidney 293 (HEK293) cell line expressing either 
MATE1 or MATE2K transporter was developed through utilisation of lipid-based transfection 
of plasmid deoyribonucleic acid (DNA), obtained from vectors encoding either MATE1 or 
MATE2K. These cell lines were then used to study potential interactions between TAF and 
TFV with the renal biomarker creatinine or the type 2 diabetes drug metformin. These drug 
interactions are of interest given the use of creatinine to calculate renal function and 
metformin’s classification of being unsuitable for use in patients with CKD (Munar 2007, 
Estrella 2010).  
 
The effect of gene variants on levonorgestrel (LNG) pharmacokinetics was assessed in 
patients receiving either EFV or NVP based antiretroviral drug regimens. SNPs in CYP2B6, 
CYP2A6, NR1I3 and NR1I2 were selected based on the role of their expressed protein in EFV 
or NVP metabolism. A cohort of Ugandan HIV-positive women participating in a drug-drug 
interaction pharmacokinetic study were selected (Scarsi 2016). Within this study an 
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interaction between EFV and LNG which resulted in suboptimal LNG pharmacokinetics had 
been observed (Scarsi 2016). 
 
These studies have relevance in light of the growing number of patients receiving ART 
through efforts to achieve the UNAIDS 2020 90:90:90 targets. A greater understanding of the 
mechanisms behind drug-drug interactions, adverse events and treatment failure in patients 
receiving ART is required to achieve these targets. Through analysing the contribution a 
patient’s genetics has to their response to ART, it is possible to determine the clinical 
relevance of these interactions, and thus determine the relevance of personalised medicine 
to global HIV treatment strategies. Furthermore, studying the mechanisms by which 
antiretroviral drugs are metabolised and excreted from the body has utility through enabling 
the prediction of potential adverse events and drug-drug interactions in patients receiving 
these drugs in the future, enabling a greater number of patients to achieve the final 90 target 
of achieving sustained viral suppression.  
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Chapter 2: Assessment of the 
Relationship Between 
Polymorphisms in ABCC10, 
ABCC2 and ABCC4 and Tenofovir-
Induced Renal Dysfunction 
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2.1 INTRODUCTION 
TFV administered as a once daily dose of the prodrug TDF, has a favourable pharmacological 
profile of high efficacy and once daily dosing with no CYP enzyme interactions. Despite early 
reports of a low toxicity profile in the kidney (Barditch-Crovo 2001, Schooley 2002) mild to 
moderate kidney toxicity is now recognised as a modest but significant risk for patients given 
TFV-containing regimens (Jülg 2005, Mauss 2005, Scherzer 2012, Quesada 2015). A number 
of different manifestations of kidney injury have been documented with TDF use, including 
acute kidney injury, Fanconi syndrome, CKD and KTD (Lee 2003, Barrios 2004, Rifkin 2004, 
Herlitz 2010). Toxicity has led to concerns over the long-term use of TDF, with a correlation 
between increasing time on TDF therapy and incidence of kidney damage being identified 
(Rifkin 2004, Fafin 2012, Quesada 2015). 
 
Host genetic polymorphisms in PTC transporters have previously been associated with TFV-
induced KTD. ABCC10 526G>A (rs9349256) and 2843T>C (rs2125739) were associated with 
TFV-induced KTD in patients receiving TDF ART (Pushpakom 2011). ABCC2 SNPs have been 
linked with KTD in multiple studies of patients of varied ethnicity (Izzedine 2006, Rodríguez-
Nóvoa 2009, Nishijima 2012). The CATC haplotype for ABCC2 at positions -24C>T (rs717620), 
1249G>A (rs2273697), 3563T>A (rs8187694) and 3972C>T (rs3740066) was shown to be a 
predisposing haplotype for TFV-associated renal dysfunction, with CGAC haplotype being 
protective against renal proximal tubulopathy (Izzedine 2006). The ABCC4 SNP, 4131T>C 
(rs3742106), has been associated with increased TFV-diphosphate in human peripheral 
mononuclear cells (Kiser 2008). Additionally, older age and low body weight have also been 
associated as risk factors for KTD (Nelson 2007). 
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In comparison to Caucasian patients, the risk of renal dysfunction in HIV-1 positive patients 
of African descent is heightened (Rostand 1982, Kopp 2003). Our study sought to assess the 
relationship between four SNPs in key genes of interest and markers of KTD and CKD in 
patients taking TFV-containing ART. With the overarching aim to further elucidate the 
relationship between host genetics and renal toxicity in HIV-1 positive patients of African 
descent. 
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2.2 METHODS 
 
2.2.1 Ethical approval 
Research ethics approval was obtained from the Committee on Human Research Publications 
and Ethics at KNUST Kumasi (CHRPE21/11), along with written informed consent from all 
patients.  
 
2.2.2 Study design and cohort 
This study was a retrospective cross-sectional study of renal dysfunction in patients from the 
Komofo Anokye Teaching Hospital in Kumasi Ghana (Chadwick 2015). The study included 66 
HIV-1 positive Ghanaian adults receiving TDF. All patients had received treatment for at least 
6 months before study entry.  
 
2.2.3 Parameter definitions 
CKD was defined as either having an eGFR < 60 mL/min or the presence of proteinuria. 
Positive proteinuria was determined through a urine dipstick (being ≥ 1 plus) then confirmed 
with a urine protein-creatinine ratio (uPCR) > 30 mg/mmol. eGFR was calculated in house 
using the Cockcroft-Gault equation. eGFR slopes using baseline (pre-treatment) and current 
(sampling) values were calculated. KTD was defined as the presence of two or more of the 
following: fractional phosphate excretion > 18%, fractional urate excretion > 15%, glycosuria 
(with normoglycaemia), hypophosphataemia < 0.8 mmol/L, presence of proteinuria, a uPCR 
> 30 mg/mmol, urinary albumin-protein ratio (uAPR) < 0.4 and either a uPCR > 20 or urine 
albumin-creatinine ratio (uACR) > 3 mg/mmol. Possible KTD was classed as positive if the 
patient presented with one of any of the above factors, excluding testing positive for the 
presence of proteinuria. 
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2.2.4 Sample and data collection 
Sampling data was collected between 2012 and 2013 from whole blood.  Serum creatinine, 
phosphate, glucose, urate and potassium values were obtained, and urine creatinine, 
phosphate, urate and protein levels were calculated from urine samples. Patients with 
known causes of kidney dysfunction or urinary tract infections (identified by positive 
dipsticks for nitrites and/or leukocytes) were excluded from the study.  
 
2.2.5 Genotyping 
Genomic DNA was extracted from whole blood using the manufacturers' protocol (E.Z.N.A 
Blood DNA Mini Kit; Omega bio-tek; Norcross, GA). In brief this consisted of the addition of 
25 μL of protease solution and 250 μL of BL buffer to 250 μL of each blood sample before 
incubation at 65 °C for 10 minutes. 260 μL of ethanol was then added to each sample before 
the sample was transferred to a HiBind® DNA Mini Column inside a collection tube. The 
sample was then centrifuged at 10,000 ×g for 1 minute. The filtrate was discarded and 500 
μL of HBC Buffer was added to the column, the sample was then span at 10,000 ×g for 1 
minute. The filtrate was discarded, and the sample was then washed twice with 700 μL of 
Wash Buffer and centrifuged at 10,000 ×g for 1 minute.  The HiBind® DNA Mini Column was 
centrifuged at 10,000 ×g for 2 minutes to dry the column membrane and remove any residual 
ethanol before elution. The HiBind® DNA Mini Column was transferred to a fresh collection 
tube and incubated with 50 μL of Elution Buffer at 65 °C for 5 minutes. The tube was then 
centrifuged at 10,000 ×g for 1 minute before repeating the incubation with elution buffer. 
The tube was centrifuged again at 10,000 × g for 1 minute. The resulting DNA was stored at 
-20 °C ready for downstream applications. Extracted DNA was quantified using NanoDrop 
(Thermo Fisher Scientific, Wilmington, DE). Genotyping was completed using real-time allelic 
discrimination polymerase chain reaction (PCR) assays on a DNA Engine Chromo4 system 
(Bio-Rad Laboratories, Hercules, CA). The PCR protocol followed denaturation at 95 °C for 10 
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minutes, followed by 50 cycles of amplification at 92 °C for 15 seconds and annealing at 60 
°C for 1 minute 30 seconds. TaqMan Genotyping Master mix and assays ABCC10 2843T>C 
(rs2125739), ABCC10 526G>A (rs9349256), ABCC2 -24C>T (rs717620) ABCC4 4131T>C 
(rs3742106) were purchased from Life Technologies (Paisley, Renfrewshire, UK). Opticon 
Monitor v.3.1 software (Bio-Rad Laboratories) was used to obtain allelic discrimination plots 
and identify genotypes. 
 
2.2.6 Statistical analysis 
Compliance with Hardy-Weinberg equilibrium was tested through previously outlined 
methods (Rodriguez 2009). Following the equation: 
𝑝2 + 2𝑝𝑞 + 𝑞2 = 1 
Where p is the frequency of the common allele and q is the frequency of the variant allele 
within the study population.  Within the equation, p2 is the frequency of the common 
homozygous genotype, q2 is the frequency of the variant homozygous genotype and 2pq is 
the frequency of the heterozygous genotype. The aim of this equation is to determine if the 
observed genotype frequencies in the study population differ from the frequencies predicted 
by the equation. With a chi squared value (X2) assigned to an associated P value range used 
to determined statistical significance. P ≤ 0.05 was considered as statistically significant.  
 
Genotypes were coded for regression analyses as 0 = homozygous common allele, 1 = 
heterozygous and 2 = homozygous variant allele. Categorical variables were described using 
relative frequencies, whilst continuous variables were described using median and N 
interquartile range (IQR). The Shapiro-Wilk Test was used to test for normality with P ≤ 0.05 
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considered as statistically significant. A univariate analysis through linear and binary logistical 
regression was carried out to identify independent variables associated with factors for renal 
toxicity. Variables with P ≤ 0.2 for the univariate analysis were carried through to a linear or 
binary logistical backwards multivariate analysis where P ≤ 0.05 was classed as statistically 
significant. All statistical analyses were carried out using SPSS Statistics v.22 (IBM Armonk, 
NY). All charts were produced using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). 
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2.3 RESULTS 
 
2.3.1 Patient characteristics 
Sixty-six patients receiving TDF-containing regimens were recruited into the study, patient 
characteristics are summarised in Table 2.1. The median (IQR) age and weight of all patients 
was 38 years (34-47 years) and 58 kg (52-65 kg). Patients were predominantly female and 
more likely to be taking EFV (than NVP or LPV/RTV) alongside TDF and zidovudine or 3TC. All 
SNPs were in Hardy-Weinberg equilibrium within the study population. Genotype 
frequencies are shown in Table 2.1. 
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Table 2.1: Characteristics of the study participants at entry. 
Characteristics Total (n = 66) Patient number per parameter 
Age (years) 38.0 (34.0-47.0) 61 
Weight (kg) 58.0 (52.0-65.0) 60 
Height (m) 1.6 (1.5-1.6) 52 
Male (n [%]) 10 (15) 62 
Hepatitis B positive (n [%]) 6 (11) 17 
CD4 count (cells/mm3) 544.5 (312.3-645.8) 31 
eGFR at start of study 93.1 (75.7-133.6) 18 
eGFR at time of sampling 105.5 (86.5-120.9) 15 
Proteinuria (n [%]) 36 (55) 66 
ART 3rd drug  
EFV (n [%]) 35 (53) 66 
NVP (n [%]) 11 (17) 
LPV/RTV (n [%]) 7 (11) 
N/A (n [%]) 13 (19) 
Genotype frequencies  
ABCC10 2843T>C (rs2125739) (n [%]) TT CT CC 66 
27 (40) 38 (58)  1 (2) 
ABCC10 526G>A (rs9349256) (n [%]) GG AG AA 66 
60 (90) 5 (8) 1 (2) 
ABCC2 -24C>T (rs717620) (n [%]) CC CT TT 66 
58 (88) 8 (12) 0 (0) 
ABCC4 4131T>C (rs3742106) (n [%]) TT TC CC 66 
26 (39) 40 (61) 0 (0) 
Values shown as median (IQR) and percentage of population. 
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2.3.2 Non-significant associations 
After univariate or multivariate regression analysis age was not significantly associated with 
log10 baseline creatinine, log10 creatinine at time of sampling, eGFR slope change per year, 
log10 urine creatinine or any incidence of KTD or CKD. No difference in log10 baseline 
creatinine, baseline eGFR, log10 creatinine at time of sampling, sampling eGFR, eGFR slope 
change per year, log10 urine creatinine, or any incidence of KTD was observed between male 
and female participants. Log10 height was not associated with log10 baseline creatinine, 
baseline eGFR, sampling eGFR, eGFR slope change per year, log10 urine creatinine, or any 
incidence of KTD or CKD. Variation in weight was not associated with log10 baseline creatinine, 
baseline eGFR, log10 creatinine at time of sampling, sampling eGFR, eGFR slope change per 
year, log10 urine creatinine, or any incidence of KTD. Time receiving TDF was not associated 
with alterations in log10 baseline creatinine, baseline eGFR, log10 creatinine at time of 
sampling, log10 urine creatinine or incidence of possible KTD or CKD. No relationship was 
observed between ABCC10 2843T>C (rs2125739) and baseline eGFR, eGFR slope change per 
year, log10 urine creatinine or possible KTD. Furthermore, no associations were seen for 
ABCC10 526G>A (rs9349256) and log10 baseline creatinine, log10 creatinine at time of 
sampling, sampling eGFR, eGFR slope change per year, log10 urine creatinine or any incidence 
of possible KTD or CKD. No associations were observed between ABCC2 -24C>T (rs717620) 
and any parameter other than eGFR at time of sampling.  No associations were observed 
between ABCC4 4131T>C (rs3742106) and any parameter other than CKD. Figure 2.1 shows 
the relationships between the non-significant SNPs and parameters of KTD after univariate 
linear regression analysis. 
  
2.3.3 Trends observed from univariate analysis 
Through univariate regression analysis a relationship was observed between ABCC10 
2843T>C (rs2125739) and incidence of KTD (P = 0.181, OR = 0.4). A trend was seen between 
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ABCC4 4131T>C (rs3742106) and incidence of CKD (P = 0.110, OR = 2.3). A relationship 
between ABCC2 -24C>T (rs717620) and higher eGFR at time of sampling (P = 0.178, β = 33.9) 
was also seen, but a low sample size for this association compromises its interpretation (CC; 
n= 13, CT; n= 1) as shown in Table 2.1. Subsequently these trends were carried through to 
multivariate analysis where they were seen to not be statistically significant.  
 
A relationship between being female and having a lower log10 creatinine concentration at 
time of sampling and higher incidence of CKD was seen (P = 0.021, β = -0.1; P = 0.078, OR = 
0.3; respectively), however the low number of male participants within our study 
compromises this association. Additionally this effect may in fact be due to stratification, 
given that typically a lower body weight is observed in females compared to males, a factor 
which has previously been linked with reduced renal function (Nelson 2007). A relationship 
between length of time on TDF and incidence of KTD was found (P = 0.120, OR = 0.1). 
Furthermore, a trend between age and log10 creatinine at time of sampling was observed (P 
= 0.033, β = 0.0). Log10 height was seen to be linked with higher eGFR slope change per year 
(P = 0.158, β = 721.0). However, these trends were not statistically significant within 
multivariate analysis. Figure 2.2 shows the relationships with parameters of KTD found to be 
linked through univariate linear regression analysis only. 
 
2.3.4 Significant associations from multivariate analysis 
As shown in Table 2.2, ABCC10 2843T>C (rs2125739) was associated with lower log10 baseline 
creatinine (P = 0.001, β = -0.4), higher baseline eGFR (P = 0.005, β = 61.6), higher log10 serum 
creatinine at time of sampling (P = 0.008, β = 0.1), lower eGFR at time of sampling (P = 0.040, 
β = -19.2) and lower eGFR slope change per year (P = 0.041, β = -43.4). ABCC10 526G>A 
(rs9349256) was associated with higher baseline eGFR (P = 0.045, β = 82.7), however this 
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result must be interpreted in light of the low sample size for this association (GG; n= 15, AG; 
n= 1) (Table 2.1).  Figure 2.3 provides a visual representation of all significant genetic 
associations within the TFV group. 
 
Increasing age was significantly associated with lower baseline eGFR (P = 0.049, β = -2.2) and 
lower eGFR at time of sampling (P = 0.018, β = -1.1). Log10 height was associated with higher 
log10 creatinine at time of sampling (P = 0.011, β = 2.0). Log10 duration on TFV was associated 
with higher eGFR slope change per year (P = 0.001, β = 155.1). Multivariate binary logistic 
regression including independent factors such as age and weight found no statistically 
significant associations between the study SNPs and KTD or CKD (Table 2.3). Low body weight 
was seen to be significantly associated with higher incidence of CKD (P = 0.012, OR = 0.9) 
(Figure 2.4 and Table 2.3).  
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Figure 2.1: Non-significant relationships between parameters of KTD and genetic variants. 
Graphs A-C: Non-significant relationships between SNPs and baseline creatinine. Graphs D-F: Non-significant relationships between SNPs and serum creatinine at time of sampling. Graphs G-J: 
Non-significant relationships between SNPs and urine creatinine at time of sampling. Graphs K-L: Non-significant relationships between SNPs and eGFR at baseline. Graph M: Non-significant 
relationship between SNP and eGFR at time of sampling. Graphs N-P: Non-significant relationships between SNPs and eGFR slope change. Data points represent the mean ± SD   
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Figure 2.2: Relationships between parameters of KTD and genetic variants or patient characteristics from univariate analysis. 
Graph A: Relationship between ABCC2 -24C>T and eGFR at time of sampling. Graph B: Relationship between gender and serum creatinine at time of sampling. Graph C: Relationship between 
incidence of KTD and length of time receiving TDF. All relationships found to be significant (P ≤ 0.2) through univariate regression analysis only. Data points represent the mean ± SD 
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Figure 2.3: Statistically significant associations between parameters of KTD and genetic variants in proximal tubule transporters from multivariate 
analysis. 
Graphs A-B: Significant associations between SNPs and eGFR at baseline. Graph C: Significant association between SNP and eGFR at time of sampling. Graph D: Significant relationship between 
SNP and serum creatinine at baseline. Graph E: Significant relationship between SNP and serum creatinine at time of sampling. All relationships found to be statistically significant (P ≤ 0.05) 
through multivariate regression analysis. Data points represent the mean ± SD  
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Figure 2.4: Relationship between weight and a positive diagnosis for CKD in patients 
receiving TDF from multivariate analysis. 
Data points represent the mean ± SD  
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Table 2.2: Statistically significant univariate and multivariate linear regression analysis. 
log10 Baseline creatinine Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
ABCC10 2843T>C (rs2125739) 0.001 -0.4 (-0.6,0.2) 0.5 0.001 -0.4 (-0.6,0.2) 0.5 
Baseline eGFR Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.095 -2.7 (-5.7,0.6) 0.1 0.049 -2.2 (-4.3,0.0) 0.7 
ABCC10 2843T>C (rs2125739) 0.008 65.2 (19.8,110.4) 0.4 0.005 61.6 (22.1,101.1) 0.7 
ABCC10 526G>A (rs9349256) 0.035 114.3 (9.3,219.3) 0.3 0.045 82.7 (2.1,163,2) 0.7 
log10 Sampling serum creatinine Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.033 0.0 (0.0,0.1) 0.3 0.382 0.0 (0.0,0.0) 0.6 
Gender 0.021 -0.1 (-0.2,0.2) 0.3 0.378 -0.1 (-0.2,0.1) 0.6 
log10 height (log10 m) 0.094 1.5 (-0.3,3.2) 0.2 0.011 2.0 (0.5,3.4) 0.5 
ABCC10 2843T>C (rs2125739) 0.115 0.1 (0.0,0.1) 0.1 0.008 0.1 (0.0,0.2) 0.5 
Sampling eGFR Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.023 -1.2 (-2.2,-2.0) 0.4 0.018 -1.1 (-2.0,-0.2) 0.6 
ABCC10 2843T>C (rs2125739) 0.024 -26.6 (-49.2,-4.1) 0.3 0.040 -19.2 (-37.3,-1.1) 0.6 
ABCC2 -24C>T (rs717620) 0.178 33.9 (-17.5,85.2) 0.1 0.549 11.4 (-29.5,52.3) 0.6 
eGFR slope change per year Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
log10 height (log10m) 0.158 721.0 (-290.2,1732.1) 0.0    
log10 time on TDF (log10 months) 0.002  126.0 (48.6,202.3) 0.2 0.001 155.1 (66.9,243.3) 0.3 
ABCC10 2843T>C (rs2125739) 0.093 -31.6 (-68.6,5.5) 0.1 0.041 -43.4 (-84.9,-1.8) 0.3 
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Univariate linear regression (P ≤ 0.2) was completed, all statistically significant results were then carried through to multivariate linear regression (P ≤ 0.05). 
All statistically significant variables from multivariate linear regression are shown in bold type. For linear regression β is the regression coefficient and 
represents incremental change in the renal toxicity parameter per unit change in a patient characteristic (e.g. per kg body weight or per allele carried). So if β 
= 0.5 an increase per unit in the patient characteristic results in the renal toxicity parameter increasing by a factor of 0.5. In the case of log transformed 
variables, the renal toxicity parameter would increase by a factor of log10 0.5. 
 
Table 2.3: Statistically significant univariate and multivariate binary logistical analysis. 
 
KTD 
 
Univariate binary logistical regression Multivariate binary logistical regression 
P Odds ratio (95%CI) P Odds ratio (95%CI) 
log10 time on TDF (log10 months) 0.120 0.1 (0.0,1.7)   
ABCC10 2843T>C (rs2125739) 0.181 0.4  (0.1,1.5)   
CKD 
 
Univariate binary logistical regression Multivariate binary logistical regression 
P Odds ratio (95%CI) P Odds ratio (95%CI) 
Gender 0.078 0.3 (0.1,1.2)   
Weight (kg) 0.012 0.9 (0.9,1.0) 0.012 0.9 (0.9,1.0) 
ABCC10 2843T>C (rs2125739) 0.183 0.5 (0.2,1.4)   
ABCC4 4131T>C (rs3742106) 0.110 2.3 (0.8,6.2)   
Univariate binary logistic regression (P ≤ 0.2) was completed, all statistically significant results were then carried through to multivariate binary logistical 
analysis (P ≤ 0.05). All statistically significant variables from multivariate linear regression are shown in bold type.  
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2.4 DISCUSSION 
 
To further elucidate the connection between PTC transporter SNPs and TFV-induced KTD, 
this study investigated the association between ABCC10 2843T>C (rs2125739), ABCC10 
526G>A (rs9349256), ABCC2 -24C>T (rs717620) and ABCC4 4131T>C (rs3742106) with renal 
function and parameters of KTD. 
 
In our study, no statistically significant associations were observed between the SNPs studied 
and TFV-induced KTD or CKD. ABCC10 2843T>C (rs2125739) was significantly associated with 
both KTD and CKD as part of univariate analysis. However, these associations did not hold as 
part of multivariate analysis. ABCC10 2843T>C was associated with reduced creatinine at 
baseline and elevated creatinine at time of sampling. ABCC10 2843T>C (rs2125739) was also 
associated with higher eGFR at baseline and lower eGFR at time of sampling. These 
associations between ABCC10 SNPs and baseline eGFR are of clinical relevance given that a 
low eGFR prior to receiving TDF has been indicated as a risk factor for developing TFV-
associated renal toxicity (Antoniou 2005). 
 
ABCC10 2843T>C (rs2125739) was associated with a decline in eGFR slope change per year 
indicating a net decline in eGFR during the study. ABCC10 526G>A (rs9349256) was also 
associated with lower eGFR at baseline however due to the low sample size conclusions 
cannot be drawn from this association. The effect of ABCC10 SNPs on TFV-induced KTD has 
been observed in two previous studies Pushpakom et al. first reported a significant 
association between the ABCC10 526G>A (rs9349256) and KTD and ABCC10 2843T>C 
(rs2125739) and KTD in a predominantly Caucasian population (Pushpakom 2011). Giacomet 
et al. also associated ABCC10 SNPs with TFV induced KTD using two patient case studies 
(Giacomet 2013). 
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The relationship described above may in part be explained by encoded transporter function. 
The ABCC10 gene encodes for the MRP7 transporter. TFV has been demonstrated to be a 
substrate of this transporter (Pushpakom 2011) and it has been suggested that TFV may be 
transported by MRP7 within PTCs, however substrate specificity of MRP7 within PTCs is yet 
to be confirmed. Potentially alterations in the frequency of production of MRP7, or its 
morphology, caused by ABCC10 2843T>C could reduce TFV transport, resulting in greater TFV 
accumulation in PTCs. This accumulation would lead to mitochondrial damage and 
subsequent cell death (Kohler 2009, Herlitz 2010, Hall 2011). Through inhibition of 
mitochondrial DNA polymerase γ by TFV, resulting in inhibition of mitochondrial DNA 
synthesis (Lewis 1995). The consequent reduction in PTCs may result in low serum creatinine 
transport, leading to an increase in serum creatinine concentration and reduced eGFR over 
time. Further study is warranted in order to delineate the physiological mechanism by which 
this SNP may contribute to an accelerated eGFR decline in patients taking TFV, given that in 
a study of patients on TDF with a decline in eGFR, the decline in function was not reversible 
in over one-third of patients (Jose 2014).  
 
In this study, lower weight was associated with increased incidence of CKD, a relationship 
that has previously been observed within a South African and a Tanzanian population 
(Mpondo 2014, De Waal 2017). Low weight has previously been defined as a risk factor for 
TFV-associated renal dysfunction in multiple studies of different ethnicities (Antoniou 2005, 
Nelson 2007, Nishijima 2011). 
 
Future studies would benefit from the inclusion of TFV urine and plasma concentrations 
alongside kidney toxicity parameters, to better study the effect of kidney toxicity on TFV 
excretion. Furthermore, the effect of SNPs included within this study on the excretion of TFV 
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when prescribed alongside co-medications for other comorbidities, such as tuberculosis, 
would be of interest considering the wide-ranging application of TDF.  
 
2.4.1 Limitations 
The association of ABCC10 2843T>C (rs2125739) with alterations in creatinine concentration 
and eGFR builds on the findings of previous pharmacogenetic studies, as outlined in Chapter 
1 (Section 1.7). However, these results should be interpreted in the context of the limitations 
of our study. An alternative method of study design could benefit this work, specifically 
applying a case-control model. This would involve dividing the total population into KTD 
positive or negative groups and comparing statistically significant associations between the 
two groups. This would allow us to determine if associations between parameters were 
found within the general patient cohort or was specific to patients with a positive phenotype.  
 
 An additional limitation of our study is the low overall sample size, which resulted in a low 
frequency of variant alleles for all of the SNPs studied within our patient population and 
limited the number of parameters which could be included in the analysis. Additionally 
incomplete population data was available for each parameter, due to patients being absent 
from clinic, meaning some parameters had significantly reduced patient numbers, 
compromising the significance of these associations, as shown in Table 2.1. This was seen for 
the significant association of ABCC10 526G>A with higher baseline creatinine which had both 
limited total patient number and low allele frequency.  
 
Interpretation of these findings within a wider context is made complex through different 
studies applying different criteria for defining KTD. Our KTD definition was defined based on 
parameters included within the primary cross-sectional observational study of KTD and CKD 
incidence within patients receiving ART (Chadwick 2015). A clinical definition of KTD for 
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research would have utility as it would enable more accurate comparisons of findings 
between studies, given that different studies may be making comparisons about findings 
based off incidence of renal dysfunction at different severity levels.   
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Chapter 3: ABCG2 421C>A 
Influences Tenofovir 
Concentrations in Plasma and 
Urine 
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3.1 INTRODUCTION 
 
TDF is currently used as part of both pre- and post- exposure prophylaxis for HIV and is 
recommended by the WHO as a preferred first-line ART for the treatment and prevention of 
HIV, and for the treatment of Hepatitis B (WHO 2016). TFV is generally well tolerated and has 
a favorable pharmacological profile. However, long-term use of TDF has previously been 
associated, in a dose-dependent manner, with increased incidence of osteomalacia and renal 
impairment in the form of Fanconi syndrome and KTD (Woodward 2009, Rodríguez-Nóvoa 
2010, Hall 2011, Fafin 2012, Ezinga 2014, Chadwick 2015). TFV is primarily excreted in the 
urine via glomerular filtration and active tubular secretion via the PTCs of the kidney (Imaoka 
2007).  
 
TFV plasma and urine concentrations are of relevance as a measure of drug pharmacokinetics 
and as potential indicators of TFV-associated renal toxicity. High plasma TFV and TDF 
concentrations have previously been identified as risk factors for TFV-associated renal 
toxicity (Rodríguez-Nóvoa 2010, Ezinga 2014, Kunimoto 2016). Furthermore, previous 
pharmacogenetics studies have linked SNPs in transporters present within PTCs with 
alterations to TFV pharmacokinetics and incidence of kidney toxicity, within multiple studies 
of different ethnicities (Moss 2011). In the case of ABCG2, the rs2231142 SNP has previously 
been associated with variation in TFV pharmacokinetics (Baxi 2017). 
 
Our study sought to investigate the relationship between pharmacogenetic variants in genes 
linked to TFV excretion (ABCC2, ABCC4, ABCC10) and TDF metabolism (ABCG2), and plasma/ 
urine TFV concentrations. The primary objectives of this study were to determine a genetic 
contribution to the inter-patient variation in TFV concentration observed between patients 
 
 
 
70 
 
receiving TDF, and to elucidate if the presence of SNPs previously shown to contribute to 
TFV-associated renal toxicity were an indicator of variable plasma/urine TFV concentrations. 
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3.2 METHODS 
 
3.2.1 Ethical approval 
Research ethics approval was obtained from NRES Committee London- Bloomsbury, along 
with written informed consent from all patients. Funding was provided by MSD. 
 
3.2.2 Study design and cohort 
This study was a retrospective sub-study of the clinical trial SSAT066 (ClinicalTrials.gov 
Identifier: NCT02351908), involving a multi-ethnic treatment naive patient population of 59 
HIV positive patients receiving TDF alongside RAL (n = 19), DTG (n = 18) or elvitegravir (EVG) 
and COBI (EVG/COBI; n = 22). Patients were recruited from the St Stephen’s AIDS Trust, 
London, UK.  
 
3.2.3 Sample and data collection 
Whole blood, plasma and urine concentrations were taken for pharmacogenetic and 
pharmacokinetic analysis 21 hours post dose, at study week 4. TFV concentrations in blood 
and urine at steady state were determined using a validated liquid chromatography tandem 
mass spectrometry (LCMS/MS) method. 
 
3.2.4 Genotyping 
Genomic DNA was extracted from whole blood through use of the manufacturers’ protocol 
(E.Z.N.A Blood DNA Mini Kit; Omega bio-tek; Norcross, GA) as outlined in Chapter 2, Section 
2.2.5. Extracted DNA was quantified using NanoDrop (Thermo Fisher Scientific, Wilmington, 
DE). Genotyping was completed using real-time allelic discrimination PCR assays on a DNA 
Engine Chromo4 system (Bio-Rad Laboratories, Hercules, CA). The PCR protocol followed 
denaturation at 95 °C for 10 minutes, followed by 50 cycles of amplification at 92 °C for 15 
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seconds and annealing at 60 °C for 1 minute 30 seconds. Taqman Genotyping Master mix and 
assays ABCC4 4131T>C (rs3742106), ABCC10 2843T>C (rs2125739), ABCC10 526G>A 
(rs9349256), ABCC2 1249G>A (rs2273697), ABCC2 -24C>T (rs717620), ABCC2 1249G>A 
(rs2273697), ABCC2 3563T>A (rs17222723), ABCC2 3972C>T (rs3740066), ABCG2 421C>A 
(rs2231142) were purchased from ThermoFisher Scientific (Wilmington, DE). Opticon 
Monitor v.3.1 software (Bio-Rad Laboratories) was used to obtain allelic discrimination plots 
and identify genotypes. 
 
3.2.5 Statistical analysis 
Compliance with Hardy-Weinberg equilibrium was tested as outlined in Chapter 2 Section 
2.2.6. Genotypes were coded for regression analyses as 0 = homozygous common allele, 1 = 
heterozygous and 2 = homozygous variant allele. Categorical variables were described using 
relative frequencies, whilst continuous variables were described using median and IQR. The 
Shapiro-Wilk test was used to test for normality with P ≤ 0.05 considered as statistically 
significant. A univariate analysis through linear regression was conducted to identify 
independent variables associated with TFV plasma and urine concentrations. Variables with 
P ≤ 0.2 for the univariate analysis were carried through to a linear backwards multivariate 
analysis where P ≤ 0.05 was classed as statistically significant. Statistical analyses were 
carried out using SPSS Statistics v.22 (IBM Armonk, NY). All charts were produced using 
GraphPad Prism 6 (GraphPad Software, La Jolla, CA). 
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3.3 RESULTS 
 
3.3.1 Patient characteristics  
Fifty-nine patients were recruited for this study from the clinical trial SSAT066, patients were 
of multiple ethnicities: Caucasian (n = 50), Black (n = 2), Asian (n = 1), Mixed race (n = 2) and 
unclassified ethnicity defined as ‘Other’ (n = 4). Patient characteristics and genotype 
frequencies are summarised in Table 3.1. The median (IQR) age and weight of all patients 
was 34 years (28-42 years) and 71 kg (64-83 kg). All SNPs were in Hardy-Weinberg 
equilibrium.  
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Table 3.1: Characteristics of the study participants at entry. 
Characteristics Total (n = 59) 
Age 34.2 (28.5-42.2) 
Weight (kg) 71.6 (64.8-83.4) 
Height (cm) 176.0 (171.0-181.0) 
Gender (Female [%]) 4 (7) 
Drug regimen with tenofovir (n [%]): 
 Raltegravir 
 Dolutegravir 
 Elvitegravir and cobicistat 
 
18 (32) 
19 (31) 
22 (37) 
Ethnicity (n [%]): 
 Caucasian 
 Black 
 Asian 
 Mixed race 
 Other 
 
45 (77) 
2 (3) 
4 (7) 
2 (3) 
6 (10) 
Time post dose plasma sample (hours.minutes) 21.5 (13.4-25.3) 
Time post dose urine sample (hours.minutes) 21.6 (14.1-25.4) 
Tenofovir urine concentration (ng/mL) 21924.3 (14837.4-47405.6) 
Tenofovir plasma concentration (ng/mL) 43.53 (28.1-72.2) 
Tenofovir plasma:urine 531.9 (316.5-855.3) 
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Genotype frequencies  
ABCC4 4131T>C (rs3742106) (n [%]) TT CT CC 
27 (46) 27 (46) 5 (8) 
ABCC10 2843T>C (rs2125739) (n [%]) TT CT CC 
38 (65) 19 (32) 2 (3) 
ABCC10 526G>A (rs9349256) (n [%]) GG AG AA 
18 (31) 25 (42)  16 (27) 
ABCC2 1249G>A (rs2273697) (n [%]) GG AG AA 
(39) (27) (5) 
ABCC2 -24C>T (rs717620) (n [%]) CC CT TT 
40 (68) 17 (29) 2 (3) 
ABCC2 3563T>A (rs17222723) (n [%]) TT AT AA 
18 (31) 41 (69) 0 (0) 
ABCC2 3972C>T (rs3740066) (n [%]) CC CT TT 
22 (37) 27 (46) 10 (17) 
ABCG2 421C>A (rs2231142) (n [%]) CC AC AA 
44 (75) 15 (25) 0 (0) 
 
Values shown as median (IQR) and percentage of population. 
 
  
 
 
 
76 
 
3.3.2 Non-significant associations  
Through univariate and multivariate linear regression analysis age was shown not to be 
associated with TFV urine concentration or TFV plasma:urine ratio. Weight, height, gender 
and co-medication with DTG where not associated with any alterations in TFV parameters. 
Co-medication with EVG/COBI was not associated with a change in TFV plasma or urine 
concentration. Sampling time post dose was not associated with TFV plasma or urine 
concentration. ABCC10 2843T>C (rs2125739), ABCC10 526G>A (rs9349256), ABCC4 4131T>C 
(rs3742106), ABCC2 3563T>A (rs17222723) and ABCC2 1249G>A (rs2273697) where not 
associated with any TFV parameters. ABCC2 -24C>T (rs717620) and ABCC2 3972C>T 
(rs3740066) where not associated with alterations in TFV plasma or urine concentration. 
Figure 3.1 shows all non-significant results for SNPs and TFV plasma concentration and Figure 
3.2 shows all non-significant results for SNPs and TFV urine concentration after univariate 
linear regression analysis. 
 
 
3.3.3 Trends observed from univariate analysis 
A trend was observed between ABCC10 2843T>C (rs2125739) and higher TFV urine 
concentration (P = 0.136, β = 0.1) through univariate linear regression analysis. Relationships 
between ABCC2 -24C>T (rs717620) and ABCC2 3972C>T (rs3740066) with a lower TFV 
plasma:urine ratio (P = 0.186, β = -0.1; P = 0.112, β = -0.1; respectively) were also seen.. A 
trend was seen between longer time post dose for urine samples and a higher TFV 
plasma:urine ratio (P = 0.036, β = 0.0). Figure 3.3 shows all genetic associations found to be 
linked through univariate linear regression analysis, however these relationships were not 
seen to be significant within multivariate regression analysis. 
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3.3.4 Significant associations from multivariate analysis 
Statistically significant univariate and multivariate regression analysis results for TFV plasma 
and urine concentrations and plasma to urine ratio are presented in Table 3.2. ABCG2 
421C>A (rs2231142) was significantly associated with lower log10 TFV plasma (P = 0.030, β = 
-0.2) and log10 TFV urine (P = 0.010, β = -0.3) concentrations. No other genetic associations 
were observed. Increasing age was significantly associated with a higher log10 TFV plasma 
concentration (P = 0.037, β = 0.0). Co-medication of TFV with EVG/COBI was significantly 
associated with lower TFV plasma to urine ratio (P = 0.005, β = -0.2) when compared to co-
medication with RAL. Time post-dose was significantly associated with higher TFV plasma to 
urine ratio (P = 0.010, β = 0.0). 
 
TFV plasma and urine concentrations are summarised by significantly associated SNP in Table 
3.3 and visually represented in Figure 3.4. TFV plasma concentration was 31.9% lower in 
heterozygous ABCG2 421 CA patients compared to those who were homozygous CC. TFV 
urine concentration was 40.0% lower in ABCG2 421 CA patients compared to patients who 
were homozygous CC. 
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Figure 3.1: Non-significant association for TFV plasma concentration. 
Graphs A-G: Non-significant relationships between SNPs and TFV plasma concentration. Graph H: Non-significant relationship between co-medication prescribed with TDF and TFV plasma 
concentration. Graph I: Non-significant relationship between gender and TFV plasma concentration. Data points represent the mean ± SD   
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Figure 3.2: Non-significant association for TFV urine concentration.  
Graphs A-F: Non-significant relationships between SNPs and TFV urine concentration. Graph G: Non-significant relationship between gender and TFV urine concentration. Graph H: Non-
significant relationship between co-medication prescribed with TDF and TFV urine concentration. Data points represent the mean ± SD   
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Figure 3.3: Relationships between TFV plasma or urine concentrations and genetic variants or patient characteristics from univariate analysis. 
Graphs A-B: Relationship between SNPs and TFV plama:urine ratio. Graph C: Relationship between SNP and TFV urine concentration. All relationships found to be significant (P ≤ 0.2) through 
univariate linear regression analysis only. Data points represent the mean ± SD 
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Figure 3.4: Statistically significant associations for tenofovir plasma and urine concentrations through multivariate regression analysis. 
Graph A: Significant relationship between SNP and TFV plasma concentration. Graph B: Significant relationship between SNP and TFV urine concentration. 
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Table 3.2: Statistically significant results through multivariate linear regression.  
TFV plasma concentration (log10 ng/mL) Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.146 0.0 (0.0,0.0) 0.0 0.037 0.0 (0.0,0.0) 0.2 
Ethnicity compared to white patients: 
 Asian 
 Other 
 
0.152 
0.104 
 
0.2 (-0.1,0.5) 
-0.3 (-0.6,0.1) 
 
0.1 
0.1 
 
 
0.037 
 
 
-0.4 (-0.7,0.0) 
 
 
0.2 
ABCG2 421C>A (rs2231142) 0.097 -0.2 (-0.3,0.0) 0.1 0.030 -0.2 (-0.4,0.0) 0.2 
TFV urine concentration (log10 ng/mL) Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Height (cm) 0.221 0.0 (0.0,0.0) 0.0    
Treatment compared to combination with raltegravir: 
 Elvitegravir and cobicistat 
 
0.135 
 
-0.2 (-0.4,0.1) 
 
0.1 
   
Ethnicity compared to white patients: 
 Other 
 
0.142 
 
-0.3 (-0.8,0.1) 
 
0.1 
 
0.024 
 
-0.5 (-1.0,0.0) 
 
0.2 
Time post dose (hours.minutes) 0.175 0.0 (0.0,0.0) 0.0    
ABCC10 2843T>C (rs2125739) 0.136 0.1 (0.0,0.3) 0.0    
ABCG2 421C>A (rs2231142) 0.025 -0.3 (-0.5,0.0) 0.1 0.010 -0.3 (-0.6,-0.1) 0.2 
TFV plasma:urine ratio Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Treatment compared to combination with raltegravir: 
 Elvitegravir and cobicistat 
 
 
0.024 
 
 
-0.2 (-0.4,0.0) 
 
 
0.1 
 
 
0.005 
 
 
-0.2 (-0.4,0.1) 
 
 
0.3 
Ethnicity compared to white patients: 
 Black 
 
0.105 
 
0.4 (-0.1,0.9) 
 
0.1 
   
Time post dose blood (hours.minutes) 0.035 0.0 (0.0,0.0) 0.1 0.010 0.0 (0.0,0.0) 0.3 
Time post dose urine (hours.minutes) 0.036 0.0 (0.0,0.0) 0.1    
ABCC2 -24C>T (rs717620) 0.186 -0.1 (-0.3,0.1) 0.0    
ABCC2 3972 C>T (rs3740066) 0.112 -0.1 (-0.2,0.0) 0.0    
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Univariate linear regression (P ≤ 0.2) completed, all statistically significant results then carried through to multivariate linear regression analysis (P ≤ 0.05). Statistically significant associations 
from the multivariate analysis are shown in bold type.  
 
 
Table 3.3: TFV concentrations, summarised by ABCG2 421C>A genotype. 
  ABCG2 421C>A (rs2231142) Percentage difference between 
genotypes (%) CC  CA AA 
TFV plasma concentration (ng/mL) 43.53 (28.1-73.4) 29.65 (19.2-54.1) - 31.9 
TFV urine concentration (ng/mL) 22662.91(15677.5-48910.2) 13601.97 (9890.6-21730.9) - 40.0 
All values shown as median (IQR) 
 
 
 
84 
 
3.4 DISCUSSION 
 
Through this secondary analysis, we studied SNPs previously associated with TFV excretion 
and TDF metabolism, with the aim of further elucidating the contribution genetics has to 
inter-patient variability in TFV concentrations and determining if these SNPs were an 
indicator of variable plasma/urine TFV concentrations. 
 
The primary finding was the association of ABCG2 421C>A (rs2231142) with lower log10 TFV 
plasma (P = 0.030, β = -0.2) and log10 TFV urine (P = 0.010, β = -0.3) concentrations. ABCG2 
421C>A is a missense variant that has previously been linked with loss of BCRP function. It 
has been shown that TDF but not TFV is a dual substrate of P-gp and BCRP (Neumanova 2014, 
Wen 2015, Roberts 2016). As TDF is broken down to TFV by esterases in intestinal tissue, 
ABCG2 421C>A may potentially alter TDF transport in the small intestine resulting in reduced 
break down to TFV and thus reduced TFV plasma and urine concentrations.  
 
The lack of significant associations between SNPs in transporters and TFV excretion that have 
previously been associated with TFV-associated renal dysfunction, may suggest that TFV 
plasma concentrations may be a minor contributor to TFV toxicity compared to other genetic 
and environmental factors such as age, weight and renal function (Moss 2014). A previous 
study also found no association between multiple ABCC2 and ABCC4 SNPs and TFV AUC, but 
did observe an association of ABCG2 421C>A (rs2231142) with a 1.51 fold increase in TFV 
AUC for variant allele carriers of ABCG2 421C>A (Baxi 2017). The contradictory nature of our 
findings in relation to this study suggests that the observed ABCG2 421C>A (rs2231142) 
association may in part be due to SNPs not included within either study, which are in linkage 
disequilibrium with ABCG2 421C>A. Differences in patient ethnicity between the two study 
groups further complicates the picture as our study consisted of a majority Caucasian cohort 
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whilst Baxi et al.’s study contained predominantly African American patients (Baxi 2017).  The 
prevalence of different genotypes for SNPs in linkage disequilibrium with one another would 
differ between ethnicity populations, making the SNPs contributing to the phenotype 
difficult to decipher. Further studies are required in different ethnicity populations, looking 
at a range of pharmacokinetic parameters, in order to understand the impact of ABCG2 
421C>A (rs2231142) on TFV plasma and urine concentrations. 
 
A second pro-drug of TFV, TAF, has an alternative activation mechanism to TDF (Birkus 2016). 
Use of TAF is associated with lower plasma TFV concentrations, and therefore reduced 
incidence of kidney toxicity, in comparison to TDF. This is most likely because efficacy is 
achieved with a much lower dose (Ray 2016). In light of this, the ABCG2 421C>A association 
observed within this study is not anticipated to significantly alter TFV plasma and urine 
concentrations within patients receiving TAF. However, given that TAF is a substrate of BCRP 
(GileadSciences 2016), it would be anticipated that the ABCG2 421C>A SNP would alter TAF 
transport. Further study is required to confirm the mechanism of this interaction and the 
potential ramifications this may have for TAF pharmacokinetics.  
 
In addition to genetics, other factors including age and weight have previously been 
associated with alterations in TFV plasma and urine concentrations (Baheti 2013, Baxi 2014, 
Rungtivasuwan 2015). Age was found to be significantly associated with an elevated log10 TFV 
plasma concentration (P = 0.037, β = 0.0), and this could be due to the decline in renal 
function that is linked to increasing age, resulting in reduced excretion of TFV (Coresh 2003). 
 
Co-medication of TFV with EVG/COBI was associated with lower TFV plasma to urine ratio (P 
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= 0.005, β = -0.2) when compared to co-medication with RAL. COBI has previously been 
shown in vitro to inhibit P-gp and BCRP, to a degree suggested to be clinically relevant for the 
intestine. This resulted in increased absorption of co-administered transporter substrates, 
(Lepist 2012) further suggesting that a reduction in TFV plasma concentration may be linked 
to a reduction in function of BCRP, within the small intestine. Furthermore, through in vitro 
study it has been demonstrated that COBI does not significantly inhibit TFV transport by 
OAT1, OAT3 or MRP4. A combination of COBI with EVG or FTC did not affect the sensitivity 
of TFV to primary renal PTCs indicating a low potential for a pharmacokinetic renal drug-drug 
interaction between COBI and TFV (Stray 2013).  
 
Through this study an association with ABCG2 421C>A and TFV plasma and urine 
concentrations was observed, further building knowledge of the contributory effect of SNPs 
on inter-patient variability in TFV concentrations. Furthermore, a lack of significance of SNPs 
previously associated with TFV-associated renal toxicity as indicators of plasma or urine TFV 
concentrations was demonstrated. Further study of the mechanism of interaction between 
ABCG2 and TFV, and the subsequent effect on TFV pharmacokinetics, is imperative given the 
frequency of use of TFV and the potential impact reduced TFV plasma concentrations could 
have for achieving a sustained virological response in patients.  
 
3.4.1 Limitations 
A limitation of our study is the low numbers of Black, Asian and mixed-race participants. 
Population numbers for these ethnicities were not large enough to enable robust statistical 
associations to be determined for each ethnicity independently. Consideration of ethnicity 
within the study population is of critical importance given the difference in frequency of SNPs 
 
 
87 
 
between ethnicities. The ABCG2 421C>A variant allele is found at a frequency of 9.4% in 
European populations, 1.3% in African populations, 29.1% in East Asian populations and 9.7% 
in South Asian populations as studied in the 1000 Genome Project 
(GenomesProjectConsortium 2015). Given that the observed differences in genotype 
frequencies between the populations included is high, these data require validation in other 
patient cohorts to ensure the observations are not influenced by stratification.  Furthermore 
our study would benefit from a larger total patient cohort, given that the frequency of variant 
alleles for some SNPs were low or absent, as shown in Table 3.1. This was seen for ABCG2 
421C>A were a homozygous variant genotype was not observed within our total population.  
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Chapter 4: The Development of 
an Overexpressing MATE1 or 
MATE2K Transporter Cell Line
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4.1 INTRODUCTION 
 
Drug transporters are known to play a significant role in the absorption, distribution, 
metabolism and elimination of drugs. Any alteration in their ability to transport substrates 
can result in changes in pharmacokinetics, drug accumulation, loss of efficacy, toxicity or 
drug-drug interactions.  The MATE 1 and 2K transporters are members of the solute carrier 
(SLC) superfamily and have previously been identified as H+ coupled organic cation exporters 
(Otsuka 2005, Masuda 2006). MATE1 is predominantly expressed on the brush border 
membrane of PTCs within the kidney, and the canalicular membrane of hepatocytes (Otsuka 
2005, Damme 2011). MATE2K is expressed almost exclusively on the brush border 
membrane of PTCs (Otsuka 2005, Tanihara 2007). Within PTCs MATE1 and MATE2K act as 
proton/cation antiporters transporting cationic endogenous substrates and xenobiotics from 
the blood into the lumen where they are excreted in the urine (Moss 2014). This transport 
occurs through utilisation of a proton gradient to enable substrate efflux (Figure 4.1). 
 
In terms of substrate affinity, most substrates have demonstrated comparable affinities for 
both MATE1 and MATE2K. However, some exceptions are observed, such as in the case of 
metformin which has a higher affinity for MATE1, and oxaliplatin which has been shown to 
be preferentially transported by MATE2K (Damme 2011).  Metformin is a first line type 2 
diabetes drug that is well characterised as a substrate for both MATE1 and MATE2K (Masuda 
2006, Tanihara 2007, Elsby 2017, Zhang 2017). Creatinine is a renal biomarker previously 
shown to be a substrate of both MATE1 and MATE2K within PTCs (Tanihara 2007).  
 
Transfection of immortalised cell lines with foreign nucleic acids can be stable or transient. 
Transient transfection results in the short term expression of the nucleic acid of interest and 
does not incorporate the nucleic acid into the host cell genome (Yin 2005). As a result of this, 
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the nucleic acid is not passed on through generations and so is lost through cell division. 
Nevertheless transient transfection results in high levels of plasmid nucleic acid within the 
cell and thus results in high expression of encoded protein (Schlaeger 1998). The key 
difference between stable transfection and transient transfection is that stable transfection 
incorporates the plasmid nucleic acid into the host genome and therefore passes the foreign 
DNA to subsequent generations. This result is obtained by transiently transfecting cells 
before exposing the cell culture to a suitable antibiotic. Incorporating a gene encoding for 
antibiotic resistance into the DNA construct to be transfected means that cells that have 
incorporated the foreign DNA into their genome are resistant to the antibiotic, and so survive 
within long-term cultures. Advantages of transient transfection over stable transfection are 
that production of plasmid overexpressing cell lines is quicker, cheaper and more 
straightforward. However, the production of stably transfected cell lines provides cell lines 
suitable for large scale and long-term study.  
 
Regardless of whether transfection is to be transient or stable, successful integration of the 
foreign nucleic acid into the cells is essential. This can be achieved through multiple methods 
as described by Gao et al (Gao 2007). Our chosen method was cationic lipid transfection. 
Cationic lipid transfection enables high efficiency transfection and is suitable for transfection 
of DNA and ribonucleic acid (RNA) of all sizes within a wide range of cell lines (Gao 2007). 
Cationic lipid transfection works through cationic lipids forming a complex with the foreign 
nucleic acid known as a lipoplex (Chesnoy 2000, Gao 2007). DNA in lipolexes are protected 
from nuclease degradation. The positive surface charge of the lipids mediates an interaction 
between the nucleic acid and the cell membrane, enabling the lipoplex to enter the cell by 
endocytosis (Chesnoy 2000, Gao 2007). The DNA then dissociates from the lipid complex, 
before entering lysosomal compartments, and enters the nucleus where it is expressed 
(Chesnoy 2000, Gao 2007).  We sought to develop a transiently transfected cell line 
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overexpressing either the MATE1 or MATE2K transporter with the final aim of studying drug-
drug interactions between TAF or TFV and known substrates of MATE1 and MATE2K. 
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Figure 4.1: Mechanism of substrate transport by MATE transporters in vitro and in vivo. 
Substrate transport through secondary active transport utilising an H
+
 pump mechanism via the antiporters MATE1 or MATE2K.  
A) Accumulation of substrate in HEK293 cells transfected with the MATE1 or MATE2K transporter. B) Mechanism of substrate efflux via MATE1 or MATE2K in proximal tubule cells 
within the kidney.  
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4.2 METHODS 
 
4.2.1 Materials 
pEZ-M01 vectors containing MATE1 (SLC47A1), MATE2K (SLC47A2), or green fluorescent 
protein (GFP) encoding DNA were purchased from GeneCopoeiaTM (Rockville, MD). 
Escherichia coli (E.coli) DH5α cells, super optimal culture (S.O.C) medium, Gel loading buffer 
II, Tris-Borate-EDTA (TBE) buffer, Lipofectamine 3000 transfection kit, OptiMEM media, 
Nunclon Delta Surface 24 well plates, SYTOX Red Dead cell stain, PierceTM BCA Protein Assay 
Kit, NuPAGETM LDS Sample Buffer (4X), NuPAGETM Sample Reducing agent (10X), NuPAGETM 
4-12% Bis-Tris Protein Gels 1.5mm 10 wells, NuPAGETM MOPS SDS Running Buffer (20X), 
Nitrocellulose membranes and ECL western blotting substrate, were obtained from 
ThermoFisher Scientific (Wilmington, DE). GenElute Plasmid mini-prep kit, Fetal Bovine 
Serum (FBS), Lysogeny broth (LB) powder, Dulbecco’s Modified Eagle’s Medium (DMEM), 
Hanks Balanced Salt Solution (HBSS), Molecular Biology Grade Water, Poly-L-lysine solution, 
Phosphate Buffered Saline (PBS), RIPA buffer, Triton X-100 and protease inhibitor cocktail 
were purchased from Sigma Aldrich (Dorset, UK). A 1 kilobase DNA ladder and the restriction 
enzyme StuI were obtained from New England BioLabs (Beverly, MA). Radiolabeled 
metformin (14C metformin) and radiolabeled creatinine (14C creatinine) was purchased from 
American Radiolabeled Chemicals (St Louis, MO). HEK293 cells were purchased from ATCC-
LGC (Middlesex, UK). Precision Plus ProteinTM KaleidoscopeTM pre-stained protein standard 
was purchased from BioRad (Watford, UK). Rabbit polyclonal antihuman SLC47A1 antibody, 
Goat polyclonal antihuman SLC47A2 antibody, Mouse monoclonal antihuman beta actin 
antibody, Donkey polyclonal anti-goat IgG heavy and light chain horse radish peroxidase 
(HRP) antibody, goat polyclonal anti-rabbit IgG heavy and light chain HRP antibody and goat 
polyclonal anti-mouse IgG1 heavy chain HRP antibody were purchased from Abcam 
(Cambridge, UK). 
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4.2.2 Transfection of E. coli DH5α cells and colony isolation 
All plasmids contained a His-tag a region encoding for ampicillin resistance. In order to 
transfect the E. coli cells with the MATE1 (SLC47A1), MATE2K (SLC47A2) or GFP encoding 
vectors the following procedure was conducted. 50 μL of E. coli DH5α cells were mixed with 
2.5 μL of each plasmid solution and kept at -20 °C for 30 minutes before heat shock at 42 °C 
for 45 seconds, followed by incubation at -20 °C for 2 minutes. 500 μL of 37 °C S.O.C medium 
was then added before incubation at 37 °C, 250 rpm, for 45 minutes. The E. coli cells were 
then plated onto LB agar and ampicillin (100 μg/mL) containing plates and incubated at 37 
°C for 14-18 hours.  
 
Individual colony isolation was then conducted through the removal of individual colonies 
from the plates before incubation in LB and ampicillin (50 μg/mL) at 37 °C, 250 rpm, for 14-
18 hours. After this time cells were stored at -80 °C. Cells were prepared for storage at -80 °C 
through a five times dilution with glycerol and molecular biology grade water prepared in a 
50:50 ratio.  
 
4.2.3 Plasmid DNA extraction and PCR 
To ensure the correct plasmid was transfected into each E. coli cell colony, StuI digestion was 
completed. Plasmid DNA was isolated from the transfected E. coli cells and a PCR was 
conducted with the restriction enzyme StuI. This digestive enzyme experiment was 
conducted to ensure each cell colony was transfected with the correct plasmid and that the 
MATE DNA localisation and position were as expected, based on the manufacturers 
information provided in the GeneCopoeiaTM SLC47A1, SLC47A2 and GFP plasmid data sheets. 
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Transfected E. coli DH5α cells were thawed and cultured for 14-18 hours at 37 °C, 250 rpm, 
in LB and ampicillin (50 μg/mL). Plasmid DNA was then extracted using a GenElute plasmid 
mini-prep kit following the user guide provided. In brief, this included harvesting cells 
through centrifugation at 12,000 × g for 1 minute and resuspension in 200 μL of Resuspension 
Solution before lysing cells with 200 μL of Lysis Solution for 5 minutes. Cell lysis was stopped 
through precipitating the cell debris in 350 μL of Neutralisation/Binding Solution. The 
solution was then centrifuged at 12,000 × g for 10 minutes. The supernatant fraction was 
removed and carried into a Miniprep Binding Column placed within a collection tube which 
had been prepped with 500 μL of Column Preparation Solution and spun at 12,000 × g for 1 
minute with the flow-through discarded. The supernatant fraction and binding column were 
then centrifuged at 12,000 × g for 1 minute, the flow-through was discarded and 500 μL of 
Optional Wash Solution was added before centrifugation at 12,000 × g for 1 minute. The 
flow-through was discarded and two washes with 750 μL of Wash Solution followed by 
centrifugation at 2,000 × g for 1 minute was completed. The column was then centrifuged at 
12,000 × g for 2 minutes in isolation to ensure the removal of excess ethanol. The column 
was transferred to a fresh collection tube and 50 μL of Elution Solution was added to the 
column followed by centrifugation at 12,000 × g for 1 minute. The DNA concentration was 
then quantified using NanoDrop (ThermoFisher Scientific, Wilmington, DE). The DNA was 
then stored at -20 °C. 
 
A PCR was completed using the extracted plasmid DNA and the StuI restriction enzyme. 1 μg 
of plasmid DNA, 5 μL of buffer, 2 μL of enzyme and 3 μL of molecular biology grade water 
were combined and PCR was conducted. The PCR protocol included 90 minutes at 37 °C 
followed by 20 minutes at 80 °C and was completed on a GeneAmp PCR9700 machine 
(Thermo Fisher Scientific, Wilmington, DE). The StuI restriction enzyme cleavage sites for 
each plasmid are detailed in Figure 4.2. After PCR, gel electrophoresis was conducted using 
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a 0.75% agarose gel. The gel was produced by dissolving 375 mg of agarose in 50 mL of (1X) 
TBE buffer in a microwave followed by the addition of 30 μL of ethidium bromide (0.5 μg/mL). 
The gel was then poured and left to set. 2 μL of gel loading buffer II was added to 8 μL of each 
DNA sample. 10 μL of each sample was then loaded into the wells of the set gel alongside 2 
μL of a 1 kilobase DNA ladder. The gel was then immersed in (1X) TBE buffer and run at a 
constant voltage of 100 volts (V) for 20 minutes. The gel was then examined using a UV light 
box attached to a backlight camera. 
 
4.2.4 Cell culture  
HEK293 cells were stored in liquid nitrogen at -196 °C, before being thawed and grown in 
10% FBS DMEM containing media at 37 °C, 5% CO2 for 72 hours.  Once cells achieved 90% 
confluence, a 1 in 3 dilution was completed. The flask was washed with HBSS solution and 
incubated with trypsin for 5 minutes at 37 °C, 5% CO2. DMEM was then added in a 1:1 ratio 
with the trypsin, the solution was then centrifuged at 600 × g for 5 minutes. The supernatant 
fraction was removed, and the cell pellet was resuspended in DMEM. 1 mL of cell solution 
was then added to a new flask containing DMEM. Cells were then incubated at 37 °C, 5% CO2 
to 90% confluence. A 100 μL aliquot of cell solution was taken and a cell count completed 
with a Nucleocounter (Chemometec, Denmark). 200,000 cells in 1 mL of DMEM per well was 
then plated onto a sterile Nunclon Delta Surface 24 well plate and incubated for 24 hours at 
37 °C, 5% CO2. Prior to the addition of cells, the Nunclon Delta 24 well plate was treated with 
250 μL of poly-L-lysine solution per well and incubated at 37 °C, 5% CO2 for 3 hours. The poly-
L-lysine was then aspirated and the plates where left for 1 hour to dry at 37 °C, 5% CO2.  
 
4.2.5 Protein lysate preparation and bicinchoninic acid (BCA) protein assay 
Two hundred thousand HEK293 cells per well were plated onto a Nunclon Delta 24 well plate 
as described in Chapter 4, Section 4.2.4 and incubated at 37 °C, 5% CO2 for 24 hours. The cells 
 
 
 97 
were transfected with either MATE1 or MATE2K plasmid DNA using a Lipofectamine 3000 
reagent kit and OptiMEM media using the manufacture protocol. This briefly consisted of 
combining per well of the 24 well plate a 1.5% or 3% of total volume Lipofectamine 3000 
reagent solution with 25 μL of OptiMEM medium. Alongside this 25 μL of OptiMEM medium, 
4% of total volume P3000 reagent and 0.5-5 μg/μL of plasmid DNA were also combined. The 
two solutions were then combined and incubated for 5 minutes at room temperature before 
50 μL of the final solution was added to each well of the plate. Cells were then incubated for 
72 hours at 37 °C, 5% CO2. 
 
After this incubation period, protein lysate preparation was conducted. The cell culture plate 
was washed with 250 μL per well of ice cold PBS (0.01 M), the PBS was then aspirated and 
250 μL of trypsin was added to each well before incubation for 10 minutes at 37 °C, 5% CO2. 
250 μL of PBS was then added to each well and the cell solution was centrifuged for 5 minutes 
at 600 × g. The supernatant was removed, and the cell pellet was resuspended in 2 mL of ice-
cold NP-40 lysis buffer and 400 μL of protease inhibitor cocktail. NP-40 buffer was made in 
house using sodium chloride (NaCl) (150 mM), 20 mL of 1% Triton X-100 and 50 mM Tris 
base. The cell solution was then incubated at 4 °C for 30 minutes on an oscillating table before 
centrifugation at 4 °C, 12,000 × g for 20 minutes.  
 
A BCA assay was completed to determine the protein concentration from each of the samples 
using a set of BCA protein standards prepared following the manufactures protocol provided 
with the PierceTM BCA protein assay kit. A set of diluted albumin standards was prepared in a 
range of concentrations from 25-2000 μg/mL. Working reagent was then prepared in a 50:1 
ratio of reagent A:B. 100 μL of each standard and protein sample was added to 2 mL of 
working reagent and vortexed before incubation for 30 minutes at 37 °C. All solutions were 
then cooled to room temperature and absorbance at 562 nm, for all samples and standards, 
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before measurement on a spectrophotometer within 10 minutes. Values were normalised 
through subtraction of the absorbance reading for a blank sample. A standard curve was 
prepared by plotting the average blank-corrected 562 nm measurement for each BSA 
standard vs its concentration (μg/mL). This standard curve was then used to calculate the 
protein concentration of the samples from their corresponding 562 nm absorbance 
measurement. The total protein concentration for the MATE1, MATE2K, or control samples 
was determined through use of the TREND function on Microsoft Excel 2010 that utilises the 
following formula: 
 
𝑇𝑅𝐸𝑁𝐷(𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒, [𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑𝑠], [𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠], [𝑐𝑜𝑛𝑠𝑡 = 0]) 
 
4.2.6 Western blot analysis 
384.6 μL of NuPAGETM sample buffer, 153.84 μL of NuPAGETM reducing agent and 1 mL of 
protein lysate was combined and incubated at 95 °C for 10 minutes. Each solution was then 
sonicated for 10 seconds. A gel electrophoresis tank was assembled containing a NuPAGETM 
4-12% Bis-Tris 1.5 mm protein gel and was filled with a 1:20 dilution of MOPS running buffer 
in distilled water. 20 μL of protein lysate solution and 10 μL of a pre-stained protein standard 
ladder with a molecular weight range of 10-250 kD was loaded onto the gel. Gels were run 
for 3 hours with an electrical current of 100 V. Once gel electrophoresis was complete the 
gel was removed from the gel cassette and washed in transfer buffer made up of 14.4 g 
glycine, 3.0 g tris base, 80 mL deionised water and 200 mL methanol. 
 
A gel transfer onto a nitrocellulose membrane was then conducted with a continuous 
electrical current of 60 V for 1 hour at 4 °C. All components were submerged in transfer buffer 
throughout the gel transfer. Subsequently, nitrocellulose membrane blocking was completed 
through incubation of the membrane with 5% no fat milk powder/ 0.1% TBST, for 2 hours at 
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room temperature on an oscillating table. TBST consisted of 50 mL of TBS (20X) (TBS solution 
made up of 175.2 g NaCl, 4.4 g potassium chloride (KCl), 60.5 g Tris base, and 1 L of deionised 
water) 1 mL of TWEEN detergent and 949 mL deionised water. The membrane was then 
washed 4 times for 5 minutes per wash with TBST before incubation with 100 μL of rabbit 
polyclonal anti-SLC47A1 antibody or 10 μL of goat polyclonal anti-SLC47A2 antibody in 20 mL 
5% no fat milk powder/ 0.1% TBST for 14 hours at 4 °C on an oscillating table.  
 
Once primary antibody incubation was complete the membrane was washed 4 times for 5 
minutes per wash with TBST and then incubated for MATE1 with 5 μL of goat anti-Rabbit HRP 
antibody and for MATE2K with 2 μL of donkey anti-goat HRP antibody in 20 mL 5% no fat milk 
powder/ 0.1% TBST for 90 minutes at 4 °C on an oscillating table. After secondary antibody 
incubation, the membrane was washed 3 times for 5 minutes with TBST and once for 5 
minutes with TBS. Signal development was conducted using ECL, which was prepared 
according to the manufactures protocol by mixing reagents 1 and 2 in a 1:1 ratio. The mixture 
was then added to the membrane and incubated for 1 minute. Excess reagent was drained 
and the membrane was covered with clear plastic wrap and stored in an x-ray cassette. Under 
zero light conditions the membrane was exposed to x-ray film in the closed cassette for 2 
minutes. The film was washed in developer until protein bands appeared and then 
submerged in fixer for 1 minute before being rinsed in water.  
 
The nitrocellulose membrane was stripped of bound antibodies through washing with TBST 
for 5 minutes followed by two 10-minute washes with stripping buffer, all of which were 
completed on an oscillating table. Stripping buffer was made up of 15 g glycine, 1 g SDS, 10 
mL TWEEN detergent, 1 L deionised water, with pH adjusted to 2.2 using hydrochloric acid (1 
M) or sodium hydroxide (NaOH) (1 M). The membrane was washed twice with TBS for 10 
minutes on an oscillating table followed by two washes with TBST for 10 minutes each.  
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The membrane was then blocked with 5% no fat milk powder/0.1% TBST for 2 hours at room 
temperature on an oscillating table. Primary antibody incubation was completed with 0.1 μL 
of anti-beta actin antibody in 40 mL 5% no fat milk powder/ 0.1% TBST for 2 hours at 4 °C on 
an oscillating table. The membrane then underwent 4 times 5-minute washes with TBST on 
an oscillating table. Secondary antibody incubation was completed using 2 μL of goat anti-
mouse HRP antibody in 20 mL 5% no fat milk powder/ 0.1% TBST for 90 minutes at 4 °C on 
an oscillating table. The membrane was washed 3 times for 5 minutes with TBST and once 
for 5 minutes with TBS. Signal development was completed as described above.  
 
4.2.7 Viability assay 
Cells were plated at 200,000 cells per well in a 24 well Nunclon Delta plate and transfected 
24 hours later with either MATE1 or MATE2K plasmid DNA using the protocol stated 
previously in Chapter 4 (Section 4.2.4 and Section 4.2.5). The MTT assay was completed after 
2, 3, 4 and 6 days of incubation post transfection. 100 μL of thiazolyl blue tetrazolium (12 
mM) was added to each well. Cells were incubated for 2 hours at 37 °C, 5% CO2. After 2 hours 
100 μL of lysis buffer (50% v/v dimethylformahyde, 20% v/v sodium dodecyl sulphate) was 
added to each well and incubated for 14 hours at 37 °C, 5% CO2. The absorbance from each 
well was then measured at 570 nm on a GENios microplate reader (TECAN, Austria). Cell 
viability was calculated as a percentage of the reading of the untreated HEK293 cells, 
normalised from the absorbance reading of the blank wells on the plate. 
 
4.2.8 Control cell line transient transfection 
As a control for plasmid transfection of the HEK293 cells, GFP expressing plasmid was 
transfected into HEK293 cells under varied conditions. A 24 well Nunclon Delta plate 
containing 200,000 HEK293 cells and 1 mL of DMEM per well, set up as previously described 
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(Section 4.2.4), was transfected after 24 hours incubation 37 °C, 5% CO2. Transfection of the 
GFP expressing plasmid DNA into the plated HEK293 cells was completed using a 
Lipofectamine 3000 reagent kit as previously outlined (Section 4.2.5). GFP fluorescence was 
measured at 48 hours post-transfection. Cell viability was measured using a Red Dead Cell 
Cytotoxicity Stain. This was conducted through incubation with 1 mL of trypsin for 10 minutes 
followed by 1 mL of 10% FBS/ DMEM media being added to the cell solution before 
centrifugation at 600 × g for 5 minutes. 1 mL of cell suspension was then added to a flow 
cytometer tube alongside 1 μL of Red Dead Cell Cytotoxicity Cell Stain. The solution was 
incubated for 15 minutes before measurement on a Macs Quant Analyser (MacQuantify 
version 2.6). GFP fluorescence was measured in channel B1 using dye FITC-A. Cell viability 
was measured using the AlexaFluoro 6 dye, which only crosses over dead cell membranes, 
fluorescence was measured in channel R1 using the APC dye. 
 
4.2.9 Uptake of 14C  metformin in MATE1 or MATE2K expressing cell lines 
To ascertain the correct functionality of the transporters within the transfected cell lines, we 
studied the accumulation of 14C metformin within the MATE1 and MATE2K transfected cell 
lines. A 24 well Nunclon Delta plate containing 200,000 HEK293 cells and 1 mL of DMEM per 
well, was set up as previously described (Section 4.2.4), before being transfected after a 24 
hour incubation at 37 °C, 5% CO2, using a Lipofectamine 3000 reagent kit as previously 
outlined (Section 4.2.5).  All cells were incubated at 37 °C, 5% CO2 for 72 hours before 
conducting the 14C metformin accumulation experiment. 
 
For the accumulation experiment, incubation media normalised to pH 7.4 using 1 M NaOH 
was prepared, containing 145 mM NaCl, 3 mM KCl, 1 mM calcium chloride (CaCl2), 0.5 mM 
magnesium chloride (MgCl2), 5 mM D-Glucose, 5 mM HEPES and distilled water. The 
transfected HEK293 cells were pre-incubated with 200 μL of incubation medium for 10 
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minutes at 37 °C, 5% CO2. Incubation medium was aspirated and for experiments including 
ammonium chloride incubation, plates were treated with 200 μL of 30 mM ammonium 
chloride per well before being incubated at 37 °C, 5% CO2 for 10 minutes. Each well was then 
incubated with 200 μL of 9.9 μM 14C metformin combined with incubation medium at either 
a pH of 7.4 or 8.4, at 37 °C, 5% CO2. Plates were then incubated for either 5, 15 or 30 minutes 
at 37 °C, 5% CO2. After this time a 100 μL sample was taken from each well and prepared for 
analysis with 4 mL of scintillation fluid. The remaining medium was then removed from each 
well and cells were washed rapidly three times with 1 mL of ice-cold incubation medium at 
pH 7.4. 500 μL of 0.5 M NaOH was then added to each well. Cells were incubated for 10 
minutes at 37 °C, 5% CO2. A second 100 μL aliquot was then taken from each well of the plate 
and prepared for analysis through the addition of 4 mL of scintillation fluid. The radioactivity 
of each sample was then analysed using a Tri-Carb scintillation counter and QuantaSmart™ 
software (DPM Solutions Ltd, Chesterfield, UK). Total cell volumes were calculated using the 
following equation:  
 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (µ𝐿) =
(𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝐻𝐸𝐾293 𝑐𝑒𝑙𝑙 (𝑝𝐿) × 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙)
1 × 106
 
 
The intracellular and extracellular concentration of radiolabeled drug was calculated using 
the following equation: 
𝐼𝑛𝑡𝑟𝑎 𝑜𝑟 𝐸𝑥𝑡𝑟𝑎 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑟𝑢𝑔 =
𝐼𝑛𝑡𝑟𝑎 𝑜𝑟 𝐸𝑥𝑡𝑟𝑎 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
𝐼𝑛𝑡𝑟𝑎 𝑜𝑟 𝑒𝑥𝑡𝑟𝑎 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
 
 
The cellular accumulation ratio (CAR) was then calculated using the following equation:  
𝐶𝐴𝑅 =
(𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
(𝑒𝑥𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛)
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4.2.10 Statistical analysis 
Normality was assessed using The Shapiro-Wilk Test, with P ≤ 0.05 considered as statistically 
significant.  An unpaired t-test was then used to analyse potential differences in 14C 
metformin accumulation and percentage cell viability between the control (untreated) and 
transfected HEK293 cells, with P ≤ 0.05 classed as significant. All statistical analyses and chart 
production were carried out using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).   
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4.3 RESULTS 
 
4.3.1 StuI restriction enzyme digest 
Figure 4.2 shows the restriction map of the pEZ-M01 vector containing either MATE1, 
MATE2K or GFP control DNA, and the StuI restriction sites within each of the vectors. 
Accompanying each is a virtual digest showing the results of a vector-containing insert in the 
correct orientation. Figure 4.3 is the output of StuI restriction enzyme cleavage for the 
colonies picked following the transformation of E. coli with the MATE1, MATE2K or GFP 
containing pEZ-M01 plasmids. As shown in Figure 4.3 for each plasmid type the band patterns 
matched the predicted digest shown in Figure 4.2 for each of the three colonies. The gel 
images confirm the correct presence and orientation of the desired transporter within each 
cell colony, with the exception of colony 2 for MATE1, which was thus excluded from the 
study.  
 
  
 
 
 
 
 105 
  
Figure 4.2: Restriction sites within the pEZ-M01 vector. 
Restriction site for StuI within the 1) MATE1 2) MATE2K 3) GFP expressing plasmids. Alongside a model gel 
image for a virtual digest of A) MATE1 B) MATE2K C) GFP by the StuI enzyme. 
1) 
2) 
3) 
A) 
B) 
C) 
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Figure 4.3: Restriction StuI enzyme digest of MATE1, MATE2K or GFP expressing plasmid DNA. 
Restriction enzyme digest output for 1) DNA from 4 colonies expressing MATE1 plasmid DNA 2) DNA from 4 colonies expressing MATE2K plasmid DNA 3) DNA from 4 colonies expressing GFP 
(control) plasmid DNA.  
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4.3.2 Cell viability and fluorescence assay  
Figure 4.4 shows the output for flow cytometry of HEK293 treated cells under three 
conditions:  
 Condition 1: HEK293 cells treated with 1.5% of total volume Lipofectamine 3000 
reagent solution and viability stained 
 Condition 2: HEK293 cells transfected with GFP plasmid DNA, treated with 1.5% of 
total volume Lipofectamine 3000 reagent solution and viability stained 
 Condition 3: HEK293 cells transfected with GFP plasmid DNA, treated with 3% of total 
volume Lipofectamine 3000 reagent solution and viability stained 
 
As shown in Figure 4.4 cells were initially gated to a population of 10,000 cells. As AlexaFluoro 
6 dye accumulates in dead cells the plot was gated to the cell population with a reading less 
than 1e1 absorbency unit (AU) for APC fluorescence. GFP production from this population 
can be seen in graph C for each condition. Cells expressing GFP less than 3e1 AU were 
excluded. As seen in Table 4.1 both Condition 2 and Condition 3 FITC-A dye fluorescence, 
measuring GFP fluorescence, was higher in both Condition 2 and 3, 934.8 AU and 919.1 AU 
respectively, than that seen in Condition 1 the control population, which produced a FITC-A 
dye fluorescence of 1.5 AU. These results confirm the expression of GFP plasmid DNA in the 
transfected HEK293 cells. 
 
A higher APC-A dye output, 2.7 AU was recorded for Condition 3, treatment with 3% of total 
volume Lipofectamine 3000 reagent solution, compared to Condition 1, 0.6 AU and Condition 
2 1.8 AU, treatment with a 1.5% of total volume Lipofectamine 3000 reagent solution. This 
indicated higher cell death in Condition 3. Given that use of 1.5% of total volume 
Lipofectamine 3000 reagent solution over 3% did not influence transfection success, with a 
negligible difference in FITC-A dye output of 934.1 AU for Condition 2 and 919.1 AU for 
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Condition 3, and that cell viability was higher in Condition 2, it was decided that all forward 
experiments would use a 1.5% of total volume Lipofectamine 3000 reagent.  
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Untreated HEK293 cells: 1.5% Lipofectamine 3000 reagent
  
 GFP expressing HEK293 cells: 1.5% Lipofectamine 3000 reagent:  
 
 GFP expressing HEK293 cells: 3% Lipofectamine 3000 reagent: 
 
Figure 4.4: Measurement of cell viability and GFP fluorescence from GFP expressing 
HEK293 cells. 
Graph A: Isolation of viable 10,000-cell population taken from total cell population. Graph B: AlexaFluoro 6 dye 
fluorescence, shown in the APC-A channel, in a gated 10,000-cell population, low fluorescence is indicative of 
healthy cells.  Graph C: FITC-A dye fluorescence from viable cell population gated from graph 2, a high 
fluorescence is indicative of greater GFP production.  
 
  
A) B) C) 
A) B) C) 
A) B) C) 
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Table 4.1: Dye outputs from flow cytometer for each experimental condition (AU). 
Condition FITC-A dye (AU) APC-A dye (AU) 
Untreated HEK293 cells:  
1.5% Lipofectamine solution 
1.47 0.64 
GFP plasmid transfected HEK293 cells: 
1.5% Lipofectamine solution 
934.84 1.81 
GFP plasmid transfected HEK293 cells: 
3% Lipofectamine solution 
919.09 2.74 
FITC-A dye output is a measure of GFP fluorescence. A higher FITC-A dye output indicates greater GFP production. 
APC-A dye represents AlexaFluoro 6 dye fluorescence. A higher APC-A dye output indicates lower cell viability.  
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4.3.3 BCA protein assay  
To produce protein lysate for western blot analysis, protein from MATE1 transfected, 
MATE2K transfected or HEK293 cells treated with Lipofectamine 3000 reagent but not 
transfected DNA (Control) was extracted and lysed. The concentration of lysed protein was 
determined through a BCA protein assay. As shown in Figure 4.5 the known concentrations 
of albumin standard were plotted against each concentrations absorbance at 562 nm, the 
concentrations of the MATE1 transfected, MATE2K transfected or Control protein samples 
where then calculated based on the samples absorbance at 562 nm. The concentration for 
the MATE1, MATE2K or control samples was found to be 1634 μg/mL, 1303 μg/mL, and 531 
μg/mL, respectively.  
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Figure 4.5: A concentration vs absorbance graph for diluted albumin standards of known 
concentrations. 
A set of albumin standards of known concentrations were prepared and plotted against absorbance at 562 nm, 
the concentration of sample protein was then determined through extrapolating the protein concentration from 
the absorbance reading at 562 nm for each sample. 
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4.3.4 Western blot analysis  
Once the total protein concentration within each of the samples was determined, a western 
blot analysis was conducted to establish the production of the protein of interest within the 
transfected HEK293 cells. Figure 4.6 shows the blots developed after staining with beta actin, 
anti-SLC47A1 (MATE1) or anti-SLC47A2 (MATE2K) antibodies. Beta actin was used as the 
loading control antibody. As shown in Figure 4.6 protein lysate from untreated HEK293 cells, 
transfected HEK293 cells overexpressing the MATE1 transporter or HEK293 cells 
overexpressing the MATE2K transporter produced protein bands for all 3 antibody stains. 
This confirms the successful production of the transporters of interest, MATE1 and MATE2K, 
within the transiently transfected HEK293 cell lines.  
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Figure 4.6: Western Blot membrane outputs after staining for MATE1, MATE2K or beta 
actin protein. 
Blots developed after staining with 1) beta actin antibody 2) anti-SLC47A1 (MATE1) antibody 3) anti-SLC47A2 
(MATE2K) antibody. Predicted band size for beta actin antibody= 45kDa, MATE1= 62kDa and MATE2K=65kDa 
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4.3.5 Accumulation of 14C metformin  
As substrate efflux via MATE1 and MATE2K is pH dependent, within the 14C metformin 
accumulation experiment the transport of substrates is reversed from that observed in vivo 
(Figure 4.1). This is completed through manipulation of extracellular and intracellular pH 
through incubating the cells with media at a controlled pH. Both MATE1 and MATE2K 
transfected HEK293 cells transport substrate into the cell from a more acidic extracellular pH 
to a less acidic intracellular pH via secondary active transport. In light of this, providing the 
transfected cells are functional, it would be expected that CAR within the transfected cells 
would be higher than within the control cells, which were HEK293 cells treated identically to 
the transfected HEK293s with the exception that they were not transfected with any type of 
vector DNA. 
 
In order to determine the best conditions in which to conduct the 14C metformin 
accumulation, several conditions were optimised: incubation with ammonium chloride 
containing media prior to incubation with radiolabeled drug, pH of the media containing 
radiolabeled drug and incubation time with radiolabeled drug.  
 
Incubation with ammonium chloride was trialed to determine if greater polarisation of 
extracellular to intracellular pH increased the level of CAR. In Figure 4.7 for MATE1 
transfected cells and in Figure 4.8 for MATE2K transfected cells, a 10-minute incubation with 
ammonium chloride prior to incubation with radiolabeled drug was shown to increase the 
CAR of 14C metformin within the HEK293 cells, compared to the cells not treated with 
ammonium chloride prior to incubation with 14C metformin. This mimicked that previously 
observed by Tanihara et al. (Tanihara 2007).  
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As seen in Figure 4.7 and 4.8 incubation with 14C metformin for 5 minutes produced a CAR 
that was observed to be statistically significant compared to control, for all conditions within 
MATE1 transfected cells and for MATE2K transfected cells incubated for 5 or 15 minutes at 
pH 7.4. As such, a 5-minute incubation with 14C metformin was completed for all experiments 
after this point. 
 
 In contrast to the results observed by Tanihara et al., comparison of the cells treated with 
14C metformin with media at pH 7.4 showed a greater difference in CAR between the 
transfected and untreated (control) cells, compared to those treated in media at pH 8.4, and 
so all future experiments used media at pH 7.4 exclusively (Tanihara 2007).  
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Figure 4.7: Cellular accumulation of 14C metformin in HEK293 cells overexpressing MATE1. 
Graph A: Accumulation at pH 7.4. Graph B: Cells incubated with ammonium chloride for 10 minutes prior to accumulation at pH 7.4. Graph C: Accumulation at pH 8.4. Graph D: Cells incubated 
with ammonium chloride for 10 minutes prior to accumulation at pH 8.4. Data points represents the mean ± SD, N = 3 
A) B) 
C) D) 
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Figure 4.8: Cellular accumulation of 14C metformin in HEK293 cells overexpressing MATE2K. 
Graph A: Accumulation at pH 7.4. Graph B: Cells incubated with ammonium chloride for 10 minutes prior to accumulation at pH 7.4. Graph C: Accumulation at pH 8.4. Graph D: Cells incubated 
with ammonium chloride for 10 minutes prior to accumulation at pH 8.4. Data points represents the mean ± SD, N = 3 
A) B) 
C) D) 
 
 
 119 
4.3.6 Cell viability assay  
To ensure that cell death was not accountable for any differences observed in CAR between 
the control and transfected cells, cell viability was measured through a MTT assay. As shown 
in Figure 4.9, for all conditions cell viability was lower in the cells incubated with transfection 
reagents for a longer length of time post incubation. Furthermore, viability was comparable 
between conditions for each of the incubation time points. Cell viability was observed to be 
greater than 80% compared to untreated HEK293 cells for incubation times of 2 or 3 days 
post transfection. Given that the manufacturer protocol for the Lipofectamine 3000 reagent 
recommended a 3-day incubation post transfection before experimentation, and that the 
MTT assay showed cell viability to be to an adequate level 3 days post transfection, it was 
decided that within all experiments going forward all cell conditions would be incubated for 
3 days post transfection prior to initiation of accumulation experiments. 
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Figure 4.9: Cell viability of HEK293 cells post transfection. 
Graph A: Cell viability for MATE1 plasmid DNA transfected HEK293 cells vs control cells. Graph B: Cell viability for MATE2K plasmid DNA transfected HEK293 cells vs control cells. Data points 
represents the mean ± SD, N = 6 
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4.4 DISCUSSION 
 
The HEK293 cell line was selected as it represents the site of interest, the proximal tubule, 
and is established in the literature as a reproducible cell line for transfection (Graham 1977, 
Baldi 2007, Tanihara 2007, Dietmair 2012). HEK293 cells have previously been shown to 
express low levels of endogenous transporters (Ahlin 2009). The human protein atlas has 
previously demonstrated that MATE1, but not MATE2K, protein coding genes are expressed 
within HEK293 cells, through the use of RNA-seq to measure the transcript abundance of 
SLC47A1 and SLC47A2 (Thul 2017). Additionally, stable transfection of HEK293s with 4 drug 
transporters did not alter endogenous gene expression of transporters to a significant degree 
(Ahlin 2009). However, endogenous gene expression must still be considered on a case by 
case basis. This indicates that changes in cell culture conditions, in order to facilitate 
transfection, do not significantly alter transporter expression on the HEK293 cell membrane. 
The exponential growth, amino acid production and consumption of HEK293 cells has been 
shown to be the same within untreated and transfected protein producing HEK293s 
(Dietmair 2012). However, glucose consumption and production differs between the two cell 
cultures (Dietmair 2012). Differential regulation of genes involved in several metabolic 
pathways including glycolysis and oxidative phosphorylation, is also observed between 
untreated and recombinant protein producing HEK293s (Dietmair 2012). 
 
HEK293 cell line transfection has been consistently utilised to study transporter morphology 
and function (Bai 1996, Bai 1997, Bai 1998, Otsuka 2005, Masuda 2006). Additionally, 
transfected HEK293s have been used to study numerous transporter-drug interactions 
(Tanihara 2007). As shown in the case of MATE1 and MATE2K and by Bai et al. who 
demonstrated the function, expression and morphology of the extracellular calcium-sensing 
receptor within transiently transfected HEK293 cells (Bai 1996, Bai 1997, Bai 1997, Bai 1998).  
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The transiently overexpressing MATE1 or MATE2K transporter cell lines described here could 
be used to study not only the interactions of TAF and TFV (See chapter 5) but also other drugs 
that may interact with these PTC transporters. This type of work has previously included the 
study of the inhibitory effect of the pharmacoenhancers COBI and RTV on creatinine 
transport by MATE1 (Lepist 2014). This interaction is of particular interest given that COBI 
may be prescribed as part of the single dose drug regimen STRIBILD, which also contains TDF, 
FTC and EVG. An elevation in creatinine concentration caused by inhibiting MATE1 could 
result in discontinuation of STRIBILD therapy, given that patients are already at increased risk 
of developing renal dysfunction when receiving a TDF-containing regimen. 
 
This study demonstrates the functionality of two transiently transfected HEK293 cell lines 
overexpressing either the MATE1 or the MATE2K transporter. These cell lines will be used 
to study the potential effect of TAF or TFV on the transport of metformin or creatinine by 
MATE1 and MATE2K.  
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Chapter 5: The Effect of 
Tenofovir Alafenamide and 
Tenofovir on the Transport of 
MATE1 and MATE2K Substrates 
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5.1 INTRODUCTION 
 
MATE1 and MATE2K are broad specificity proton/cation transporters studied in the kidney 
for a multitude of aims, including investigating multidrug resistance, drug-drug interactions 
and kidney toxicity (Tanihara 2007, Damme 2011, Lu 2016). Drug interactions with MATE 
transporters are wide ranging and have previously included ART, with the pharmacokinetic 
booster COBI inhibiting MATE1 and moderately inhibiting MATE2K (Tanihara 2007, Nies 
2011, German 2012, Gutierrez 2014). 
 
TAF has been shown to be a substrate of P-gp and BCRP within the small intestine and a 
substrate of the hepatic uptake transporters OATP1B1 and OATP1B3 
(EuropeanMedicinesAgency 2015). TAF is not an inducer of P-gp or UGT1A1 and is unlikely 
to activate PXR xenobiotic receptors (EuropeanMedicinesAgency 2015). Furthermore, TAF 
induces CYP isoenzymes at a concentration of 10 µM but not at a concentration of 1 µM 
(EuropeanMedicinesAgency 2015). TAF is a minimal inhibitor of the renal transporters OCT1 
and MATE1 but does not inhibit P-gp, BCRP, OAT1, OAT3 and OCT2 
(EuropeanMedicinesAgency 2015). TFV is not a substrate of either MATE1 or MATE2K 
(Tanihara 2007) and previous studies have shown TFV does not inhibit OCT2 or MATE1 
(EuropeanMedicinesAgency 2015). 
 
The type 2 diabetes drug metformin is a common co-medication for several diseases such as 
CKD and cardiovascular disease (Plantinga 2010, Jellinger 2012). Metformin has previously 
been highlighted as unsuitable for use in patients with renal dysfunction, a known side effect 
of TDF therapy (Munar 2007, Moss 2014). In light of this, potential drug-drug interactions 
between TAF and metformin are of interest, as the use of this agent is anticipated to increase 
through the prescription of PrEP and the licensing of TAF as an alternative to TDF.  
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Creatinine’s use as a biomarker for kidney dysfunction makes its efflux from PTCs a 
mechanism of interest, given that a diagnosis of renal impairment for HIV positive patients 
can result in discontinuation of TFV therapy in some circumstances (Röling 2006, Wyatt 
2007). A lack of specific biological markers for renal toxicity hinders early detection and 
intervention in drug associated renal toxicity. Therefore, further understanding the way in 
which antiretroviral drugs can interfere with the mechanism of active secretion of creatinine 
via PTCs is important not only in terms of drug development but also for the relevance of 
serum creatinine as a clinical biomarker for renal toxicity. Multiple drugs have been reported 
to alter eGFR filtration rate with minimal evidence of actual kidney damage (Berglund 1975, 
Van Acker 1992, German 2012, Lepist 2014). This includes DTG which inhibits OCT2, the influx 
transporter of creatinine into PTCs, resulting in increased levels of serum creatinine without 
altering kidney function (Koteff 2013).  
 
Cimetidine is a H2 receptor antagonist known to inhibit MATE1 and MATE2K, as such it is 
frequently used as a model inhibitor of these transporters within transporter interaction 
studies (van Acker 1992, Otsuka 2005, Tanihara 2007, Tsuda 2009, Ito 2012, Elsby 2017). 
Metformin transport by MATE1 and MATE2K has been shown to be inhibited by cimetidine 
in vitro (Tanihara 2007, Tsuda 2009, Ito 2012, Elsby 2017) and in vivo (Somogyi 1987, Wang 
2008). Furthermore, creatinine clearance is known to be influenced by cimetidine in vivo, 
with a reduction in creatinine clearance observed due to inhibition of tubular transport by 
cimetidine (van Acker 1992, Serdar 2001, Kabat-Koperska 2007). 
 
This chapter sought to determine the effect of TFV and its prodrug TAF on the transport of 
metformin and creatinine by the MATE1 and MATE2K transporters.  TDF and TAF release the 
active metabolite TFV through different metabolic pathways. TDF is rapidly metabolised in 
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plasma releasing TFV, whereas TAF is broken down by cathepsin A in peripheral blood 
mononuclear cells and carboxylesterase 1 in the liver (Birkus 2016). As such, renal exposure 
to TDF is minor and so the interaction of TDF with renal transporters was not included within 
this study. Inhibition of MATE1 or MATE2K by TAF or TFV has the potential to have 
ramifications beyond creatinine’s use as a renal biomarker and an increase in metformin 
pharmacokinetics. As drug interactions may alter exposure to concomitantly prescribed 
drugs, metabolites and endogenous compounds, resulting in unanticipated drug-drug 
interactions and potential toxicity (Chu 2016).  
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5.2 METHODS 
 
5.2.1 Materials 
Lipofectamine 3000 transfection kit, OptiMEM media, Nunclon Delta Surface 24 well plate, 
FBS, DMEM, HBSS, Molecular Biology Grade Water and Poly-L-lysine solution were purchased 
from Sigma Aldrich (Dorset, UK).   14C metformin and 14C creatinine were purchased from 
American Radiolabeled Chemicals (St Louis, MO). HEK293 cells were purchased from ATCC-
LGC (Middlesex, UK). TFV and TAF were purchased from FisherScientific (Leicestershire, UK). 
 
5.2.2 Cell culture  
HEK293 cells were cultured using the same method previously described in Chapter 4 
(Section 4.2.4). 
 
5.2.3 Viability assay 
Cell viability was assessed using the same protocol outlined in Chapter 4 (Section 4.2.7). 
 
5.2.4 Uptake of radiolabeled drug  
A 24 well Nunclon Delta plate containing 200,000 HEK293 cells and 1 mL of DMEM per well, 
set up as previously described in Chapter 4 (Section 4.2.4), was transfected after 24 hours 
incubation at 37 °C, 5% CO2, using a Lipofectamine 3000 reagent kit as previously outlined in 
Chapter 4 (Section 4.2.5). All cells were incubated at 37 °C, 5% CO2 for 72 hours before 
conducting the accumulation experiment. 
 
For the accumulation experiment, incubation media normalised to pH 7.4 using 1 M NaOH 
was prepared, containing 145 mM NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM D-
 
 
128 
 
 
glucose, 5 mM HEPES and distilled water. The transfected HEK293 cells were pre-incubated 
with 200 μL of incubation media for 10 minutes at 37 °C, 5% CO2. Incubation media was 
aspirated, and cells were treated with 200 μL of 30 mM ammonium chloride at 37 °C, 5% CO2 
for 10 minutes. Post ammonium chloride incubation, cells were incubated for 5 minutes with 
200 μL of 9.9 μM 14C metformin or 5 μM 14C creatinine combined with either 500 μM 
cimetidine, TAF or TFV at concentrations ranging from 3.3 nM to 33 μM at pH 7.4 at 37 °C, 
5% CO2. A 500 μM concentration of cimetidine was chosen due to previous demonstration 
of maximum inhibition of MATE1 and MATE2K at this concentration (Ito 2012). TAF and TFV 
concentration ranges were selected to produce a full log10 concentration response curve.  
 
After drug incubation, 100 μL of media was removed from each well and prepared for analysis 
within 4 mL of scintillation fluid. The remaining media was then removed from each well and 
cells were washed rapidly three times with 1 mL of ice-cold incubation medium at pH 7.4. 
500 μL of 0.5 M NaOH was then added to each well. Cells were incubated for 10 minutes at 
37 °C, 5% CO2. A second 100 μL aliquot was then taken from each well of the plate and 
prepared for analysis through the addition of 4 mL of scintillation fluid. The radioactivity of 
each sample was then analysed using a Tri-Carb scintillation counter and QuantaSmart™ 
software (DPM Soultions Ltd, Chesterfield, UK). The cellular volume, intra- and extra-cellular 
concentration and CAR were calculated as described in Chapter 4 (Section 4.2.9).  
 
5.2.5 Statistical analysis 
The Shapiro-Wilk Test was used to test for normality, with P ≤ 0.05 considered as statistically 
significant. An unpaired t test was then used to analyse potential differences in radiolabeled 
drug accumulation and percentage cell viability between conditions, with P ≤ 0.05 considered 
to be statistically significant. EC50 values were calculated through fitting a sigmoidal 
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concentration-response model to the TAF or TFV concentration-response curves, using the 
following equation: 
Y =
Bottom +  (Top − Bottom)
(1 + 10^((LogEC50 − X))) 
 
All statistical analyses, chart production and sigmoidal concentration-response model 
production was carried out using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).   
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5.3 RESULTS 
 
5.3.1 Cell viability assay  
To determine that the difference in CAR between experimental conditions was not due to 
cell death, cell viability was determined. HEK293 cells were incubated with either 500 μM 
cimetidine, TAF or TFV at the 5 highest concentrations to be included within the experiment, 
for 10 minutes under experimental conditions (Figure 5.1). Greater than 80% of the cell 
viability observed for the untreated cells was observed at each of these conditions and so all 
drug concentrations were deemed non-toxic and therefore suitable for the experiments.  
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Figure 5.1: Cell viability assay.  
Graph A: HEK293 cells incubated with TAF or cimetidine. Graph B: HEK293 cells incubated with TFV or cimetidine. Data points represent the mean ± SD, N = 3
A) B) 
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5.3.2 14C metformin cellular accumulation 
As shown in Figure 5.2 the CAR of 14C metformin within the transiently transfected HEK293 
cells was statistically significant compared to untreated cells within the MATE1 TAF 
incubation (P = 0.006), TFV incubation (P = 0.001) and MATE2K TAF incubation (P = 0.023) 
experiments, but not within the MATE2K TFV incubation (P = 0.904).  
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Figure 5.2: Effect of TAF or TFV on the cellular accumulation of 14C metformin within cells overexpressing either the MATE1 or the MATE2K transporter. 
Graph A: MATE1 overexpressing HEK293 cells incubated with TAF. Graph B: MATE1 overexpressing HEK293 cells incubated with TFV. Graph C: MATE2K overexpressing HEK293 cells incubated 
with TAF. Graph D: MATE2K overexpressing HEK293 cells incubated with TFV. Data points represents the mean ± SD, N = 3 from 3 experiments 
A) B) 
C) D) 
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Figure 5.3 demonstrates that incubation of 14C metformin with cimetidine at concentrations 
ranging from 10-4 μM to 30 μM within HEK293 cells overexpressing either the MATE1 or 
MATE2K transporter, resulted in a CAR comparable to that observed in untreated HEK293 
cells. Furthermore, inhibition of 14C metformin accumulation for each cimetidine 
concentration was comparable to that observed after incubation with cimetidine 500 μM. 
Demonstrating the effective inhibition of the MATE1 and MATE2K transporter by cimetidine.  
 
14C metformin cellular accumulation in the presence of TAF or TFV at concentrations ranging 
from 0.3 μM to 30 μM combined with 500 μM cimetidine, was found to be comparable 
between untreated, MATE1 overexpressing and MATE2K overexpressing HEK293 cells (Figure 
5.3). This indicates that the alterations in 14C metformin accumulation observed within this 
chapter was mediated by TAF or TFV at either the MATE1 or MATE2K transporter, and not 
due to an off-target interaction.  
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Figure 5.3: Comparison of 14C metformin accumulation by cell type, post incubation with TAF or TFV with cimetidine. 
Graph A: MATE1 overexpressing HEK293 cells incubated with cimetidine. Graph B: MATE2K overexpressing HEK293 cells incubated with cimetidine. Graph C: HEK293 cells untreated, expressing 
MATE1 or expressing MATE2K incubated with TAF and cimetidine. Graph D: HEK293 cells untreated, expressing MATE1 or expressing MATE2K incubated with TFV and cimetidine. Data points 
represent the mean ± SD, of N = 3 from 3 experiments 
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As seen in Figure 5.4 the CAR of 14C metformin was observed to be higher in MATE1 
overexpressing cells compared to untreated HEK293 cells or MATE2K overexpressing cells in 
the presence of either TAF or TFV.  
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Figure 5.4: Comparison of 14C metformin accumulation by cell type, post incubation with TAF or TFV. 
Graph A: HEK293 cells untreated or expressing MATE1 or MATE2K incubated with TAF. Graph B: HEK293 cells untreated or expressing MATE1 or MATE2K incubated with TFV. Data points 
represent the mean ± SD, N = 3 from 3 experiments 
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As shown in Figure 5.2 Graph A, accumulation of 14C metformin incubated with TAF at 
concentrations of 0.3 μM and above, within HEK293 cells transiently transfected to 
overexpress the MATE1 transporter, increased to a significant level (P < 0.020), compared to 
cells incubated with 14C metformin alone. Figure 5.5 demonstrates the effect of TAF on 
MATE1 (EC50 =1.7 x 10-4 µM) mediated transport of 14C metformin.  
 
Cellular accumulation of 14C  metformin was elevated with increasing concentration of TFV 
from 0.3 µM and above (P < 0.019), up to the point of saturation at a concentration greater 
than 10 µM. Demonstrating the effect of TFV on the efflux of 14C metformin by MATE1 (EC50 
= 3.9 x 10-4 µM; Figure 5.2 and 5.5). 
 
As shown in Figure 5.2, exposure to TAF did not alter the accumulation ratio of 14C metformin 
within HEK293 cells transiently overexpressing MATE2K. Because of this, the sigmoidal 
concentration-response model applied in Figure 5.5 was unable to produce an R2 value or 
EC50 value.  
 
Accumulation of 14C metformin in the presence of TFV at varied concentrations within 
MATE2K overexpressing HEK293 cells was shown to be comparable to that observed within 
MATE2K overexpressing HEK293s incubated with 14C metformin in isolation up to a 
concentration of TFV at 1 µM (Figure 5.2). Incubation with TFV concentrations of 3 µM and 
above resulted in a higher CAR of 14C metformin compared to MATE2K overexpressing cells 
incubated with 14C metformin alone (P < 0.003; EC50 = 2.4 µM; Figure 5.2 and 5.5).  
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Figure 5.5: TAF or TFV concentration dependent accumulation of 14C metformin. 
A sigmoidal concentration response model fitted to calculate EC50. Graph A: HEK293 cells overexpressing MATE1 incubated with TAF. Graph B: HEK293 cells overexpressing MATE1 incubated 
with TFV. Graph C: HEK293 cells overexpressing MATE2K incubated with TAF. Graph D: HEK293 cells overexpressing MATE2K incubated with TFV. Data points represent the mean ± SD, N = 3 
from 3 experiments 
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5.3.3 14C creatinine cellular accumulation  
As shown in Figure 5.6 Graph A, accumulation of 14C creatinine incubated with TAF at 
concentrations of 0.1 μM and above, within HEK293 cells transiently transfected to 
overexpress the MATE1 transporter, was decreased to a significant level (P < 0.030; IC50 = 0.3 
nM; Figure 5.7), compared to cells incubated with 14C creatinine alone. Cellular accumulation 
of 14C creatinine was not altered by incubation with increasing concentration of TFV, within 
cells overexpressing the MATE1 transporter (Figure 5.6). However, Figure 5.7 Graph B 
indicates an inhibitory effect of TFV on the CAR of 14C creatinine at concentrations greater 
than 3 µM, although not to a statistically significant degree. 
 
Accumulation of 14C creatinine in the presence of increasing concentrations of TAF within 
MATE2K overexpressing HEK293 cells was shown to be statistically significant to that 
observed in cells incubated with 14C creatinine in isolation (P ≤ 0.039; IC50 = 2.3 µM; Figure 
5.6 and 5.7).  
 
Figure 5.6 shows incubation of HEK293 cells overexpressing MATE2K with 14C creatinine and 
TFV at concentrations ranging from 0.001-0.3 µM resulted in lower CAR of 14C creatinine 
compared to cells incubated with 14C creatinine alone (P < 0.030; IC50 = 0.3 µM; Figure 5.7). 
 
As seen in Figure 5.8 the CAR of 14C creatinine was lower in MATE1 overexpressing cells 
compared to MATE2K overexpressing cells in the presence of TAF. Indicating that the 
inhibitory effect of TAF is greater for MATE1 compared to MATE2K. In the presence of TFV 
there was a general trend of higher CAR of 14C creatinine within MATE1 transfected cells 
compared to MATE2K.  
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Figure 5.6: Effect of TAF or TFV on the cellular accumulation of 14C creatinine within cells overexpressing either the MATE1 or MATE2K transporter. 
Graph A: HEK293 cells overexpressing MATE1 incubated with TAF. Graph B: HEK293 cells overexpressing MATE1 incubated with TFV. Graph C: HEK293 cells overexpressing MATE2K incubated 
with TAF. Graph D: HEK293 cells overexpressing MATE2K incubated with TFV. Data points represent the mean ± SD, N = 3 from 3 experiments  
A) B) 
C) D) 
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Figure 5.7: TAF or TFV concentration dependent accumulation of 14C creatinine.  
A sigmoidal concentration response model was fitted to calculate EC50. Graph A: HEK293 cells overexpressing MATE1 incubated with TAF. Graph B: HEK293 cells overexpressing MATE1 incubated 
with TFV. Graph C: HEK293 cells overexpressing MATE2K incubated with TAF. Graph D: HEK293 cells overexpressing MATE2K incubated with TFV. Data points represent the mean ± SD, N = 3 
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Figure 5.8: Comparison of 14C creatinine accumulation by cell type, post incubation with TAF or TFV. 
Graph A: HEK293 cells overexpressing either MATE1 or MATE2K incubated with TAF. Graph B: HEK293 cells overexpressing either MATE1 or MATE2K incubated with TFV. Data points represent 
the mean ± SD, N = 3 
A) B) 
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5.4 DISCUSSION 
 
This chapter investigated the effect of TAF and TFV on the transport of metformin and 
creatinine by the MATE1 and MATE2K transporters, utilising a transiently transfected HEK293 
cell line. The data demonstrated an effect of TAF on MATE1 mediated transport of 
metformin, and an effect of TFV on MATE1 and MATE2K mediated transport of metformin. 
Furthermore, our study showed an inhibitory effect of TAF for MATE1 and MATE2K mediated 
transport of creatinine and of TFV for MATE2K mediated transport of creatinine.  
 
The effect of TAF on MATE1 mediated accumulation of metformin and MATE1 and MATE2K 
mediated accumulation of creatinine is of interest given the limited data currently available 
on the interaction of TAF with renal transporters. TAF has previously been shown to inhibit 
MATE1 to a marginal degree at concentrations 200 fold in excess to those achieved in plasma 
after dosing to patients (EuropeanMedicinesAgency 2015). Given that TAF is able to achieve 
higher intracellular concentrations and lower circulating concentrations of TFV compared to 
TDF treatment, and that TAF is minimally eliminated in urine as unchanged drug, TAF is 
projected to have fewer renal complications compared to TDF (Markowitz 2014, Bonora 
2016). Although TAF is minimally eliminated in urine as unchanged drug, TAF exposure in 
patients with renal impairment has been observed to be elevated, which the authors 
hypothesise to be a result of reduced P-gp mediated transport of TAF, resulting in increased 
absorption (Custodio 2016). Unlike TFV, TAF has been shown not to be a substrate of OAT1 
and OAT3, and so accumulation within PTCs through this mechanism is unlikely (Bam 2014). 
Multiple Phase 2 and 3 studies have demonstrated TAF to have a reduced impact on renal 
function compared to TDF containing regimens, and so the clinical impact of the observed 
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inhibition of creatinine transport may be limited but is nevertheless important in terms of 
developing understanding of TAF transporter interactions.  
 
Accumulation of metformin within MATE1 or MATE2K overexpressing cells was elevated by 
incubation with TFV, with a 6,000-fold difference in EC50 value between MATE1 and MATE2K 
overexpressing cell lines. Given that MATE1 is the primary efflux transporter of metformin 
within PTCs (Tanihara 2007, Damme 2011) the higher impact of TFV on MATE1 compared to 
MATE2K could potentially result in a reduction in metformin pharmacokinetics, due to an 
increase in clearance of metformin. Incubation with TAF resulted in alterations in the 
accumulation of creatinine within MATE1 and MATE2K overexpressing cells. A 7,000-fold 
difference in TAF IC50 was observed between the two cells lines. The higher impact of TAF on 
MATE1 may result in elevation in serum creatinine, and thus a potential false indication of 
renal toxicity, as previously observed within patients who receive TDF (Yombi 2014). Study 
of TAF in combination with EVG/COBI and FTC within patients with renal impairment 
demonstrated no effect on eGFR in patients who had previously received TDF but did observe 
a worsening of eGFR (median change = -0.6 mL/min) in six ART naive patients (Pozniak 2016). 
 
An inhibitory effect of TFV on MATE2K, but not MATE1, mediated creatinine transport was 
observed within this chapter. This effect on MATE1 was previously outlined by the European 
Medicines Agency (EuropeanMedicinesAgency 2015). Further study into the structural 
determinants for this inhibitor specificity would be of use given the broadly overlapping 
substrate specificity of the two transporters. As MATE1 but not MATE2K is expressed on 
HEK293 cells endogenously, inhibition of the endogenous MATE1 transporter on MATE2K 
overexpressing cells could be of use in future studies to show conclusively that any 
alterations in substrate transport are caused by interaction with MATE2K exclusively. This 
could be achieved through incubating the cells with famotidine, a selective MATE1 inhibitor, 
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before incubating the cells with MATE substrate and TAF or TFV. Additionally, development 
of a multiple-transporter expressing HEK293 cell line expressing both influx and efflux 
transporters of creatinine may be of use, enabling the study of the effect of TAF and TFV on 
the full transporter profile of creatinine within the kidney.  
 
We observed probe substrate-specific differences in CAR between metformin and creatinine 
despite utilising the same assay conditions for both substrates and incubating both 
substrates with the same concentration range of TAF or TFV. Incubation of metformin with 
TAF or TFV was shown to elevate CAR within MATE1 overexpressing cells, with the same 
observed for metformin accumulation with TFV in MATE2K overexpressing cells. This 
indicates an activation effect of the antiretrovirals on substrate transport by MATE1 and 
MATE2K. However, in the case of creatinine, incubation with TAF within MATE1 
overexpressing cells and with TAF or TFV in MATE2K overexpressing cells resulted in a 
reduction in CAR of creatinine. Indicating an inhibitory effect of TAF on MATE1 and MATE2K 
and of TFV on MATE2K. 
 
The difference observed in TAF and TFV interactions with metformin and creatinine may be 
due to differential binding of the substrates to allosteric binding sites on the MATE 
transporters, occurring as a result of differences in the chemical compositions of the two 
substrates.  A previous study has suggested that MATE substrates may influence the 
interaction of inhibitors with MATE transporters. This study demonstrated that the inhibitory 
effect of 3 salts in liquid state on MATE activity was dependent on the substrate being 
transported, suggesting a kinetically complex mechanism of substrate-inhibitor interaction 
with the transport protein (Martínez-Guerrero 2013). Additionally, probe substrate-specific 
differences in IC50 values have previously been seen within studies investigating MATE2K and 
OCT2 (Zolk 2009, Müller 2015, Shen 2015). These observations suggest that substrate 
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interactions with transporters may be a combination of competitive and allosteric 
interactions, as previously suggested for OCT (Gorboulev 2005). This could be explained 
through the potential presence of multiple binding sites on MATE transporters (Martínez-
Guerrero 2013). Further studies are required to determine the exact mechanism 
underpinning the observations in this chapter. These studies could include biochemical and 
mechanistic studies to investigate the current mechanism by which MATE transporters select 
cations or drugs from the cytoplasm, which has yet to be elucidated (Lu 2016). 
 
Since MATE function is determined in vitro through alteration of extracellular pH, 
interpretation of in vitro data assumes that there is equal affinity for transporter substrates 
and inhibitors at both the intra- and extra-cellular binding sites. Potential differences in CAR 
between creatinine and metformin may in part be attributed to preferential binding of 
metformin to the extracellular binding site of MATE transporters, and of creatinine to the 
intracellular binding site of MATE transporters, resulting in a higher level of transport of each 
substrate in the corresponding direction.  
 
Finally, the clinical impact of these findings must be taken into consideration. Whilst TAF was 
shown to inhibit MATE1 and MATE2K transport of creatinine to a statistically significant level 
compared to control, at the full range of concentrations studied (10-2 – 30 µM), the clinical 
relevance of this interaction may be negligible in light of the fewer cases of TFV-associated 
renal dysfunction that have been reported with prescription of TAF over TDF (Yombi 2014). 
Nevertheless further knowledge of the way this recently approved ART drug interacts with 
endogenous substrates at a key site for excretion is of utility and provides further evidence 
for the unsuitability of creatinine as a reliable indicator of renal function (Moss 2014). 
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5.4.1 Limitations 
Limitations of this chapter includes the use of a restricted number of MATE1 and MATE2K 
substrates. Given that in vitro inhibition data for some antiretroviral drugs has previously 
been shown to be highly variable, with the IC50 value for RTV with MATE1 showing a 193-fold 
variability between studies, (Chu 2016) data on a greater number of substrate-drug 
interactions will aid interpretation. Future studies could include other established and novel 
probe substrates for the study of MATE inhibition. Including the frequently studied retinol-
binding protein and the more recently used endogenous probe N-methylnicotimide (NMN), 
which has the same transporter profile as creatinine and has previously been used within 
multiple studies as an endogenous probe for drug-drug interactions involving MATEs (Yombi 
2014, Chu 2016).  
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Chapter 6: The Effect of Gene 
Variants on Levonorgestrel 
Pharmacokinetics when 
Combined with Antiretroviral 
Therapy Containing Efavirenz or 
Nevirapine
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6.1 INTRODUCTION  
 
Hormonal contraceptives and ART are critical components of healthcare for the estimated 
17 million women living with HIV and are key pillars in the effort to globally reduce mother-
to-child HIV transmission.  The subdermal LNG implant is a highly effective and desirable 
method of contraception (Lehtovirta 2007, Heikinheimo 2011). LNG is released from the 
implant initially at 100 mcg/day, decreasing to 40 mcg/day within one year and to 30 mcg/day 
within three years, providing relatively stable daily drug concentrations over this timeframe 
(Kopp 2003). Notably, the use of contraceptive implants is rapidly expanding in low and 
middle income countries (Phillips 2013). In these same settings, the WHO recommends ART 
containing two NRTIs in combination with EFV as a first-line regimen for HIV treatment (WHO 
2016). The use of EFV-based ART in women of childbearing potential has expanded in the 
past decade, first following characterisation of the lower than expected level of fetal risk 
during in-utero EFV exposure (Ford 2011, WHO 2012, WHO 2013), and subsequently due to 
recent WHO recommendations for universal use of ART, irrespective of CD4+ cell count (WHO 
2010). Considered an alternate first-line option, NVP is still used by many women in low and 
middle income countries (WHO 2016). In light of this, identifying safe and efficacious 
combinations of both therapies with hormonal contraceptives in HIV positive women is a 
critical public health priority.  
 
A significant drug-drug interaction between the LNG implant and EFV-based ART in HIV-
positive Ugandan women, which resulted in 47% lower LNG concentrations compared to 
control participants, and a high rate of unintended pregnancy, in women receiving EFV-based 
ART [3 (15%) of 20 participants] has previously been described (Scarsi 2016). Induction of 
CYP3A4 and CYP3A5 mediated metabolism of LNG is the proposed mechanism of the 
observed interaction with EFV. No pharmacokinetic interaction or unintended pregnancies 
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were observed in women receiving NVP-based ART within the same study. These findings are 
supported by a retrospective cohort study of Kenyan women that found a three-fold higher 
adjusted pregnancy incidence in HIV-positive women receiving the implant plus EFV-based 
ART compared to those receiving NVP-based ART (Patel 2015).  
 
LNG, EFV and NVP are substrates of CYP enzymes; LNG is metabolised by CYP3A4 and 
CYP3A5, (Moreno 2012) EFV is metabolised by CYP2B6 with minor contributions from 
CYP2A6, CYP3A4, and UGT2B7, (Bélanger 2009, Ogburn 2010) while NVP is metabolised by 
CYP2B6, CYP3A4 and partially by CYP2D6 (Cammett 2009, Fan-Havard 2013). The nuclear 
receptor genes NR1I2 and NR1I3 are known to regulate the expression and activity of several 
CYPs, including CYP2B6 and CYP3A4 (Zhang 2001, Wyen 2011, Swart 2012). SNPs within the 
genes expressing the aforementioned proteins have been associated with alterations in EFV 
and NVP pharmacokinetics, as outlined in Chapter 1 (Section 1.6 and Section 1.8).  
 
The primary objective of this secondary study analysis was to ascertain the contributory 
effect of SNPs in key genes of interest in LNG, EFV, and NVP metabolism (CYP2B6, CYP2A6, 
NR1I2 and NR1I3) on plasma LNG pharmacokinetics when the subdermal implant was given 
in combination with EFV or NVP based ART (EFV and NVP groups, respectively) in HIV-positive 
women. Since these SNPs have been shown to influence NNRTI pharmacokinetics, our 
underlying hypothesis was that there would be consequences of different NNRTI 
concentrations for the degree of CYP3A induction, and therefore a genetic basis for the 
subsequent magnitude of the interaction with LNG.  
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6.2 METHODS 
 
6.2.1 Ethical approval 
All study procedures followed the Helsinki Declaration of 1975 and were approved by ethics 
boards at the Joint Clinical Research Centre Kampala, Uganda National Council for Science 
and Technology, and the University of Nebraska Medical Centre. The study was registered on 
clinicaltrials.gov (NCT01789879). 
 
6.2.2 Study design and cohort 
This was a prospective pharmacokinetic evaluation of HIV-positive Ugandan women 
receiving EFV-based ART (EFV group, n = 20) or NVP-based ART (NVP group, n = 20). For the 
pharmacogenetic study, all participants in the EFV and NVP group were included (n = 40) and 
the ART-naïve group was excluded. The two-rod (75 mg/rod) LNG sub-dermal implant was 
inserted in all patients upon study entry. Inclusion criteria for the EFV and NVP groups 
included prescription of EFV or NVP plus 2 NRTIs for 30 days or longer and a HIV-RNA of < 
400 copies/mL (Habtewold 2011). 
 
6.2.3 Sample and data collection  
Over a total of 48 weeks, a plasma sample was collected at weeks 1, 4, 12, 24, 36 and 48 to 
assess LNG, NVP and EFV pharmacokinetics. Follow-up was interrupted for 9 subjects 
between weeks 36-44 after 3 pregnancies were identified in the EFV group. The primary 
endpoint for the pharmacokinetic analysis was 24 weeks. Timing of blood sample collection 
for the EFV group was based on EFV mid-dosing interval at 12-14 hours post dose and for the 
NVP group based on the end dosing interval of 11-13 hours post dose. pharmacokinetic 
parameters included AUC from entry to week 24 (AUC0-24 weeks), maximum concentration 
(Cmax), time to Cmax (Tmax) and minimum concentration (Cmin). Cmax and Cmin represent the 
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highest and lowest concentrations observed over the entire study period. AUC was calculated 
using the trapezoidal rule (Phoenix WinNonlin, Certara®). LNG concentrations were analysed 
by a validated LC-MS/MS method; EFV and NVP plasma concentrations were determined 
using high performance liquid chromatography (HPLC) assays with ultraviolet detection as 
previously outlined by Scarsi et al. (Scarsi 2016). 
 
6.2.4 Genotyping 
Genomic DNA was extracted from whole blood through use of the manufacturers’ protocol 
(E.Z.N.A Blood DNA Mini Kit; Omega bio-tek; Norcross, GA) as outlined in Chapter 2 (Section 
2.2.6). Extracted DNA was quantified using NanoDrop (Thermo Fisher Scientific, Wilmington, 
DE). Genotyping was completed using real-time allelic discrimination PCR assay on a DNA 
Engine Chromo4 system (Bio-Rad Laboratories, Hercules, CA). The PCR protocol followed 
denaturation at 95 °C for 10 minutes, followed by 50 cycles of amplification at 92 °C for 15 
seconds and annealing at 60 °C for 1 minute 30 seconds. Taqman Genotyping Master mix and 
assays CYP2B6 516G>T (rs3745274), CYP2B6 983T>C (rs28399499), CYP2B6 15582C>T 
(rs4803419), CYP2A6 -48A>C (rs28399433) CYP2A6*9B 1836G>T (rs8192726) NR1I2 
63396C>T (rs2472677), NR1I3 540C>T (rs2307424) and NR1I3 1089T>C (rs3003596) were 
purchased from Life Technologies (Paisley, Renfrewshire, UK). Opticon Monitor v.3.1 
software (Bio-Rad Laboratories) was used to obtain allelic discrimination plots and identify 
genotypes. 
 
6.2.5 Statistical analysis 
Compliance with Hardy-Weinberg equilibrium was tested as outlined in Chapter 2 Section 
2.2.6. Genotypes were coded for regression analyses as 0 = homozygous common allele, 1 = 
heterozygous and 2 = homozygous variant allele. Categorical variables were described using 
relative frequencies, whilst continuous variables were described using median and IQR. The 
 
 
154 
 
 
Shapiro-Wilk Test was used to test for normality, with P ≤ 0.05 considered as statistically 
significant. A univariate analysis through linear regression was carried out in order to identify 
independent variables associated with LNG pharmacokinetic parameters within the EFV 
group, or the NVP group separately. Variables with P ≤ 0.2 for the univariate analysis were 
carried through to a linear backwards multivariate analysis were P ≤ 0.05 was deemed to be 
statistically significant. All statistical analyses were carried out using IBM SPSS Statistics v.22 
(IBM Armonk, NY). All charts were produced using GraphPad Prism 6 (GraphPad Software, La 
Jolla, CA).   
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6.3 RESULTS 
 
6.3.1 Patient characteristics  
All women in the EFV and NVP group from the primary study were included in this analysis 
(n = 40) (Scarsi 2016). Patient characteristics and genotype frequencies are summarised in 
Table 6.1. The median (IQR) age and weight of all patients was 31 years (29-34 years) and 59 
kg (53-68 kg). All SNPs were in Hardy-Weinberg equilibrium, except CYP2B6 15582C>T 
(rs4803419; P < 0.001, X2 = 20.6) and NR1I3 540C>T (rs2307424; P < 0.001, X2 = 12.4), which 
compromises their interpretation. Univariate and multiple regression analysis for LNG 
pharmacokinetic parameters based on EFV and NVP groups are presented in Table 6.3. All 
patients in the EFV group (n = 20) received EFV 600 mg daily plus 2 NRTIs for a median (IQR) 
of 10.5 months (6.3-37.8 months) prior to study entry. Patients in the NVP group (n = 20) 
received NVP 200 mg twice daily plus 2 NRTIs for a median (IQR) of 30.5 months (13.5-80.3 
months) prior to study entry.
 
 
156 
 
 
Table 6.1: Characteristics of the study participants at entry. 
Characteristics Total (n = 40) Efavirenz group (n = 20) Nevirapine group (n = 20) 
Age (years) 31.0 (29.0-34.0) 31.0 (28.3-34.0) 32.5 (31.0-35.8) 
Weight (kg) 59.0 (53.0-68.0) 59.5 (52.3-63.8) 59.5 (54.3-69.8) 
CD4 count (cells/mm3) 579.0 (464.0-731.0) 556.5 (477.3-663.5) 626.0 (399.8-857.3) 
Albumin concentration at baseline (g/L) 43.7 (41.5-46.5) 43.3 (40.7-45.1) 43.1 (41.8-45.6) 
SHBG at baseline (nmol/L) 105.0 (82.3-136.0) 100.0 (79.4-125.9) 100.0 (100.0-125.9) 
Genotype frequencies  
CYP2B6 516G>T (rs3745274) (n [%]) GG GT TT GG GT TT GG GT TT 
 17 (43) 22 (55) 1 (2) 8 (40) 11 (55) 1 (5) 9 (45) 11 (55) 0 (0) 
CYP2B6 983T>C (rs28399499) (n [%]) TT CT CC TT CT CC TT CT CC 
32 (80) 7 (18) 1 (2) 17 (85) 3 (15) 0 (0) 15 (75) 4 (20) 1 (5) 
CYP2B6 15582C>T (rs4803419) (n [%]) CC CT TT CC CT TT CC CT TT 
11 (28) 28 (70) 1 (2) 5 (25) 15 (75) 0 (0) 6 (30) 13 (65) 1 (5) 
CYP2A6*9B 1836G>T (rs8192726) (n [%]) GG GT TT GG GT TT GG GT TT 
31 (82) 9 (18) 0 (0) 16 (80) 4 (20) 0 (0) 15 (75) 5 (25) 0 (0) 
CYP2A6 48A>C (rs28399433) (n [%]) AA AC CC AA AC CC AA AC CC 
29 (78) 10 (22) 1 (2) 15 (75) 5 (25) 0 (0) 14 (70) 5 (25) 1 (5) 
NR1I2 63396C>T (rs2472677) (n [%]) CC CT TT CC CT TT CC CT TT 
25 (63) 12 (30) 3 (7) 13 (65) 6 (30) 1 (5) 12 (60) 6 (30) 2 (10) 
NR1I3 540C>T (rs2307424) (n [%]) CC CT TT CC CT TT CC CT TT 
10 (25) 30 (75) 0 (0) 6 (30) 14 (70) 0 (0) 4 (20) 16 (80) 0 (0) 
NR1I3 1089T>C (rs3003596) (n [%]) TT CT CC TT CT CC TT CT CC 
14 (35) 22 (55) 4 (10) 6 (30) 12 (60) 2 (10) 8 (40) 10 (50) 2 (10) 
Values shown as median (IQR) and percentage of population. SHBG: sex hormone-binding globulin. 
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6.3.2 Levonorgestrel, efavirenz and nevirapine pharmacokinetics 
LNG Cmax, Tmax, Cmin, and AUC0-24week are summarised by study group and SNP in Table 6.2. EFV 
C12-14h (mg/L) was 76% higher in homozygous CYP2B6 516 TT participants compared to those 
who were homozygous for the G allele. Within the NVP group NVP C11-13h (mg/L) was 5% lower 
in heterozygous CYP2B6 516 CT participants compared to homozygotes for the G allele.  
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Table 6.2: Levonorgestrel, efavirenz and nevirapine pharmacokinetic, summarised by associated CYP2B6, NR1I2 or CYP2A6 genotype. 
LNG Cmax (pg/mL) CYP2B6 516G>T (rs3745274) CYP2B6 15582C>T (rs4803419) CYP2A6 1836G>T (rs8192726) NR1I2 63396C>T (rs2472677) 
GG  GT  TT  CC  CT  TT  GG GT TT CC CT TT 
EFV group 692.6 
(486.8-888.0) 
402.4 
(223.1-1027.7) 
200.6 692.6 
(501.1-706.6) 
486.8 
(347.1-775.3) 
- 486.8 
(359.7-
706.6) 
585.2 
(223.1-
1405.4) 
- 486.8 
(347.1-
775.3) 
463.0 
(419.8-
1027.7) 
585.2 
NVP group 1310.8 
(1070.0-
2530.1) 
1449.5 
(1053.4-1837.0) 
- 1097.9 
(814.90-
2157.0) 
1449.5 
(1070.0-
1836.9) 
1267.2 1449.5 
(1267.2-
1836.9) 
1097.9 
(1070.0-
1543.1) 
- 1436.4 
(1054.4-
1877.4) 
1310.8 
(1303.2-
818.5) 
1466.5(776
.0-2157.0) 
LNG Tmax (wk)      
EFV group 1.0 
(1.0-1.0) 
1.00  
(1.0-1.0) 
4.0 
 
1.0 
(1.0-1.0) 
1.0 
(1.0-12.0) 
- 1.0 
(1.0-4.0) 
1.0 
(1.0-36.0) 
- 1.0  
(1.0-12.0) 
1.0  
(1.0-1.0) 
1.0 
NVP group 1.0 
(1.0-1.0) 
1.0 
(1.0-12.0) 
- 1.0 
(1.0-1.0) 
1.0 
(1.0-1.0) 
1.0 1.0 
(1.0-1.0) 
1.0 
(1.0-1.0) 
- 1.0 
(1.0-1.0) 
1.0 
(1.0-1.0) 
6.5 
(1.0-12.0) 
LNG Cmin (pg/mL)     
EFV group 272.2 
(189.5-377.9) 
202.2 
(175.9-359.7) 
121.8 299.0 
(273.0-307.3) 
208.1 
(188.2-274.2) 
- 224.7 
(188.2-
307.3) 
202.2 
(189.5-
1405.4) 
- 223.1 
(188.2-
359.7) 
202.2 
(189.1-299.0) 
189.5 
NVP group 553.7 
(365.2-
1094.1) 
562.6 
(504.4-807.7) 
- 504.4 
(343.7-714.0) 
562.38 
(512.46-
986.40) 
526.4 562.4 
(504.4-
807.7) 
725.0 
(540.2-986.4) 
- 540.2 
(501.0-
957.0) 
562.6 
(562.4-986.4) 
599.3 
(512.5-
686.2) 
LNG AUC0-24weeks 
(pg*wk/mL) 
    
EFV group 10114.6 
(8069.3-
12862.2) 
6311.8 
(6569.7-
14937.7) 
3622.1 10114.6 
(8500.0-
12798.8) 
7754.4 
(5676.9-
9435.6) 
- 7754.4 
(6311.8-
11399.6) 
8069.3 
(4321.3-
11070.0) 
- 6830.6 
 (5677.0-
11340.0) 
7754.4 
(7371.6-
10114.6) 
8069.3 
NVP group 19970.2 
(15259.3-
30339.9) 
15965.4 
(15729.6-
26301.1) 
- 15761.9 
(11338.7-
22478.4) 
20167.2 
(15729.6-
27442.0) 
19970.2 19970.2 
(15761.9-
26301.1) 
16948.7 
(15258.3-
21199.9) 
- 16948.7 
(15730.0-
26301.1) 
16759.1 
(15258.3-
27442.0) 
19189.4 
(15900.4-
22478.4) 
EFV C12-14h (mg/L) 2.1 
(1.4-2.6) 
2.6 
(2.1-6.9) 
8.7 2.4 
(2.2-2.6) 
2.4 
(1.8-5.1) 
- 2.4 
(1.8-3.0) 
2.4 
(2.0-6.6) 
- 2.6 
(2.1-6.6) 
2.2 
(2.0-2.4) 
1.62 
NVP C11-13h (mg/L) 6.5 
(4.4-7.4) 
6.2 
(5.1-10.0) 
- 6.8 
(5.9-8.3) 
6.1 
(5.0-8.3) 
8.0 6.1 
(5.1-8.4) 
6.6 
(5.5-7.1) 
- 6.8 
(4.8-8.4) 
6.2 
 (5.5-6.9) 
7.1 
(5.9-8.3) 
EFV C12-14h (mg/L) and NVP C11-13h (mg/L) determined from individual participants geometric mean value calculated from concentration measured at study entry, week 1, 4, 12, 24, 
36 and 48 and summarised for the group as median (IQR). LNG: levonorgestrel. EFV: efavirenz. NVP: nevirapine 
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6.3.3 Efavirenz group 
 
6.3.3.1 Non-significant associations 
No associations between CYP2B6 516G>T (rs3745274) and LNG Tmax and log10 LNG Cmin were 
observed within this study. CYP2B6 983T>C (rs28399499) was not associated with log10 LNG 
Cmax and log10 LNG AUC0-24weeks. CYP2B6 15582C>T (rs4803419) was not associated with LNG 
Tmax, log10 LNG Cmin or log10 LNG Cmax. CYP2A6*9B 1836G>T (rs8192726) and NR1I3 1089T>C 
(rs3003596) were only associated with LNG Tmax and log10 LNG Cmin respectively. No 
associations were seen between CYP2A6 48A>C (rs28399433), NR1I2 63396C>T (rs2472677), 
NR1I3 540C>T (rs2307424) and any pharmacokinetic parameters of LNG. No relationship was 
seen between age and log10 LNG Cmax, LNG Tmax and log10 LNG Cmin. Weight, log10 sex hormone-
binding globulin (SHBG) and albumin concentration at baseline were not associated with any 
LNG pharmacokinetic parameters. log10 CD4 was only associated with log10 LNG AUC0-24weeks. 
Figure 6.1 shows all non-significant interactions between SNPs and LNG pharmacokinetic 
parameters. 
 
6.3.3.2 Relationships observed from univariate analysis 
Through univariate regression analysis a trend between CYP2B6 983T>C (rs28399499) and 
higher log10 LNG Cmin and Tmax (P = 0.114, β = 0.2; P = 0.069, β = 17.7; respectively) was 
observed. NR1I3 1089T>C (rs3003596) was seen to be linked with higher log10 LNG Cmin (P = 
0.143, β = 0.1). A trend was seen between CYP2A6*9B 1836G>T (rs8192726) and lower Tmax 
(P = 0.195, β = 11.5). Age was linked with lower log10 LNG Cmax (P = 0.049, β = 0.0), and a 
relationship between log10 CD4 and higher log10 LNG AUC0-24weeks (P = 0.085, β = 0.5) was seen. 
However, these associations did not persist through multivariate regression analysis. Figure 
6.2 shows all factors linked with LNG pharmacokinetic parameters and genetics found 
through univariate linear regression analysis only.  
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Consistent with previous reports, through univariate linear regression analysis, CYP2B6 
516G>T was linked with higher EFV concentration (P = 0.011, β = 0.3), meaning that C12-14h 
values were 2.1, 2.6 and 8.7 mg/L in GG, GT and TT genotype groups, respectively (76% 
difference between homozygote groups). Additionally, a correlation was seen between 
higher EFV C12-14h (log10 mg/L) and lower LNG log10 AUC0-24week (P = 0.003, β = 0.0). 
 
6.3.3.3 Significant associations from multivariate analysis 
After multivariate analysis, CYP2B6 516G>T (rs3745274) was associated with lower log10 LNG 
Cmax (P = 0.021, β = -0.2) and log10 LNG AUC0-24weeks (P = 0.023, β = -0.1). This meant that LNG 
Cmax   median values were 692.8, 402.4 and 200.6 pg/mL in the GG, GT and TT genotype 
groups, respectively (71% difference between homozygote groups) and LNG AUC0-24weeks 
median values were 10114.6, 6311.8 and 3622.1 pg*wk/mL in the GG, GT and TT genotype 
groups, respectively (64% difference between homozygote groups). CYP2B6 15582C>T 
(rs4803419) was associated with lower log10 LNG AUC0-24weeks (P = 0.021, β = -0.2), resulting in 
LNG AUC0-24weeks median values of 10114.6 and 7754.4 pg*wk/mL in the CC and CT genotype 
groups, respectively (23% difference between groups). Figure 6.3 illustrates the LNG AUC0-
24weeks within the EFV group according to these genotypes. In addition to these genetic 
associations, age was inversely associated with log10 LNG AUC0-24weeks (P = 0.039, β = 0.0 per 1 
year; Table 6.3).  
 
6.3.3.4 Levonorgestrel pharmacokinetics by metaboliser status 
Additional assessment of LNG pharmacokinetic parameters with CYP2B6 SNPs was 
completed through assignment of a CYP2B6 metaboliser status. In our patient population, 
the following genotypes were absent: intermediate metaboliser: 15582 TT, 516 GG, 983 TT 
and 15582 CC, 516 GG, 983 CT. No patients met the criteria to be assigned as a slow 
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metaboliser. Statistical analysis through multiple linear regression linked CYP2B6 extensive 
metaboliser status with greater log10 LNG AUC0-24 weeks (P = 0.002, β = 0.7) and higher log10 LNG 
Cmax (P = 0.049, β = 0.483). Figure 6.4 shows EFV plasma and serum LNG concentration 
separated by CYP2B6 metaboliser status.  
 
6.3.3.5 Pharmacodynamic outcome in the EFV group 
Three women in the EFV group became pregnant between study weeks 36 and 48 (3 (15%) 
of 20 participants). Pharmacogenetic characteristics of these three patients were as follows 
for the statistically significant genotypes within the EFV group: One woman was both 
homozygous TT for CYP2B6 516G>T (rs3745274) and heterozygous CT for CYP2B6 15582C>T 
(rs4803419). She was the only patient who possessed both of these genotypes in the study 
group, and her LNG concentration at the study visit prior to pregnancy (week 36) was 122 
pg/mL (LNG AUC0-24weeks 3622 pg*wk/mL). The other two women were heterozygous CT for 
CYP2B6 516G>T and homozygous CC for CYP2B6 1582C>T. They were the only patients in the 
EFV group who possessed these genotypes, and their LNG concentration prior to pregnancy 
(week 36) were 299 and 303 pg/mL (LNG AUC0-24weeks 10,115 and 8500 pg*wk/mL), 
respectively. Figure 6.5 shows the relationship between EFV plasma concentration and 
serum LNG concentration based on CYP2B6 516G>T (rs3745274) and CYP2B6 15582C>T 
(rs4803419) genotype.
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Figure 6.1: Non-significant associations for SNPs within the EFV group. 
Graphs A-F: Non-significant relationships between SNPs and LNG Cmin. Graphs G-M: Non-significant relationships between SNPs and LNG Cmax. Graphs N-S: Non-significant relationships 
between SNPs and LNG AUC0-24 weeks. Data points represent the mean ± SD   
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Figure 6.2: Relationships between levonorgestrel pharmacokinetic parameters and patient genotypes, within the EFV group, determined through 
univariate analysis.  
Graphs A and B: Relationship between SNPs and LNG Cmin. All relationships found to be significant (P ≤ 0.2) through univariate regression analysis only. Data points represent the mean ± SD  
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Figure 6.3: Levonorgestrel pharmacokinetic parameters compared by statistically significant genotype, within the EFV group, determined through 
multivariate analysis. 
Graph A: Significant relationship between SNP and LNG Cmax. Graphs B and C: Significant relationships between SNPs and LNG AUC0-24 weeks. All relationships found to be statistically significant 
(P ≤ 0.05) through multivariate regression analysis. Data points represent the mean ± SD 
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Figure 6.4: Efavirenz and levonorgestrel concentration at week 24 based on CYP2B6 metaboliser status.  
Graph A: Relationship between CYP2B6 metaboliser status and EFV plasma concentration at week 24 of study. Graph B: Relationship between CYP2B6 metaboliser status and LNG serum 
concentration at week 24 of study.  Data points represent the mean ± SD  
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Figure 6.5: Relationship between efavirenz and levonorgestrel concentrations at week 24 based on CYP2B6 516G>T and CYP2B6 15582C>T genotype. 
Graph A: Relationship between plasma EFV and serum LNG concentration at week 24 of study colour coded by CYP2B6 516G>T genotype. Graph B:  Relationship between plasma EFV and 
serum LNG concentration at week 24 of study colour coded by CYP2B6 15582C>T genotype.
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6.3.4 Nevirapine group  
 
6.3.4.1 Non-significant associations 
Through univariate and multivariate linear regression analysis CYP2B6 516G>T (rs3745274) 
was not associated with LNG Tmax. NR1I2 63396C>T (rs2472677) was not associated with log10 
LNG Cmax, log10 LNG Cmin or log10 LNG AUC0-24weeks. No associations were observed between 
CYP2B6 983T>C (rs28399499), CYP2B6 15582C>T (rs4803419), CYP2A6*9B 1836G>T 
(rs8192726), CYP2A6 48A>C (rs28399433), NR1I3 540C>T (rs2307424) or NR1I3 1089T>C 
(rs3003596) and any parameters of LNG pharmacokinetics. Figure 6.6 shows all non-
significant associations between SNPs and pharmacokinetics of LNG within the NVP group. 
 
Age was not associated with log10 LNG Cmin or log10 LNG AUC0-24weeks. Log10 weight was not 
associated with log10 LNG Cmax or log10 LNG AUC0-24weeks. SHBG was not associated with LNG 
Tmax. Log10 CD4 count and albumin concentration at baseline were not associated with any 
parameters of LNG pharmacokinetics. 
 
6.3.4.2 Trends observed from univariate analysis  
A trend was observed between CYP2B6 516G>T (rs3745274) and higher log10 LNG AUC0-24weeks 
through univariate linear regression analysis (P = 0.179, β = 0.1) within the NVP group. Age 
was correlated with lower LNG Tmax (P = 0.043, β = -0.3). Log10 weight was linked with lower 
log10 LNG Cmin (P = 0.168, β = -0.8). Log10 CD4 count was linked with lower LNG Tmax (P = 0.157, 
β = -3.5) and log10 LNG AUC0-24weeks (P = 0.034, β = -0.3). Albumin concentration at baseline 
was linked with log10 LNG Cmax (P = 0.076, β = 0.0). However, these relationships were not 
significant when carried through to multivariate linear regression analysis. Figure 6.7 shows 
the relationship between CYP2B6 516G>T (rs3745274) genotype and LNG AUC found to be 
associated through univariate regression analysis only.  
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6.3.4.3 Significant associations from multivariate analysis  
As shown in Figure 6.8, CYP2B6 516G>T (rs3745274) was associated with higher log10 LNG 
Cmax (P = 0.034, β = 0.1) and log10 LNG Cmin (P = 0.048, β = 0.1). Resulting in LNG Cmax median 
values of 1310.8 and 1449.5 pg/mL in the GG and GT genotype groups, respectively (10% 
difference between homozygote groups) and LNG Cmin median values of 553.7 and 562.6 
pg/mL in the GG and GT genotype groups (2% difference between groups). NR1I2 63396C>T 
was associated with delayed LNG Tmax (P = 0.003, β = 1.6) with a median value of 1.0, 1.0 and 
6.5 weeks in the CC, CT and TT genotype groups. Additionally, log10 weight (P = 0.002, β = -
15.9) and albumin concentration at baseline (P = 0.003, β = -0.3) were associated with shorter 
LNG Tmax. Log10 SHBG was associated with higher log10 LNG AUC0-24weeks (P = 0.004, β = 0.5), 
log10 LNG Cmin (P = 0.011, β = 0.5) and log10 LNG Cmax (P = 0.007, β = 0.5). Age was associated 
with higher log10 LNG Cmax (P = 0.044, β = 0.0) (Table 6.3). 
 
No other genetic associations were observed in any of the groups; however, the sample size 
was insufficient to robustly assess the CYP2B6 983T>C variant (rs28399499).  
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Figure 6.6: Non-significant associations for SNPs within the NVP group. 
Graphs A-G: Non-significant relationships between SNPs and LNG Cmin. Graphs H-M: Non-significant relationships between SNPs and LNG Cmax. Graphs N-T: Non-significant relationships 
between SNPs and LNG AUC0-24 weeks. Data points represent the mean ± SD   
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Figure 6.7: Relationship between CYP2B6 516G>T and levonorgestrel AUC0-24weeks, within the nevirapine group, determined through univariate analysis.  
Relationship found to be significant (P ≤ 0.2) through univariate regression analysis only. Data points represent the mean ± SD  
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Figure 6.8: Levonorgestrel pharmacokinetic parameters compared by statistically significant genotype, within the nevirapine group, determined through 
multivariate analysis. 
Graph A: Significant relationship between CYP2B6 516G>T and LNG Cmin. Graph B: Significant relationship between CYP2B6 516G>T and LNG Cmax. All relationships found to be statistically 
significant (P ≤ 0.05) through multivariate regression analysis. Data points represent the mean ± SD 
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Table 6.3: Univariate and multivariate linear regression analysis from each study group. 
 
Efavirenz group 
log10 Cmax Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.049 -0.3 (-0.01,0.0) 0.2    
CYP2B6 516G>T (rs3745274) 0.021 -0.2 (-0.4,0.0) 0.3 0.021 -0.2 (-0.4,0.0) 0.3 
log10 AUC0-24 weeks Univariate linear regression Multivariate linear regression 
P value β (pg/mL) (95% CI) r2 P value β (pg/mL) (95% CI) r2 
Age (years) 0.028 -0.0 (0.0,0.0) 0.2 0.039 -0.0 (-0.0,0.0) 0.8 
CD4 (log10 cells/mm3) 0.085 0.5 (-0.1,1.1) 0.2    
CYP2B6 516G>T (rs3745274) <0.000 -0.2 (-0.3,-0.1) 0.5 0.023 -0.1 (-0.2,0.0) 0.8 
CYP2B6 15582C>T (rs4803419) 0.058 -0.2 (-0.3,0.0) 0.2 0.021 -0.2 (-0.3,0.0) 0.8 
Nevirapine Group 
log10 Cmax Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.056 0.0 (0.0,0.0) 0.2 0.044 0.0 (0.0,0.3) 0.6 
Albumin concentration at baseline (g/L) 0.076 0.0 (0.0,0.0) 0.2    
SHBG at baseline (log10 pg/mL) 0.017 0.5 (0.1,0.9) 0.3 0.007 0.5 (0.0,0.8) 0.6 
CYP2B6 516G>T (rs3745274) 0.115 0.1 (0.0,0.2) 0.1 0.034 0.1 (0.0,0.2) 0.6 
Tmax Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
Age (years) 0.043 -0.3 (-0.5,0.0) 0.2    
Weight (log10 kg) 0.029 -17.0 (-31.9,-0.2) 0.2 0.002 -15.9 (-24.9,-6.9) 0.8 
CD4 (log10 cells/mm3) 0.157 -3.5 (-8.5,1.5) 0.1    
Albumin concentration at baseline (g/L) 0.001 -0.5 (-0.8,0.2) 0.4 0.003 -0.3 (-0.5,-0.1) 0.8 
NR1I2 63396C>T (rs2472677) 0.013 2.0 (0.5,3.5) 0.3 0.003 1.6 (0.6,2.6) 0.8 
log10 Cmin Univariate linear regression Multivariate linear regression 
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P value β value (95% CI) r2 P value β value (95% CI) r2 
Weight (log10 kg) 0.168 -0.8 (-1.8,0.3) 0.1    
SHBG at baseline (log10 nmol/L) 0.022 0.5 (0.1,0.9) 0.3 0.011 0.5 (0.1,0.9) 0.6 
CYP2B6 516G>T (rs3745274) 0.118 0.1 (0.0,0.2) 0.1 0.048 0.1 (0.0,0.2) 0.6 
log10 AUC0-24 weeks Univariate linear regression Multivariate linear regression 
P value β value (95% CI) r2 P value β value (95% CI) r2 
CD4 (log10 cells/mm3) 0.034 -0.3 (-0.5,0.0) 0.2    
SHBG at baseline (log10 pg/mL) 0.008 0.5 (0.1,0.8) 0.3 0.004 0.5 (0.2,0.8) 0.5 
CYP2B6 516G>T (rs3745274) 0.179 0.1 (0.0,0.0) 0.1    
 
Univariate linear regression analysis (P ≤ 0.2) was completed, all statistically significant results where then carried through to multivariate linear regression analysis (P ≤ 0.05). All statistically 
significant variables from multivariate linear regression shown in bold type. 
β is the regression coefficient and represents incremental change in the log10 LNG pharmacokinetic parameter per unit change in a patient characteristic (e.g. per kg body weight or per allele 
carried). Therefore, if β = 0.5 an increase per unit in the patient characteristic results in the log10 LNG pharmacokinetic parameter increasing by a factor of 0.5. 
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6.4 DISCUSSION  
 
The impact of this investigation is greatest for women receiving a combination of EFV based 
ART with an LNG subdermal implant. Women receiving this drug combination are at risk for 
suboptimal LNG exposure, which results in a higher rate of contraceptive failures (Patel 2015, 
Scarsi 2016). For women who are heterozygous or homozygous for CYP2B6 516G>T or 
CYP2B6 15582C>T, which were associated with lower LNG AUC when combined with EFV, 
this drug-drug interaction will be more pronounced. This was evidenced by the three patients 
who became pregnant in the EFV group, who all possessed at least one of these genotypes. 
Importantly, the patient who possessed both these genotypes had the lowest LNG exposure 
of any study participant. Nine additional women in the EFV group were heterozygous for 
either CYP2B6 516G>T or CYP2B6 15582C>T and had LNG exposure (median LNG AUC0-24weeks 
6831 pg*wk/mL), consistent with those women who became pregnant, indicating that they 
were also at risk for contraceptive failure.  We hypothesise that high EFV plasma 
concentrations associated with these SNPs may result in greater EFV induction of CYP3A4, 
resulting in increased LNG metabolism and lower LNG exposure in the patients who were 
heterozygous or homozygous for CYP2B6 516G>T or CYP2B6 15582C>T. Further contributing 
to this effect may be the modest inhibitory effect of LNG on CYP2B6 (Palovaara 2003, Walsky 
2006). It is possible that LNG may inhibit CYP2B6 activity, resulting in high EFV concentrations 
and further inhibition of CYP3A4.  
 
Within the NVP group, the significant association between CYP2B6 516G>T and higher LNG 
log10 Cmax and LNG log10 Cmin was surprising, given that NVP is an inducer of CYP3A4, the 
enzyme believed to be primarily responsible for LNG metabolism. In a previous study of three 
HIV-positive Malawian women receiving 30 μg ethinyl estradiol/300 μg norgestrel (a racemic 
mixture of LNG and dextronorgestrel) and NVP based ART, higher LNG exposure was also 
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observed compared to HIV uninfected women (Stuart 2011). Notably, two of the three 
women were heterozygous for CYP2B6 516G>T. Furthermore, CYP2B6 516G>T has been 
associated with elevated NVP concentrations in previous studies (Rotger 2005, Penzak 2007). 
Therefore, the association between CYP2B6 516G>T and LNG pharmacokinetic parameters 
could be attributed to NVP-mediated inhibition of LNG metabolism by CYP3A4, or potential 
inhibition of CYP3A5. However, this result must be interpreted with caution, given that 
overall exposure (as measured by AUC) was not associated with the same SNP. Further 
investigation is required to determine the mechanism underpinning this finding.  
 
We observed an association between NR1I2 63396C>T (rs2472677) and delayed LNG Tmax in 
patients receiving NVP, which has the potential to result in suboptimal LNG concentrations. 
Previously, NR1I2 63396C>T (in linkage disequilibrium with NR1I2 63704G>A, 
63813(CAAA)n/(CA)n, and NR1I2 65104T>C) has been associated with higher NR1I2 
expression, elevated CYP3A4 expression, and unboosted ATV plasma concentrations (Lamba 
2008, Siccardi 2008, Schipani 2010). NR1I2 63396C>T may be directly or indirectly associated 
with inducibility of CYP3A4 and hence reduced LNG metabolism. This is supported by 
observations in primary human hepatocytes where the 63396 T allele was associated with 
higher basal activity but lower rifampicin-mediated inducibility of CYP3A4 (Lamba 2008). 
 
LNG pharmacokinetics demonstrate high inter-individual variability, often attributed to 
variations in protein binding (Coukell 1998) and bodyweight (Sivin 1997, Sivin 1997, Sivin 
2001). Although we did not observe a consistent association with weight and LNG 
pharmacokinetics, this may be related to the lower median body weight of HIV-infected 
Ugandan women compared to those in other studied populations. LNG is highly protein-
bound to SHBG and albumin (Coukell 1998). Elevated log10 SHBG concentration has 
previously been associated with higher serum LNG concentration (Abdalla 1992). However, 
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the observed association of log10 SHBG concentration at baseline with higher LNG log10 Cmax, 
LNG log10 Cmin and LNG log10 AUC0-24weeks, and of albumin concentration at baseline with lower 
Tmax within the NVP group, may reflect some influence of baseline protein binding on overall 
LNG exposure.  
 
The study demonstrates pharmacogenetic associations with LNG pharmacokinetics when 
administered as a LNG subdermal implant in HIV positive women receiving EFV or NVP based 
ART. Despite the EFV interaction with LNG, effectiveness of the LNG subdermal implant may 
still be higher for oral contraception, due to improved medication adherence (Patel 2015, 
Shelton 2015). Notwithstanding, any increased risk of pregnancy when receiving 
contraception is important, given the impact that unintended pregnancy has for women 
living with HIV. Based upon our findings, screening for SNPs associated with low LNG 
exposure in patients receiving EFV represents a novel approach to identify women at the 
highest risk for an unintended pregnancy. Added pharmacogenetic knowledge would allow 
clinicians to personalise counseling of women on their choice of a contraceptive method 
based on individualised risks and benefits. Overall, this study highlights the potential role of 
affordable, accessible and clinically relevant pharmacogenetic screening in resource-
constrained settings. Future studies with larger populations and a more diverse range of 
ethnicities, should focus upon prospective evaluation of the relationship between 
pharmacogenetics and the effectiveness of the LNG implant in the presence of EFV-related 
drug-drug interactions.  
 
6.4.1 Limitations 
A limitation of this study was the relatively small sample size, particularly related to CYP2B6 
15582C>T (rs4803419) and NR1I3 540C>T (rs2307424), as both SNPs were not in Hardy-
Weinberg equilibrium. An increase in sample size would be of use in light of the low number 
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of patients within the statistically significant patient populations. With some variant 
genotypes represented by a single outlier. Given that the frequency of the variant alleles for 
some of the SNPs included within this analysis are low within the general population, as 
discussed in Chapter 1 (Table 1.2), a greater study population size would enable us to 
determine if these associations persist outside of the original study group. Additionally, the 
consequences of the Tmax associations are unclear, but should in any case be interpreted 
cautiously given the intermittent measurement of LNG pharmacokinetics during the study 
period.   
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Chapter 7: General Discussion 
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7.1 CONTEXT OF WORK  
 
The work within this thesis sits within the context of a wider research environment. As 
outlined in Figure 7.1 the clinical trial process is divided into 4 phases. Pre-clinical studies are 
completed through a range of methodologies. These studies include, but are not limited to, 
toxicology studies utilising in vitro cell lines, determination of pharmacokinetic parameters 
through in vivo studies in non-human animal models and defining a starting dose via 
physiologically-based pharmacokinetic modelling. Phase I is designed to study the 
absorption, distribution, metabolism and excretion of the drug and assesses drug safety 
within a small cohort of healthy volunteers. Phase II focuses on drug efficacy, through 
comparing the novel drug to a standard treatment or placebo within a randomised trial. 
Phase III involves larger scale testing of the therapeutic agent with randomised blind trials 
involving thousands of patients. These studies provide more information about the adverse 
effects of the drug and its effectiveness in comparison to drugs already on the market. Phase 
IV occurs post regulatory approval and is an ongoing process. Pharmacogenetics studies 
including those described in Chapters 2, 3 and 6 fit within Phase IV post-marketing research. 
As does the in vitro cell line work completed in Chapters 4 and 5. Phase IV studies are 
essential to continuously assess the suitability of the recommended drug dosage, and the 
occurrence of adverse drug responses or drug-drug interactions that were not observed 
within the previous phases. They also allow for the mechanisms by which these events 
occurred to be investigated, and there are numerous examples of how clinical management 
has been optimised through such careful ongoing analysis.  
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Figure 7.1: Clinical trial process from pre-clinical experimentation through to approval for general use.
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7.2 EXPANDING USE OF ANTIRETROVIRALS 
 
The interactions studied within Chapters 2, 3, 4 and 5 within this thesis are of particular 
relevance in light of the UNAIDS 90:90:90 target. This target has galvanised global initiatives 
to provide improved testing, access to sustained ART and achievement of viral suppression 
through innovative projects which target at risk populations (UNAIDS 2016). An example of 
this is The Global Fund initiative to reduce HIV incidence within adolescent girls and young 
women in high HIV burden settings, who represent a disproportionate number of new HIV 
cases (TheGlobalFund 2017). Current projections by UNAIDS indicate that the 90:90:90 target 
is achievable (UNAIDS 2016), however, a standardised monitoring and evaluation system is 
required in order to accurately evaluate the progress towards these targets (Granich 2017). 
More work is still needed to ensure all targets are reached and further ingenuity and 
investment is required. Nevertheless, progression towards 27 million additional people 
receiving treatment by 2020 (Williams 2017) will not only benefit patients in at risk groups, 
particularly in high HIV burden settings, but also enable a greater understanding of drug 
toxicity and drug-drug interactions within these previously understudied populations. It is 
important to consider the positive impact that greater access to ART will have on the study 
of pharmacogenetic interactions, providing a more diverse and larger pool of patients from 
which interactions can occur and be investigated. 
 
As access to PrEP is increased, through drug assistance programs such as PEPFAR DREAMS or 
access via government run infrastructure such as in that seen in Brazil and Scotland, the 
incidence of drug-drug interactions and toxicity not previously observed in trials focusing 
solely on HIV positive participants are likely to increase. There is a need to consider the 
implications that PrEP use could have for a patients’ pre-existing drug regimen, whether in 
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the form of a contraceptive or for the treatment of a comorbidity. This problem is 
demonstrated within Chapter 6, where the indirect effect of EFV on LNG pharmacokinetics 
resulted in LNG treatment failure.  At the time of writing, no data is currently available from 
earlier implementer sites in the UK that discusses the number of incidents of drug-drug 
interactions that led to discontinuation of PrEP. The release of this data would provide an 
invaluable foundation from which to base guidance on PrEP prescription in patients with pre-
existing clinical needs.  
 
7.3 PHARMACOGENETICS CLINICAL IMPLEMENTATION 
 
7.3.1 Clinical implementation 
A number of barriers to implementation need to be overcome in order for stratified medicine 
to be realised (Duthey 2013). A general consensus on what criteria must be met in order for 
a SNP to be considered as having clinical value must be agreed. Furthermore, a 
multidisciplinary strategy should be used to prepare clinical practitioners for the process and 
realities of providing care based on stratified approaches. Once clear guidelines have been 
established for the clinical relevance of a SNP, regulatory authorities can use preexisting tools 
and methods to disseminate this knowledge to practitioners in the field. Furthermore, these 
guidelines can be incorporated into the current clinical trials framework, outlined in Figure 
7.1, enabling pharmacogenetic interactions to be considered throughout drug development. 
Through these processes being implemented there is an increased likelihood of 
pharmacogenetic research having a greater impact, and a global effort to understand 
subpopulation differences will enable patients to benefit globally from research outcomes.  
 
Pharmacogenetics studies have yielded clinically impactful data, as summarised in Chapter 1 
(Section 1.4 and Table 1.1). Clinical guidelines for abacavir use are currently implemented 
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based on HCP5 733T>G (rs2395029) genotype. The single nucleotide polymorphism HCP5 
733T>G (rs2395029) known as the HLA-B*57-01 allele, is found in ~6% of patients and has 
been strongly associated with a significantly increased risk of developing abacavir 
hypersensitivity. Hypersensitivity presents as two or more of the following: fever, rash, 
gastrointestinal symptoms, fatigue, cough, and dyspnea, and results in discontinuation of 
abacavir therapy (Martin 2012, Dean 2015). The FDA and the European Medicines Agency 
now recommend genetic pre-screening for HLA-B*57-01 for all patients before initiating 
abacavir-containing regimens (Martin 2012). Abacavir hypersensitivity has been observed in 
both Caucasian and Hispanic populations, but Black ethnicity populations have been shown 
to have a lowered risk of developing abacavir hypersensitivity (Mallal 2002, Symonds 2002, 
Hughes 2004, Martin 2004). This monogenic association has a categorical phenotype and 
provides an example of a direct link between a single SNP and a phenotype in the form of an 
adverse event. More often pharmacokinetic associations are complex interactions involving 
multiple genes and environmental factors, which contribute to a phenotype in varying 
degrees depending on the other variables instigating an effect. As such determining the 
degree of effect of a single SNP on a change in pharmacokinetics within a general population 
is difficult to do conclusively.   
 
7.3.2 Influence of proteins 
The interplay between transporter, enzyme and transcription factor expression and co-
regulation, creates an intricate network of regulation that can influence study results. The 
complexity of these interactions coupled with variation in environmental factors feeds 
ambiguity for some variants. Given that less than 1% of all SNPs result in variations in 
proteins, the task of ‘sifting for gold’ is a laborious one (Venter 2001). Nevertheless, ground 
has been made in revealing SNPs that explain a proportion of inter-individual response. The 
next challenge will be to determine the overall impact of multiple polymorphisms in 
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combination. One example of this utilises the CYP2B6 516G>T SNP found to be statistically 
significant in Chapter 6. CYP2B6 516G>T, CYP2B6 983T>C and 15582C>T genotypes are used 
to define a person’s EFV metaboliser status as a slow, intermediate or extensive metaboliser 
based on the presence or absence of the variant allele for each polymorphism. Further work 
is also required to understand how multiple variants in multiple loci across multiple 
chromosomes may be implemented in unison. 
 
7.3.2 Ethnicity 
Chapters 2 and 6 include pharmacogenetic analysis within African populations of single 
ethnicities. To achieve the definitive goal of pharmacogenetic studies, a stratified medicine 
approach that would enable the prescription and dosage of drugs to be founded on a sound 
understanding of how subpopulation genetics would influence their response, further work 
must be completed. As technology becomes cheaper and therefore more broadly accessible, 
it is hoped that the frequency of studies involving small or remote populations should 
increase over time. For this to happen it is imperative that a collaborative approach continues 
be adopted such as those being promoted through the H3Africa initiative. This provides the 
exchange of technology, knowledge and experience to broaden research across diverse 
populations. There is also a need to account for environmental and cultural differences, and 
the socio-economic factors that may influence an individual’s response to antiretroviral 
drugs, which cannot be underestimated. Additionally, thought needs to be given to the way 
in which ethnicity is defined within studies, with a move away from self-classified ethnicity 
towards genetically-defined ethnicity, as more priority is given to investigating differences in 
response within population groups with overlapping ethnicity classifications.  
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7.4 CONCLUSIONS 
 
Through conducting pharmacogenetics studies involving multi-ethnic populations receiving 
one of two first line HIV therapy drugs TFV or EFV, this thesis sought to gain insight into the 
degree of influence a patient’s genetics has on their drug response. This response was 
defined as incidence of toxicity, alteration in drug pharmacokinetics or degree of drug-drug 
interaction. Furthermore, the work aimed to determine the effect of transporter interactions 
at the site of TFV toxicity, the proximal tubule, and the impact this had on the transport of 
two substrates.  
 
These studies yielded valuable information surrounding the contribution of 
pharmacogenetics to the drug-drug interaction observed between EFV and LNG and defined 
a genetic association between TFV transporter SNPs and TFV plasma and urine 
concentrations. Both interactions have potential ramifications for a patient’s overall 
response to ART, and build on current knowledge of how a patient’s genetics can contribute 
to achieving sustained virological response. The work investigating the effect of TAF and TFV 
on MATE1 and MATE2K transport of metformin and creatinine produced novel data on the 
effect of TAF and TFV on the MATE2K mediated transport of metformin and creatinine. 
Demonstrating inhibition of MATE2K by TFV at a concentration of 0.01 µM and above. These 
studies have clinical impact through further elucidating potential mechanisms of toxicity 
caused by antiretroviral drug regimens and thus improving patient safety. 
 
Further work is required to fully define the transporter profile of TFV in terms of its 
metabolism and excretion, in light of its prevailing use in ART. The release of advisory 
guidelines by regulatory bodies, including the FDA and EMA, on the need to assess clinically 
relevant transporters during drug development is thought to have led to the observed  
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increase in transporter related information on prescribing information (Sheetal Agarwal 
2013).  However, future work may benefit from the full transporter profile of newly 
developed antiretroviral drugs being evaluated. Section 7.3 of this chapter explores several 
factors that must be considered in order for personalised medicine to be implemented. The 
use of pharmacogenetics-based therapeutic recommendations in drug labels has been 
shown to be lacking (Lee 2017). The inclusion of pharmacogenetic evaluation into the drug 
development process and labelling information for novel drugs could potentially lead to rapid 
development in our knowledge of how genetics influence drug response and reduce adverse 
events in patients receiving ART. 
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